<?xml version='1.0' encoding='utf-8'?>
<graphml xmlns="http://graphml.graphdrawing.org/xmlns" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://graphml.graphdrawing.org/xmlns http://graphml.graphdrawing.org/xmlns/1.0/graphml.xsd"><key id="d9" for="edge" attr.name="context" attr.type="string"/>
<key id="d8" for="edge" attr.name="type" attr.type="string"/>
<key id="d7" for="node" attr.name="canonical_name" attr.type="string"/>
<key id="d6" for="node" attr.name="name" attr.type="string"/>
<key id="d5" for="node" attr.name="entity_type" attr.type="string"/>
<key id="d4" for="node" attr.name="paper_id" attr.type="string"/>
<key id="d3" for="node" attr.name="statement" attr.type="string"/>
<key id="d2" for="node" attr.name="year" attr.type="long"/>
<key id="d1" for="node" attr.name="content" attr.type="string"/>
<key id="d0" for="node" attr.name="type" attr.type="string"/>
<graph edgedefault="directed"><node id="PDF_4">
  <data key="d0">Paper</data>
  <data key="d1">nature medicine
Article
a
https://doi.org/10.1038/s41591-024-02996-7
Long-term weight loss effects of semaglutide
in obesity without diabetes in the SELECT trial
Received: 1 March 2024
Accepted: 12 April 2024
Published online: 13 May 2024
Check for updates
Donna H. Ryan', Ildiko Lingvay 2, John Deanfield³, Steven E. Kahn,
Eric Barros, Bartolome Burguera, Helen M. Colhoun, Cintia Cercato 8,
Dror Dicker, Deborah B. Horn¹º, G. Kees Hovingh, Ole Kleist Jeppesen,
Alexander Kokkinos", A. Michael Linco</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_16">
  <data key="d0">Paper</data>
  <data key="d1">RESEARCH
Effect of perindopril on physical function in elderly people
with functional impairment: a randomized controlled trial
Deepa Sumukadas MBBS MD, Miles D. Witham MBChB PhD, Allan D. Struthers MBChB MD,
Marion E.T. McMurdo MBChB MD
8
See related article page 891
ABSTRACT
Background: Physical function and exercise capacity decline
with age and are a major source of disability in older people.
Recent evidence suggests a potential role for the renin-
angiotensin system in modulating muscle fu</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_16_Hypothesis_-1001928361261613389">
  <data key="d0">Hypothesis</data>
  <data key="d1">ACE inhibitors may have direct effects on skeletal muscle.</data>
  <data key="d3">ACE inhibitors may have direct effects on skeletal muscle.</data>
  <data key="d4">PDF_16</data>
</node>
<node id="Gene_ACE">
  <data key="d0">Entity</data>
  <data key="d5">Gene</data>
  <data key="d6">ACE</data>
  <data key="d7">ACE</data>
</node>
<node id="Process_SKELETAL MUSCLE">
  <data key="d0">Entity</data>
  <data key="d5">Process</data>
  <data key="d6">SKELETAL MUSCLE</data>
  <data key="d7">skeletal muscle</data>
</node>
<node id="PDF_16_Method_1405357716690634200">
  <data key="d0">Method</data>
  <data key="d1">Participants aged 65 years and older who had problems with mobility or functional impairment were randomly assigned to receive either perindopril or placebo for 20 weeks.</data>
  <data key="d3">Participants aged 65 years and older who had problems with mobility or functional impairment were randomly assigned to receive either perindopril or placebo for 20 weeks.</data>
  <data key="d4">PDF_16</data>
</node>
<node id="Compound_PERINDOPRIL">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">PERINDOPRIL</data>
  <data key="d7">Perindopril</data>
</node>
<node id="PDF_16_Result_-4603631527809478861">
  <data key="d0">Result</data>
  <data key="d1">At 20 weeks, the mean 6-minute walking distance was significantly improved in the perindopril group relative to the placebo group</data>
  <data key="d3">At 20 weeks, the mean 6-minute walking distance was significantly improved in the perindopril group relative to the placebo group</data>
  <data key="d4">PDF_16</data>
</node>
<node id="PDF_16_Result_-4860963387706469022">
  <data key="d0">Result</data>
  <data key="d1">quality of life was maintained in the perindopril group</data>
  <data key="d3">quality of life was maintained in the perindopril group</data>
  <data key="d4">PDF_16</data>
</node>
<node id="PDF_16_Conclusion_6611930757598402587">
  <data key="d0">Conclusion</data>
  <data key="d1">Use of the ACE inhibitor perindopril improved exercise capacity in functionally impaired elderly people who had no heart failure and maintained health-related quality of life.</data>
  <data key="d3">Use of the ACE inhibitor perindopril improved exercise capacity in functionally impaired elderly people who had no heart failure and maintained health-related quality of life.</data>
  <data key="d4">PDF_16</data>
</node>
<node id="Disease_HEART FAILURE">
  <data key="d0">Entity</data>
  <data key="d5">Disease</data>
  <data key="d6">HEART FAILURE</data>
  <data key="d7">heart failure</data>
</node>
<node id="PDF_17">
  <data key="d0">Paper</data>
  <data key="d1">Here is the complete text extracted from the provided scientific PDF, as requested:

**373**

**CARDIOVASCULAR MEDICINE**

**Perindopril improves six minute walking distance in older
patients with left ventricular systolic dysfunction:
a randomised double blind placebo controlled trial**

SD Hutcheon, N D Gillespie, I K Crombie, A D Struthers, MET McMurdo

*Heart* 2002;88:373-377

See end of article for
authors' affiliations

Objective: To evaluate the effects of the angiotensin converting enzym</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_17_Hypothesis_-660013291876930389">
  <data key="d0">Hypothesis</data>
  <data key="d1">To evaluate the effects of the angiotensin converting enzyme inhibitor perindopril on six minute walking distance and quality of life in very old patients with left ventricular systolic dysfunction.</data>
  <data key="d3">To evaluate the effects of the angiotensin converting enzyme inhibitor perindopril on six minute walking distance and quality of life in very old patients with left ventricular systolic dysfunction.</data>
  <data key="d4">PDF_17</data>
</node>
<node id="PDF_17_Method_-7388902424420068180">
  <data key="d0">Method</data>
  <data key="d1">Prospective, double blind placebo controlled trial with 66 patients (average age 81) with left ventricular systolic dysfunction identified by echocardiography. Treatment with titrated doses of perindopril or placebo for 10 weeks.</data>
  <data key="d3">Prospective, double blind placebo controlled trial with 66 patients (average age 81) with left ventricular systolic dysfunction identified by echocardiography. Treatment with titrated doses of perindopril or placebo for 10 weeks.</data>
  <data key="d4">PDF_17</data>
</node>
<node id="PDF_17_Result_5344063052469787024">
  <data key="d0">Result</data>
  <data key="d1">In patients with left ventricular systolic dysfunction, six minute walking distance was significantly increased in the treatment group (37.1 m) compared with the placebo group (-0.3 m, p &lt; 0.001).</data>
  <data key="d3">In patients with left ventricular systolic dysfunction, six minute walking distance was significantly increased in the treatment group (37.1 m) compared with the placebo group (-0.3 m, p &lt; 0.001).</data>
  <data key="d4">PDF_17</data>
</node>
<node id="PDF_17_Conclusion_4691730757618169805">
  <data key="d0">Conclusion</data>
  <data key="d1">Six minute walking distance is improved considerably by treatment with perindopril in older patients with heart failure caused by left ventricular systolic dysfunction.</data>
  <data key="d3">Six minute walking distance is improved considerably by treatment with perindopril in older patients with heart failure caused by left ventricular systolic dysfunction.</data>
  <data key="d4">PDF_17</data>
</node>
<node id="PDF_14">
  <data key="d0">Paper</data>
  <data key="d1">Here is the full extracted text from the scientific PDF, with no summarization and only English text:

JAFRICA CARDIOVASCULAR JOURNAL OF AFRICA • Vol 20, No 2, March/April 2009
127
Review Article
Perindopril: do randomised, controlled trials support an
ACE inhibitor class effect? A meta-analysis of clinical
trials
JACQUES R SNYMAN, FRANCOIS WESSELS
Summary
Background: Due to the lack of face-to-face trials between
ACE inhibitors, clinicians and third-party funders may
assume they provide similar</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_14_Result_-7955122279640508438">
  <data key="d0">Result</data>
  <data key="d1">Perindopril resulted in significantly fewer patients reaching the primary endpoint versus all other ACEIs combined. The results were consistent for myocardial infarction, stroke and mortality (5 vs 11%, p = 0.0001).</data>
  <data key="d3">Perindopril resulted in significantly fewer patients reaching the primary endpoint versus all other ACEIs combined. The results were consistent for myocardial infarction, stroke and mortality (5 vs 11%, p = 0.0001).</data>
  <data key="d4">PDF_14</data>
</node>
<node id="Disease_MYOCARDIAL INFARCTION">
  <data key="d0">Entity</data>
  <data key="d5">Disease</data>
  <data key="d6">MYOCARDIAL INFARCTION</data>
  <data key="d7">myocardial infarction</data>
</node>
<node id="Disease_STROKE">
  <data key="d0">Entity</data>
  <data key="d5">Disease</data>
  <data key="d6">STROKE</data>
  <data key="d7">stroke</data>
</node>
<node id="PDF_14_Conclusion_-1068359777605661893">
  <data key="d0">Conclusion</data>
  <data key="d1">Perindopril alone or as part of combination therapy in clinical trials seemed to deliver clear and consistent outcome differences compared to other ACEI trials. In the presence of positive outcomes from robust randomised, controlled trials for perindopril, one cannot assume a class effect for all ACEIs.</data>
  <data key="d3">Perindopril alone or as part of combination therapy in clinical trials seemed to deliver clear and consistent outcome differences compared to other ACEI trials. In the presence of positive outcomes from robust randomised, controlled trials for perindopril, one cannot assume a class effect for all ACEIs.</data>
  <data key="d4">PDF_14</data>
</node>
<node id="PDF_14_Method_-1294717443288242483">
  <data key="d0">Method</data>
  <data key="d1">Published randomised, controlled trials were selected using an applicable literature search for all ACEIs, irrespective of drug combination, for any cardiovascular outcome (both composite and individual outcomes were included). The average length of ACEI exposure per trial had to be longer than six months). This meta-analysis was performed using odds ratios as the parameter of efficacy in a fixed-effects model.</data>
  <data key="d3">Published randomised, controlled trials were selected using an applicable literature search for all ACEIs, irrespective of drug combination, for any cardiovascular outcome (both composite and individual outcomes were included). The average length of ACEI exposure per trial had to be longer than six months). This meta-analysis was performed using odds ratios as the parameter of efficacy in a fixed-effects model.</data>
  <data key="d4">PDF_14</data>
</node>
<node id="PDF_13">
  <data key="d0">Paper</data>
  <data key="d1">Efficacy and Safety of Perindopril in Patients with Essential Hypertension

DOI: 10.5455/msm.2020.32.4-9
Received: JAN 09 2020; Accepted: MAR 02, 2020

2020 Enisa Hodzic, Ehlimana Pecar, Alen Dzubur, Elnur Smajic, Zorica Hondo, Daniela Delic, Edhem Rustempasic
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-
nc/4.0/) which permits unrestricted non-commercial use, distribution, and reprod</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_13_Method_5818618468528436876">
  <data key="d0">Method</data>
  <data key="d1">This prospective cohort study included primary care patients with essential hypertension.</data>
  <data key="d3">This prospective cohort study included primary care patients with essential hypertension.</data>
  <data key="d4">PDF_13</data>
</node>
<node id="Disease_HYPERTENSION">
  <data key="d0">Entity</data>
  <data key="d5">Disease</data>
  <data key="d6">HYPERTENSION</data>
  <data key="d7">Hypertension</data>
</node>
<node id="PDF_13_Result_-7821153563378710597">
  <data key="d0">Result</data>
  <data key="d1">In the great majority of the study patients (more than 96%) perindopril was effective as monotherapy, achieving a significant reduction in both systolic and diastolic blood pressure, and in three-quarters of the study patients it normalized both systolic and diastolic blood pressure.</data>
  <data key="d3">In the great majority of the study patients (more than 96%) perindopril was effective as monotherapy, achieving a significant reduction in both systolic and diastolic blood pressure, and in three-quarters of the study patients it normalized both systolic and diastolic blood pressure.</data>
  <data key="d4">PDF_13</data>
</node>
<node id="PDF_13_Result_9070215760168419076">
  <data key="d0">Result</data>
  <data key="d1">The effectiveness of perindopril was shown in both patients with previously and newly diagnosed hypertension, adverse events were mild and rare, even hyperkalemia was encountered less often than before the onset of the therapy with perindopril.</data>
  <data key="d3">The effectiveness of perindopril was shown in both patients with previously and newly diagnosed hypertension, adverse events were mild and rare, even hyperkalemia was encountered less often than before the onset of the therapy with perindopril.</data>
  <data key="d4">PDF_13</data>
</node>
<node id="PDF_13_Conclusion_5059259856092741698">
  <data key="d0">Conclusion</data>
  <data key="d1">Our study confirmed excellent effectiveness of perindopril in the treatment of essential hypertension and its remarkable safety.</data>
  <data key="d3">Our study confirmed excellent effectiveness of perindopril in the treatment of essential hypertension and its remarkable safety.</data>
  <data key="d4">PDF_13</data>
</node>
<node id="PDF_15">
  <data key="d0">Paper</data>
  <data key="d1">ORIGINAL ARTICLE
Journal of Human Hypertension (2000) 14, 321-325
© 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00
www.nature.com/jhh
Antihypertensive efficacy of the ACE-
inhibitor perindopril in the elderly
FHH Leenen¹, J Tanner² and CF McNally³
1University of Ottawa Heart Institute, Ottawa, Ontario, Canada; 2General Practice Research Group,
Toronto, Ontario, Canada; ³Clinical Research Partners, Mount Laurel, NJ, USA
To assess the antihypertensive efficacy of the angiote</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_15_Hypothesis_6165205839212340986">
  <data key="d0">Hypothesis</data>
  <data key="d1">To assess the antihypertensive efficacy of the angiotensin-converting enzyme (ACE)-inhibitor, perindopril, in the elderly.</data>
  <data key="d3">To assess the antihypertensive efficacy of the angiotensin-converting enzyme (ACE)-inhibitor, perindopril, in the elderly.</data>
  <data key="d4">PDF_15</data>
</node>
<node id="Protein_ACE">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">ACE</data>
  <data key="d7">ACE</data>
</node>
<node id="PDF_15_Method_-3745470565031048406">
  <data key="d0">Method</data>
  <data key="d1">patients &gt;65 years of age with supine diastolic blood pressure (BP) ≥90 and ≤110 mm Hg at the end of a 4-week placebo washout period were treated with perindopril 4-8 mg/daily vs placebo using a multi-centre, randomised, double-blind, parallel group design.</data>
  <data key="d3">patients &gt;65 years of age with supine diastolic blood pressure (BP) ≥90 and ≤110 mm Hg at the end of a 4-week placebo washout period were treated with perindopril 4-8 mg/daily vs placebo using a multi-centre, randomised, double-blind, parallel group design.</data>
  <data key="d4">PDF_15</data>
</node>
<node id="PDF_15_Result_-2010676726385772421">
  <data key="d0">Result</data>
  <data key="d1">In the perindopril-group, diastolic BP decreased by 6-7 mm Hg and systolic BP by 10-13 mm Hg (both P &lt; 0.01 vs placebo).</data>
  <data key="d3">In the perindopril-group, diastolic BP decreased by 6-7 mm Hg and systolic BP by 10-13 mm Hg (both P &lt; 0.01 vs placebo).</data>
  <data key="d4">PDF_15</data>
</node>
<node id="PDF_15_Result_-5701829914027310010">
  <data key="d0">Result</data>
  <data key="d1">Perindopril caused additional decreases in diastolic BP by about 2 mm Hg, and in systolic BP by 4-5 mm Hg.</data>
  <data key="d3">Perindopril caused additional decreases in diastolic BP by about 2 mm Hg, and in systolic BP by 4-5 mm Hg.</data>
  <data key="d4">PDF_15</data>
</node>
<node id="PDF_15_Conclusion_3200986636981088749">
  <data key="d0">Conclusion</data>
  <data key="d1">the present double-blind, placebo-controlled study shows a significant antihypertensive effect of placebo, and additional effect of perindopril in an elderly population.</data>
  <data key="d3">the present double-blind, placebo-controlled study shows a significant antihypertensive effect of placebo, and additional effect of perindopril in an elderly population.</data>
  <data key="d4">PDF_15</data>
</node>
<node id="PDF_15_Conclusion_8062723024005871718">
  <data key="d0">Conclusion</data>
  <data key="d1">The extent of this effect may be less than observed in middle-aged hypertensives.</data>
  <data key="d3">The extent of this effect may be less than observed in middle-aged hypertensives.</data>
  <data key="d4">PDF_15</data>
</node>
<node id="PDF_1">
  <data key="d0">Paper</data>
  <data key="d1">nature metabolism
Letter
a
https://doi.org/10.1038/s42255-023-00943-3
Randomized open-label trial of semaglutide
and dapagliflozin in patients with type 2
diabetes of different pathophysiology
Received: 9 May 2023
A list of authors and their affiliations appears at the end of the paper
Accepted: 8 November 2023
Published online: 4 January 2024
Check for updates
The limited understanding of the heterogeneity in the treatment response
to antidiabetic drugs contributes to metabolic deterioration an</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_1_Result_-8454390891778832376">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide induced a larger reduction in HbA1c levels than dapagliflozin, with a pronounced effect in those with SIDD.</data>
  <data key="d3">Semaglutide induced a larger reduction in HbA1c levels than dapagliflozin, with a pronounced effect in those with SIDD.</data>
  <data key="d4">PDF_1</data>
</node>
<node id="Compound_HBA1C">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">HBA1C</data>
  <data key="d7">HbA1c</data>
</node>
<node id="Compound_SEMAGLUTIDE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">SEMAGLUTIDE</data>
  <data key="d7">Semaglutide</data>
</node>
<node id="Compound_DAPAGLIFLOZIN">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">DAPAGLIFLOZIN</data>
  <data key="d7">dapagliflozin</data>
</node>
<node id="Disease_TYPE 2 DIABETES MELLITUS">
  <data key="d0">Entity</data>
  <data key="d5">Disease</data>
  <data key="d6">TYPE 2 DIABETES MELLITUS</data>
  <data key="d7">type 2 diabetes mellitus</data>
</node>
<node id="PDF_1_Result_3026515512155509167">
  <data key="d0">Result</data>
  <data key="d1">Participants on semaglutide had larger improvements in fasting and postprandial glucose, insulin secretion and BMI than those on dapagliflozin.</data>
  <data key="d3">Participants on semaglutide had larger improvements in fasting and postprandial glucose, insulin secretion and BMI than those on dapagliflozin.</data>
  <data key="d4">PDF_1</data>
</node>
<node id="PDF_1_Result_587467621871043712">
  <data key="d0">Result</data>
  <data key="d1">Dapagliflozin treatment improved the homoeostasis model assessment 2 estimate of insulin resistance (HOMA2-IR) compared with semaglutide treatment.</data>
  <data key="d3">Dapagliflozin treatment improved the homoeostasis model assessment 2 estimate of insulin resistance (HOMA2-IR) compared with semaglutide treatment.</data>
  <data key="d4">PDF_1</data>
</node>
<node id="Process_INSULIN RESISTANCE">
  <data key="d0">Entity</data>
  <data key="d5">Process</data>
  <data key="d6">INSULIN RESISTANCE</data>
  <data key="d7">insulin resistance</data>
</node>
<node id="PDF_1_Result_-2587084149367949985">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide was found to result in greater reductions in fasting glucose, glucose at 2 h of the oral glucose tolerance test (OGTT) and average glucose concentration during continuous monitoring, as well as a higher time in range in participants with SIDD than in those with SIRD.</data>
  <data key="d3">Semaglutide was found to result in greater reductions in fasting glucose, glucose at 2 h of the oral glucose tolerance test (OGTT) and average glucose concentration during continuous monitoring, as well as a higher time in range in participants with SIDD than in those with SIRD.</data>
  <data key="d4">PDF_1</data>
</node>
<node id="PDF_1_Result_-2651618173839202636">
  <data key="d0">Result</data>
  <data key="d1">Dapagliflozin resulted in a significantly larger improvement in 2-h glucose and a tendency for greater improvements in fasting glucose and HOMA2-IR in participants with SIDD than in those with SIRD.</data>
  <data key="d3">Dapagliflozin resulted in a significantly larger improvement in 2-h glucose and a tendency for greater improvements in fasting glucose and HOMA2-IR in participants with SIDD than in those with SIRD.</data>
  <data key="d4">PDF_1</data>
</node>
<node id="PDF_1_Result_-60329191782281013">
  <data key="d0">Result</data>
  <data key="d1">Continuous pathophysiological variables can predict the likely treatment response to these common drugs and provide more information than stratified subgroups.</data>
  <data key="d3">Continuous pathophysiological variables can predict the likely treatment response to these common drugs and provide more information than stratified subgroups.</data>
  <data key="d4">PDF_1</data>
</node>
<node id="PDF_6">
  <data key="d0">Paper</data>
  <data key="d1">nature medicine
a
Article
https://doi.org/10.1038/s41591-024-03463-z
Subcutaneous weekly semaglutide with
automated insulin delivery in type 1 diabetes:
a double-blind, randomized, crossover trial
Received: 12 August 2024
Accepted: 11 December 2024
Published online: 10 January 2025
Check for updates
Melissa-Rosina Pasqua 1,2,3 Michael A. Tsoukas 1,2,3, Alessandra Kobayati 2,3,
Wedyan Aboznadah¹4, Adnan Jafar &amp; Ahmad Haidar 1,2,3,5
Efforts to improve glycemic control in type 1 diabetes are ongoin</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_6_Result_7807270647179962157">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide improves glycemic control with automated insulin delivery compared to placebo.</data>
  <data key="d3">Semaglutide improves glycemic control with automated insulin delivery compared to placebo.</data>
  <data key="d4">PDF_6</data>
</node>
<node id="PDF_6_Result_-7733577376683516890">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide increased time in the target glucose range by a mean 4.8 (s.d. = 7.6) percentage points compared to placebo.</data>
  <data key="d3">Semaglutide increased time in the target glucose range by a mean 4.8 (s.d. = 7.6) percentage points compared to placebo.</data>
  <data key="d4">PDF_6</data>
</node>
<node id="PDF_6_Result_-3766554712485558065">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide reduces glycated hemoglobin (HbA1c).</data>
  <data key="d3">Semaglutide reduces glycated hemoglobin (HbA1c).</data>
  <data key="d4">PDF_6</data>
</node>
<node id="PDF_6_Result_1450101461538820557">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide reduces weight.</data>
  <data key="d3">Semaglutide reduces weight.</data>
  <data key="d4">PDF_6</data>
</node>
<node id="PDF_6_Result_-5543974218509804172">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide reduces insulin requirements.</data>
  <data key="d3">Semaglutide reduces insulin requirements.</data>
  <data key="d4">PDF_6</data>
</node>
<node id="PDF_6_Result_7097652081495334130">
  <data key="d0">Result</data>
  <data key="d1">High-density lipoprotein (HDL) cholesterol was lower with semaglutide than placebo.</data>
  <data key="d3">High-density lipoprotein (HDL) cholesterol was lower with semaglutide than placebo.</data>
  <data key="d4">PDF_6</data>
</node>
<node id="PDF_6_Result_1226396694637456463">
  <data key="d0">Result</data>
  <data key="d1">Weight was reduced by 5.3 (2.9) kg with semaglutide compared to placebo.</data>
  <data key="d3">Weight was reduced by 5.3 (2.9) kg with semaglutide compared to placebo.</data>
  <data key="d4">PDF_6</data>
</node>
<node id="PDF_6_Result_3901098566409783361">
  <data key="d0">Result</data>
  <data key="d1">Daily insulin use was reduced by 11.3 units with semaglutide compared to placebo.</data>
  <data key="d3">Daily insulin use was reduced by 11.3 units with semaglutide compared to placebo.</data>
  <data key="d4">PDF_6</data>
</node>
<node id="PDF_6_Result_39484958943931859">
  <data key="d0">Result</data>
  <data key="d1">Daily carbohydrate intake was also reduced by 36 g with semaglutide compared to placebo.</data>
  <data key="d3">Daily carbohydrate intake was also reduced by 36 g with semaglutide compared to placebo.</data>
  <data key="d4">PDF_6</data>
</node>
<node id="PDF_6_Conclusion_-2120543418135045177">
  <data key="d0">Conclusion</data>
  <data key="d1">Semaglutide improved glycemic control, with lower insulin requirements, in adults with T1D when used with AID.</data>
  <data key="d3">Semaglutide improved glycemic control, with lower insulin requirements, in adults with T1D when used with AID.</data>
  <data key="d4">PDF_6</data>
</node>
<node id="PDF_6_Conclusion_-5975492430483773805">
  <data key="d0">Conclusion</data>
  <data key="d1">Semaglutide also reduced carbohydrate intake, body weight, BMI and waist and hip circumferences compared to placebo.</data>
  <data key="d3">Semaglutide also reduced carbohydrate intake, body weight, BMI and waist and hip circumferences compared to placebo.</data>
  <data key="d4">PDF_6</data>
</node>
<node id="PDF_6_Conclusion_-4228870845903613936">
  <data key="d0">Conclusion</data>
  <data key="d1">Those who had the highest weight reduction had the most glycemic benefits.</data>
  <data key="d3">Those who had the highest weight reduction had the most glycemic benefits.</data>
  <data key="d4">PDF_6</data>
</node>
<node id="PDF_18">
  <data key="d0">Paper</data>
  <data key="d1">communications biology
Article
a
https://doi.org/10.1038/s42003-024-07387-9
Resveratrol does not mimic the positive
effects of calorie restriction on lifespan in
Microcebus murinus
Fabien Pifferi¹
Jérémy Terrien¹, Julia Marchal¹, Alexandre Dal-Pan¹, Fathia Djelti 1,2,
Martine Perret¹, Jacques Epelbaum¹, Stéphane Blanc³, Jean-Luc Picq¹, Marc Dhenain5,6 &amp;
Fabienne Aujard¹
Check for updates
Resveratrol (RSV), a polyphenol with anti-aging properties affecting metabolism and energy balance,
is consid</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_18_Hypothesis_-6096125481521144220">
  <data key="d0">Hypothesis</data>
  <data key="d1">We hypothesize that long-term supplementation with intermediate dose of RSV (i.e. 200 mg/kg.day¯¹) affects health and lifespan of the grey mouse lemur.</data>
  <data key="d3">We hypothesize that long-term supplementation with intermediate dose of RSV (i.e. 200 mg/kg.day¯¹) affects health and lifespan of the grey mouse lemur.</data>
  <data key="d4">PDF_18</data>
</node>
<node id="Compound_RESVERATROL">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">RESVERATROL</data>
  <data key="d7">Resveratrol</data>
</node>
<node id="PDF_18_Method_5193417751340496414">
  <data key="d0">Method</data>
  <data key="d1">Longitudinal monitoring of cognitive and motor performances, occurrence of age-related pathologies, age-related brain atrophy and mortality was performed from adulthood to death in a cohort of male grey mouse lemurs receiving RSV (200 mg.kg¯¹ body weight.day¯¹).</data>
  <data key="d3">Longitudinal monitoring of cognitive and motor performances, occurrence of age-related pathologies, age-related brain atrophy and mortality was performed from adulthood to death in a cohort of male grey mouse lemurs receiving RSV (200 mg.kg¯¹ body weight.day¯¹).</data>
  <data key="d4">PDF_18</data>
</node>
<node id="PDF_18_Result_-407893529333615044">
  <data key="d0">Result</data>
  <data key="d1">RSV supplementation improved cognitive and motor performance at middle age as compared to control animals.</data>
  <data key="d3">RSV supplementation improved cognitive and motor performance at middle age as compared to control animals.</data>
  <data key="d4">PDF_18</data>
</node>
<node id="PDF_18_Result_-6385519272228046690">
  <data key="d0">Result</data>
  <data key="d1">Median-lifespan was greater in RSV-fed animals (7.9 years compared to 6.4 years for CTL) but long-term RSV supplementation did not significantly affect all-cause nor age-related mortality.</data>
  <data key="d3">Median-lifespan was greater in RSV-fed animals (7.9 years compared to 6.4 years for CTL) but long-term RSV supplementation did not significantly affect all-cause nor age-related mortality.</data>
  <data key="d4">PDF_18</data>
</node>
<node id="PDF_18_Result_1089460308327150157">
  <data key="d0">Result</data>
  <data key="d1">Brain grey matter atrophy accelerated in the RSV group at old age as compared to the CTL group.</data>
  <data key="d3">Brain grey matter atrophy accelerated in the RSV group at old age as compared to the CTL group.</data>
  <data key="d4">PDF_18</data>
</node>
<node id="PDF_18_Conclusion_8827001182071805207">
  <data key="d0">Conclusion</data>
  <data key="d1">Long-term RSV supplementation procures health benefits at middle-age in male mouse lemurs but has limited long-term effects on health and longevity and might even impair brain integrity at older ages.</data>
  <data key="d3">Long-term RSV supplementation procures health benefits at middle-age in male mouse lemurs but has limited long-term effects on health and longevity and might even impair brain integrity at older ages.</data>
  <data key="d4">PDF_18</data>
</node>
<node id="PDF_18_Conclusion_-8389163720824783125">
  <data key="d0">Conclusion</data>
  <data key="d1">Long-term RSV supplementation does not mimic the lifespan extension provided by chronic CR, and does not reduce either the risk of age-associated diseases or age-associated mortality.</data>
  <data key="d3">Long-term RSV supplementation does not mimic the lifespan extension provided by chronic CR, and does not reduce either the risk of age-associated diseases or age-associated mortality.</data>
  <data key="d4">PDF_18</data>
</node>
<node id="PDF_18_Result_8810086388341940152">
  <data key="d0">Result</data>
  <data key="d1">RSV animals exhibited better motor abilities than the CTL group</data>
  <data key="d3">RSV animals exhibited better motor abilities than the CTL group</data>
  <data key="d4">PDF_18</data>
</node>
<node id="PDF_18_Result_-4438071127433426661">
  <data key="d0">Result</data>
  <data key="d1">In RSV animals, an age-related grey matter atrophy occurred in the amygdala as well as in Brodmann areas 13-16, 1-3 (primary somato-sensory area), and to a lesser extent in area 24 (anterior cingulate cortex)</data>
  <data key="d3">In RSV animals, an age-related grey matter atrophy occurred in the amygdala as well as in Brodmann areas 13-16, 1-3 (primary somato-sensory area), and to a lesser extent in area 24 (anterior cingulate cortex)</data>
  <data key="d4">PDF_18</data>
</node>
<node id="PDF_18_Result_491250402134037445">
  <data key="d0">Result</data>
  <data key="d1">White matter areas from posterior brain regions presented a marked atrophy in RSV</data>
  <data key="d3">White matter areas from posterior brain regions presented a marked atrophy in RSV</data>
  <data key="d4">PDF_18</data>
</node>
<node id="PDF_2">
  <data key="d0">Paper</data>
  <data key="d1">JCI INSIGHT
RESEARCH ARTICLE
Semaglutide lowers body weight in
rodents via distributed neural pathways
Sanaz Gabery,¹ Casper G. Salinas,¹ Sarah J. Paulsen, ¹ Jonas Ahnfelt-Rønne,¹ Tomas Alanentalo,¹ Arian
F. Baquero, Stephen T. Buckley,² Erzsébet Farkas, Csaba Fekete,³ Klaus S. Frederiksen,¹ Wouter
Frederik Johan Hogendorf, Hans Christian C. Helms,² Jacob F. Jeppesen,¹ Linu M. John,¹ Charles
Pyke,¹ Jane Nøhr,¹ Tess T. Lu,¹ Joseph Polex-Wolf,¹ Vincent Prevot, 4 Kirsten Raun,¹ Lotte Simonsen,¹
Gao</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_2_Hypothesis_-2070621026036629826">
  <data key="d0">Hypothesis</data>
  <data key="d1">GLP-1RAs may reduce food intake and BW through distributed effects in the CNS, rather than through a specific localized population of GLP-1Rs.</data>
  <data key="d3">GLP-1RAs may reduce food intake and BW through distributed effects in the CNS, rather than through a specific localized population of GLP-1Rs.</data>
  <data key="d4">PDF_2</data>
</node>
<node id="Protein_GLP-1R">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">GLP-1R</data>
  <data key="d7">GLP-1R</data>
</node>
<node id="PDF_2_Method_8186109347083392772">
  <data key="d0">Method</data>
  <data key="d1">DIO mice and rats fed a high-fat diet received semaglutide, administered subchronically, and the effects on food intake and BW were evaluated.</data>
  <data key="d3">DIO mice and rats fed a high-fat diet received semaglutide, administered subchronically, and the effects on food intake and BW were evaluated.</data>
  <data key="d4">PDF_2</data>
</node>
<node id="PDF_2_Result_-3239342030352855854">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide dose-dependently reduced BW and suppressed food intake in DIO mice.</data>
  <data key="d3">Semaglutide dose-dependently reduced BW and suppressed food intake in DIO mice.</data>
  <data key="d4">PDF_2</data>
</node>
<node id="PDF_2_Result_7307697403183768988">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide transiently reduced dark phase EE until day 6 of treatment.</data>
  <data key="d3">Semaglutide transiently reduced dark phase EE until day 6 of treatment.</data>
  <data key="d4">PDF_2</data>
</node>
<node id="PDF_2_Result_7724462909747946980">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide decreased chocolate intake compared with vehicle.</data>
  <data key="d3">Semaglutide decreased chocolate intake compared with vehicle.</data>
  <data key="d4">PDF_2</data>
</node>
<node id="PDF_2_Result_-5511250891358556857">
  <data key="d0">Result</data>
  <data key="d1">SemaglutideVT750 was observed in the choroid plexus</data>
  <data key="d3">SemaglutideVT750 was observed in the choroid plexus</data>
  <data key="d4">PDF_2</data>
</node>
<node id="PDF_2_Result_5262244793152732578">
  <data key="d0">Result</data>
  <data key="d1">GLP-1R was coexpressed with CART in the ARH.</data>
  <data key="d3">GLP-1R was coexpressed with CART in the ARH.</data>
  <data key="d4">PDF_2</data>
</node>
<node id="Gene_CART">
  <data key="d0">Entity</data>
  <data key="d5">Gene</data>
  <data key="d6">CART</data>
  <data key="d7">CART</data>
</node>
<node id="PDF_2_Result_5363330739030996411">
  <data key="d0">Result</data>
  <data key="d1">GLP-1R was highly coexpressed with somatostatin in the ARH and the LSc.</data>
  <data key="d3">GLP-1R was highly coexpressed with somatostatin in the ARH and the LSc.</data>
  <data key="d4">PDF_2</data>
</node>
<node id="Protein_SOMATOSTATIN">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">SOMATOSTATIN</data>
  <data key="d7">Somatostatin</data>
</node>
<node id="PDF_2_Result_-5931998345472062457">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide colocalized with GLP-1R, CART, SST, and TH in the ARH.</data>
  <data key="d3">Semaglutide colocalized with GLP-1R, CART, SST, and TH in the ARH.</data>
  <data key="d4">PDF_2</data>
</node>
<node id="Gene_SOMATOSTATIN">
  <data key="d0">Entity</data>
  <data key="d5">Gene</data>
  <data key="d6">SOMATOSTATIN</data>
  <data key="d7">Somatostatin</data>
</node>
<node id="Gene_TH">
  <data key="d0">Entity</data>
  <data key="d5">Gene</data>
  <data key="d6">TH</data>
  <data key="d7">TH</data>
</node>
<node id="PDF_2_Result_509783133794400544">
  <data key="d0">Result</data>
  <data key="d1">POMC/CART neurons were depolarized in response to semaglutide.</data>
  <data key="d3">POMC/CART neurons were depolarized in response to semaglutide.</data>
  <data key="d4">PDF_2</data>
</node>
<node id="Gene_POMC">
  <data key="d0">Entity</data>
  <data key="d5">Gene</data>
  <data key="d6">POMC</data>
  <data key="d7">POMC</data>
</node>
<node id="PDF_2_Result_-3638402075649209858">
  <data key="d0">Result</data>
  <data key="d1">NPY/AgRP neurons elicited membrane hyperpolarization and became inactivated in response to semaglutide.</data>
  <data key="d3">NPY/AgRP neurons elicited membrane hyperpolarization and became inactivated in response to semaglutide.</data>
  <data key="d4">PDF_2</data>
</node>
<node id="Gene_NPY">
  <data key="d0">Entity</data>
  <data key="d5">Gene</data>
  <data key="d6">NPY</data>
  <data key="d7">NPY</data>
</node>
<node id="Gene_AGRP">
  <data key="d0">Entity</data>
  <data key="d5">Gene</data>
  <data key="d6">AGRP</data>
  <data key="d7">AgRP</data>
</node>
<node id="PDF_2_Result_-6642779959515258451">
  <data key="d0">Result</data>
  <data key="d1">Increased c-Fos activity was observed in the bed nuclei of the stria terminalis, central amygdala nucleus, OV, parasubthalamic nucleus, SFO, midline group of the dorsal thalamus, PB, AP, DMX, and NTS after acute s.c. semaglutide</data>
  <data key="d3">Increased c-Fos activity was observed in the bed nuclei of the stria terminalis, central amygdala nucleus, OV, parasubthalamic nucleus, SFO, midline group of the dorsal thalamus, PB, AP, DMX, and NTS after acute s.c. semaglutide</data>
  <data key="d4">PDF_2</data>
</node>
<node id="Protein_C-FOS">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">C-FOS</data>
  <data key="d7">c-Fos</data>
</node>
<node id="PDF_2_Conclusion_2992662053797503356">
  <data key="d0">Conclusion</data>
  <data key="d1">Semaglutide lowers body weight by direct interaction with diverse GLP-1R populations and by directly and indirectly affecting the activity of neural pathways involved in food intake, reward, and energy expenditure.</data>
  <data key="d3">Semaglutide lowers body weight by direct interaction with diverse GLP-1R populations and by directly and indirectly affecting the activity of neural pathways involved in food intake, reward, and energy expenditure.</data>
  <data key="d4">PDF_2</data>
</node>
<node id="PDF_2_Conclusion_-5766293106915615546">
  <data key="d0">Conclusion</data>
  <data key="d1">These data demonstrate that peripherally injected semaglutide enters GLP-1R-positive neurons, which likely interface with central appetite regulation pathways.</data>
  <data key="d3">These data demonstrate that peripherally injected semaglutide enters GLP-1R-positive neurons, which likely interface with central appetite regulation pathways.</data>
  <data key="d4">PDF_2</data>
</node>
<node id="PDF_8">
  <data key="d0">Paper</data>
  <data key="d1">ELSEVIER
DIABETES RESEARCH AND CLINICAL PRACTICE 93 (2011) 410-420
Contents lists available at ScienceDirect
Diabetes Research
and Clinical Practice
journal homepage: www.elsevier.com/locate/diabres
International
Diabetes
Federation
DIABETES
RESEARCH AND
CLINICAL PRACTICE
Peptide complex containing GLP-1 exhibited long-acting
properties in the treatment of type 2 diabetes
Xuemin Zheng a,1, Ying Lib,1, Xin Li, Lida Tanga, Weiren Xud, Min Gong b,d,*
a Department of Pharmaceutical Analysis, Tianjin</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_8_Hypothesis_-2155207627074218973">
  <data key="d0">Hypothesis</data>
  <data key="d1">Peptides known as GLP-1 protectors are predicted to increase the half-life of GLP-1 in vivo.</data>
  <data key="d3">Peptides known as GLP-1 protectors are predicted to increase the half-life of GLP-1 in vivo.</data>
  <data key="d4">PDF_8</data>
</node>
<node id="Protein_GLP-1">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">GLP-1</data>
  <data key="d7">GLP-1</data>
</node>
<node id="PDF_8_Method_1964857229919188915">
  <data key="d0">Method</data>
  <data key="d1">GLP-1 and protecting peptides (peptide 1 or peptide 2) were mixed at various ratios and then incubated at 25 °C for 5 min.</data>
  <data key="d3">GLP-1 and protecting peptides (peptide 1 or peptide 2) were mixed at various ratios and then incubated at 25 °C for 5 min.</data>
  <data key="d4">PDF_8</data>
</node>
<node id="PDF_8_Method_9032079059677385326">
  <data key="d0">Method</data>
  <data key="d1">Sprague Dawley rats (n = 5 per group, male) were subcutaneously injected with GLP-1/peptide 1 (1:10, containing of 750 µg GLP-1/kg body weight) and GLP-1/peptide 2 (1:10, containing of 750 µg GLP-1/kg body weight), respectively.</data>
  <data key="d3">Sprague Dawley rats (n = 5 per group, male) were subcutaneously injected with GLP-1/peptide 1 (1:10, containing of 750 µg GLP-1/kg body weight) and GLP-1/peptide 2 (1:10, containing of 750 µg GLP-1/kg body weight), respectively.</data>
  <data key="d4">PDF_8</data>
</node>
<node id="PDF_8_Method_-4829911658522364862">
  <data key="d0">Method</data>
  <data key="d1">Male Zucker Diabetic Fatty (ZDF) rats (n = 6 per group) were treated with GLP-1/peptide 1 complex (GLP-1 ~300 µg/kg/4 days), exenatide (100 µg/kg/12 h) and liraglutide (300 µg/kg/ daily) for 28 days.</data>
  <data key="d3">Male Zucker Diabetic Fatty (ZDF) rats (n = 6 per group) were treated with GLP-1/peptide 1 complex (GLP-1 ~300 µg/kg/4 days), exenatide (100 µg/kg/12 h) and liraglutide (300 µg/kg/ daily) for 28 days.</data>
  <data key="d4">PDF_8</data>
</node>
<node id="Compound_EXENATIDE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">EXENATIDE</data>
  <data key="d7">exenatide</data>
</node>
<node id="Compound_LIRAGLUTIDE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">LIRAGLUTIDE</data>
  <data key="d7">Liraglutide</data>
</node>
<node id="PDF_8_Result_3531943023714543105">
  <data key="d0">Result</data>
  <data key="d1">The HPLC results predicted that the visible peak with a retention time of 18.8 min might be the GLP-1/ peptide 1 complex.</data>
  <data key="d3">The HPLC results predicted that the visible peak with a retention time of 18.8 min might be the GLP-1/ peptide 1 complex.</data>
  <data key="d4">PDF_8</data>
</node>
<node id="PDF_8_Result_-9175753306507436856">
  <data key="d0">Result</data>
  <data key="d1">The half-life of GLP-1 inside the GLP-1/peptide 1 complex was 90 h and inside the GLP-1/peptide 2 complex was 75 h in human serum. However, the half-life of the GLP-1 monomer was only 2.5 min.</data>
  <data key="d3">The half-life of GLP-1 inside the GLP-1/peptide 1 complex was 90 h and inside the GLP-1/peptide 2 complex was 75 h in human serum. However, the half-life of the GLP-1 monomer was only 2.5 min.</data>
  <data key="d4">PDF_8</data>
</node>
<node id="PDF_8_Result_-575873265780513373">
  <data key="d0">Result</data>
  <data key="d1">Data in Fig. 3B demonstrated that after a single dose administration in Sprague Dawley rats,there was a significant increase in the concentration of GLP-1.</data>
  <data key="d3">Data in Fig. 3B demonstrated that after a single dose administration in Sprague Dawley rats,there was a significant increase in the concentration of GLP-1.</data>
  <data key="d4">PDF_8</data>
</node>
<node id="PDF_8_Result_-1490347002616043120">
  <data key="d0">Result</data>
  <data key="d1">The concentration of GLP-1 reached a plateau at 10 h and gradually decreased but remained detectable until 150 h.</data>
  <data key="d3">The concentration of GLP-1 reached a plateau at 10 h and gradually decreased but remained detectable until 150 h.</data>
  <data key="d4">PDF_8</data>
</node>
<node id="PDF_8_Result_-5185130707825005661">
  <data key="d0">Result</data>
  <data key="d1">The secreted insulin level was dramatically raised to 956.7 37.84 pmol/l (GLP-1/peptide 1) and 827.9 31.40 pmol/l (GLP-1/peptide 2).</data>
  <data key="d3">The secreted insulin level was dramatically raised to 956.7 37.84 pmol/l (GLP-1/peptide 1) and 827.9 31.40 pmol/l (GLP-1/peptide 2).</data>
  <data key="d4">PDF_8</data>
</node>
<node id="Protein_INSULIN">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">INSULIN</data>
  <data key="d7">insulin</data>
</node>
<node id="PDF_8_Result_-1244192531941085761">
  <data key="d0">Result</data>
  <data key="d1">Compared to GLP-1 treated rats, there were 1.6-fold increases in the AUCglucose value of GLP-1/peptide complex treated rats (GLP-1/peptide and GLP-1/peptide 2, Fig. 5B).</data>
  <data key="d3">Compared to GLP-1 treated rats, there were 1.6-fold increases in the AUCglucose value of GLP-1/peptide complex treated rats (GLP-1/peptide and GLP-1/peptide 2, Fig. 5B).</data>
  <data key="d4">PDF_8</data>
</node>
<node id="PDF_8_Conclusion_5848802722130182223">
  <data key="d0">Conclusion</data>
  <data key="d1">Based upon these results, it is suggested that the GLP-1/peptide 1 complex might be utilized as a possible potent anti-diabetic drug in the treatment of type 2 diabetes mellitus.</data>
  <data key="d3">Based upon these results, it is suggested that the GLP-1/peptide 1 complex might be utilized as a possible potent anti-diabetic drug in the treatment of type 2 diabetes mellitus.</data>
  <data key="d4">PDF_8</data>
</node>
<node id="PDF_20">
  <data key="d0">Paper</data>
  <data key="d1">SCIENTIFIC
REPORTS

OPEN
SUBJECT AREAS:
DRUG DEVELOPMENT
NATURAL PRODUCTS

Received
2 September 2014

Accepted
5 January 2015

Published
28 January 2015

Correspondence and
requests for materials
should be addressed to
A.K.S. (Shetty@
medicine.tamhsc.edu)

* These authors
contributed equally to
this work.

† Current address:
Department of
Radiation Oncology,
Univ California Irvine.

Resveratrol Prevents Age-Related
Memory and Mood Dysfunction with
Increased Hippocampal Neurogenesis
and Microvasc</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_20_Hypothesis_-5301540700550017463">
  <data key="d0">Hypothesis</data>
  <data key="d1">Resveratrol can counteract age-related memory and mood impairments and the associated detrimental changes in the hippocampus.</data>
  <data key="d3">Resveratrol can counteract age-related memory and mood impairments and the associated detrimental changes in the hippocampus.</data>
  <data key="d4">PDF_20</data>
</node>
<node id="PDF_20_Method_6161906745008828660">
  <data key="d0">Method</data>
  <data key="d1">Two groups of male F344 rats in late middle-age having similar learning and memory abilities were chosen and treated with resveratrol or vehicle for four weeks.</data>
  <data key="d3">Two groups of male F344 rats in late middle-age having similar learning and memory abilities were chosen and treated with resveratrol or vehicle for four weeks.</data>
  <data key="d4">PDF_20</data>
</node>
<node id="PDF_20_Result_6101583909347351880">
  <data key="d0">Result</data>
  <data key="d1">Analyses at ~25 months of age uncovered improved learning, memory and mood function in resveratrol-treated animals but impairments in vehicle-treated animals.</data>
  <data key="d3">Analyses at ~25 months of age uncovered improved learning, memory and mood function in resveratrol-treated animals but impairments in vehicle-treated animals.</data>
  <data key="d4">PDF_20</data>
</node>
<node id="PDF_20_Result_-6598078894435798902">
  <data key="d0">Result</data>
  <data key="d1">Resveratrol-treated animals also displayed increased net neurogenesis and microvasculature, and diminished astrocyte hypertrophy and microglial activation in the hippocampus.</data>
  <data key="d3">Resveratrol-treated animals also displayed increased net neurogenesis and microvasculature, and diminished astrocyte hypertrophy and microglial activation in the hippocampus.</data>
  <data key="d4">PDF_20</data>
</node>
<node id="PDF_20_Conclusion_-7391324592977041247">
  <data key="d0">Conclusion</data>
  <data key="d1">Resveratrol treatment in late middle age is efficacious for improving memory and mood function in old age.</data>
  <data key="d3">Resveratrol treatment in late middle age is efficacious for improving memory and mood function in old age.</data>
  <data key="d4">PDF_20</data>
</node>
<node id="PDF_20_Result_-1236927307856544601">
  <data key="d0">Result</data>
  <data key="d1">RESV treatment enhanced net neurogenesis in the hippocampus of aged rats.</data>
  <data key="d3">RESV treatment enhanced net neurogenesis in the hippocampus of aged rats.</data>
  <data key="d4">PDF_20</data>
</node>
<node id="PDF_20_Result_-3905280296332344895">
  <data key="d0">Result</data>
  <data key="d1">RESV treatment promoted increased neurogenesis in aged rats for prolonged periods.</data>
  <data key="d3">RESV treatment promoted increased neurogenesis in aged rats for prolonged periods.</data>
  <data key="d4">PDF_20</data>
</node>
<node id="PDF_20_Result_-5082324705917866817">
  <data key="d0">Result</data>
  <data key="d1">RESV treatment enhanced microvasculature in the hippocampus of aged rats.</data>
  <data key="d3">RESV treatment enhanced microvasculature in the hippocampus of aged rats.</data>
  <data key="d4">PDF_20</data>
</node>
<node id="PDF_20_Result_-2458969671575563981">
  <data key="d0">Result</data>
  <data key="d1">RESV treatment reduced the hypertrophy of astrocytes in aged rats.</data>
  <data key="d3">RESV treatment reduced the hypertrophy of astrocytes in aged rats.</data>
  <data key="d4">PDF_20</data>
</node>
<node id="PDF_20_Result_1639635215569233018">
  <data key="d0">Result</data>
  <data key="d1">RESV treatment reduced activation of microglia in aged rats.</data>
  <data key="d3">RESV treatment reduced activation of microglia in aged rats.</data>
  <data key="d4">PDF_20</data>
</node>
<node id="PDF_20_Result_5320510106815831434">
  <data key="d0">Result</data>
  <data key="d1">RESV treatment did not alter the volume of hippocampus.</data>
  <data key="d3">RESV treatment did not alter the volume of hippocampus.</data>
  <data key="d4">PDF_20</data>
</node>
<node id="PDF_20_Result_-2312552359889964690">
  <data key="d0">Result</data>
  <data key="d1">RESV treatment improved mood function in aged rats.</data>
  <data key="d3">RESV treatment improved mood function in aged rats.</data>
  <data key="d4">PDF_20</data>
</node>
<node id="PDF_20_Method_7481165225366016652">
  <data key="d0">Method</data>
  <data key="d1">Analyses of immobility (or floating) time in a forced swim test (FST) was used as a measure of depressive-like behavior in VEH and RESV treated rats</data>
  <data key="d3">Analyses of immobility (or floating) time in a forced swim test (FST) was used as a measure of depressive-like behavior in VEH and RESV treated rats</data>
  <data key="d4">PDF_20</data>
</node>
<node id="PDF_20_Result_2005892203652200507">
  <data key="d0">Result</data>
  <data key="d1">RESV treatment enhanced net neurogenesis in the last week of RESV treatment, and maintained increased neurogenesis and microvasculature when examined at ~25 months of age (i.e. ~6 weeks after the termination of RESV treatment).</data>
  <data key="d3">RESV treatment enhanced net neurogenesis in the last week of RESV treatment, and maintained increased neurogenesis and microvasculature when examined at ~25 months of age (i.e. ~6 weeks after the termination of RESV treatment).</data>
  <data key="d4">PDF_20</data>
</node>
<node id="PDF_7">
  <data key="d0">Paper</data>
  <data key="d1">nature medicine
Article
a
https://doi.org/10.1038/s41591-024-03355-2
Proteomic changes upon treatment with
semaglutide in individuals with obesity
Received: 22 March 2024
Accepted: 14 October 2024
Published online: 3 January 2025
Check for updates
Lasse Maretty1,11, Dipender Gill 2,3, Lotte Simonsen, Keng Soh',
Loukas Zagkos2, Michael Galanakis¹5, Jonas Sibbesen¹,
Miquel Triana Iglesias¹, Anna Secher, Dirk Valkenborg,
Jonathan Q. Purnell, Lotte Bjerre Knudsen, Abd A. Tahrani 9,10,13 &amp;
Milan Geyb</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_7_Result_-3090687357896771049">
  <data key="d0">Result</data>
  <data key="d1">After 68 weeks of treatment, 495 protein targets (438 unique proteins) were identified to be significantly affected by semaglutide treatment (compared with placebo) in STEP 1 (P &lt;0.05, after Holm-Bonferroni correction for the 7,289 aptamers tested). In the STEP 2 trial, the relative abundance of 277 protein targets (244 unique proteins) was changed significantly in response to semaglutide treatment relative to placebo.</data>
  <data key="d3">After 68 weeks of treatment, 495 protein targets (438 unique proteins) were identified to be significantly affected by semaglutide treatment (compared with placebo) in STEP 1 (P &lt;0.05, after Holm-Bonferroni correction for the 7,289 aptamers tested). In the STEP 2 trial, the relative abundance of 277 protein targets (244 unique proteins) was changed significantly in response to semaglutide treatment relative to placebo.</data>
  <data key="d4">PDF_7</data>
</node>
<node id="PDF_7_Result_4746371245348940570">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide treatment downregulated proteins involved in key biological pathways governing xenobiotic metabolism, fatty acid metabolism and mammalian target of rapamycin complex 1 (MTORC1) signaling, among others.</data>
  <data key="d3">Semaglutide treatment downregulated proteins involved in key biological pathways governing xenobiotic metabolism, fatty acid metabolism and mammalian target of rapamycin complex 1 (MTORC1) signaling, among others.</data>
  <data key="d4">PDF_7</data>
</node>
<node id="Protein_MTORC1">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">MTORC1</data>
  <data key="d7">MTORC1</data>
</node>
<node id="PDF_7_Result_7075294896616740654">
  <data key="d0">Result</data>
  <data key="d1">Levels of digestive enzymes secreted from the exocrine pancreas were increased by semaglutide.</data>
  <data key="d3">Levels of digestive enzymes secreted from the exocrine pancreas were increased by semaglutide.</data>
  <data key="d4">PDF_7</data>
</node>
<node id="PDF_7_Result_7945670712715370278">
  <data key="d0">Result</data>
  <data key="d1">Adjusting for body weight and HbA1c changes at the end of treatment identified 47 (38 unique proteins) and 15 (14 unique proteins) protein targets significantly altered by semaglutide treatment in STEP 1 and STEP 2, respectively.</data>
  <data key="d3">Adjusting for body weight and HbA1c changes at the end of treatment identified 47 (38 unique proteins) and 15 (14 unique proteins) protein targets significantly altered by semaglutide treatment in STEP 1 and STEP 2, respectively.</data>
  <data key="d4">PDF_7</data>
</node>
<node id="PDF_7_Result_-4324159728268611067">
  <data key="d0">Result</data>
  <data key="d1">Significantly downregulated proteins when adjusting for body weight effects in STEP 1 known to be associated with CVD risk included tenascin C (TNC), NT-proBNP, thrombospondin 2 (THBS2), complement component C1q receptor (cluster of differentiation 93 (CD93)), macrophage scavenger receptor 1-extra- cellular domain (MSR1) and angiopoietin-2 (ANGPT2).</data>
  <data key="d3">Significantly downregulated proteins when adjusting for body weight effects in STEP 1 known to be associated with CVD risk included tenascin C (TNC), NT-proBNP, thrombospondin 2 (THBS2), complement component C1q receptor (cluster of differentiation 93 (CD93)), macrophage scavenger receptor 1-extra- cellular domain (MSR1) and angiopoietin-2 (ANGPT2).</data>
  <data key="d4">PDF_7</data>
</node>
<node id="Protein_TNC">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">TNC</data>
  <data key="d7">TNC</data>
</node>
<node id="Protein_THBS2">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">THBS2</data>
  <data key="d7">THBS2</data>
</node>
<node id="Protein_ANGPT2">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">ANGPT2</data>
  <data key="d7">ANGPT2</data>
</node>
<node id="PDF_7_Result_-2500740769242565691">
  <data key="d0">Result</data>
  <data key="d1">The final trained signature included 30 aptamers (Extended Data Fig. 4a). The signature included proteins implicated in biological processes related to obesity and T2D (for example, adipogenesis, fatty acid metabolism, glycolysis and signaling pathways), consistent with the protein set analysis described above (Extended Data Fig. 2a), along with proteins related to fat mass and function, weight loss, CVD, endothelial function, lipid metabolism, pancreatic endocrine and exocrine function, inflammation and possibly cancer risk. The STEP 1 signature had a high classification performance (internal nested cross-validation area under the curve (AUC) = 0.94), showing that semaglutide treatment results in a specific serum proteomic signature.</data>
  <data key="d3">The final trained signature included 30 aptamers (Extended Data Fig. 4a). The signature included proteins implicated in biological processes related to obesity and T2D (for example, adipogenesis, fatty acid metabolism, glycolysis and signaling pathways), consistent with the protein set analysis described above (Extended Data Fig. 2a), along with proteins related to fat mass and function, weight loss, CVD, endothelial function, lipid metabolism, pancreatic endocrine and exocrine function, inflammation and possibly cancer risk. The STEP 1 signature had a high classification performance (internal nested cross-validation area under the curve (AUC) = 0.94), showing that semaglutide treatment results in a specific serum proteomic signature.</data>
  <data key="d4">PDF_7</data>
</node>
<node id="PDF_7_Result_-181240583450137585">
  <data key="d0">Result</data>
  <data key="d1">Using data from STEP 1 and STEP 2, we found that semaglutide treatment reduced this CVD risk score compared with placebo</data>
  <data key="d3">Using data from STEP 1 and STEP 2, we found that semaglutide treatment reduced this CVD risk score compared with placebo</data>
  <data key="d4">PDF_7</data>
</node>
<node id="PDF_7_Result_8316280004690137734">
  <data key="d0">Result</data>
  <data key="d1">Proteins that were significantly elevated with higher genetic risk for increased BMI or T2D in the deCODE population were significantly downregulated by semaglutide and vice versa.</data>
  <data key="d3">Proteins that were significantly elevated with higher genetic risk for increased BMI or T2D in the deCODE population were significantly downregulated by semaglutide and vice versa.</data>
  <data key="d4">PDF_7</data>
</node>
<node id="PDF_7_Conclusion_-163162194050676099">
  <data key="d0">Conclusion</data>
  <data key="d1">Semaglutide might lower CVD risk, even in populations without established CVD.</data>
  <data key="d3">Semaglutide might lower CVD risk, even in populations without established CVD.</data>
  <data key="d4">PDF_7</data>
</node>
<node id="PDF_7_Conclusion_5799145113198410169">
  <data key="d0">Conclusion</data>
  <data key="d1">Analyses of the clinical trial data also support effects of semaglutide beyond those that can be explained by the observed weight loss and HbA1c reductions.</data>
  <data key="d3">Analyses of the clinical trial data also support effects of semaglutide beyond those that can be explained by the observed weight loss and HbA1c reductions.</data>
  <data key="d4">PDF_7</data>
</node>
<node id="PDF_9">
  <data key="d0">Paper</data>
  <data key="d1">The text from the scientific PDF is as follows:

Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1
(IDO1) Inhibitors
Ute F. Röhrig,*,† Somi Reddy Majjigapu, *,* u,*,* Pierre Vogel,*$ Vincent Zoete,*,† and Olivier Michielin*,†,||,$
*Molecular Modeling Group, SIB Swiss Institute of Bioinformatics, CH-1015 Lausanne, Switzerland
*Laboratory of Glycochemistry and Asymmetric Synthesis, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne,
Switzerland
Ludwig Center for Cancer Re</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_9_Method_-1688702638989591655">
  <data key="d0">Method</data>
  <data key="d1">Enzymatic assays were performed to determine IDO1 inhibitory activity of small organic molecules using a specific incubation medium composition.</data>
  <data key="d3">Enzymatic assays were performed to determine IDO1 inhibitory activity of small organic molecules using a specific incubation medium composition.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="Protein_IDO1">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">IDO1</data>
  <data key="d7">IDO1</data>
</node>
<node id="PDF_9_Method_375044847436254170">
  <data key="d0">Method</data>
  <data key="d1">IDO1 inhibition was assessed using purified ferric IDO1 reduced by ascorbic acid, with methylene blue as an electron carrier and catalase to prevent inhibition by H2O2.</data>
  <data key="d3">IDO1 inhibition was assessed using purified ferric IDO1 reduced by ascorbic acid, with methylene blue as an electron carrier and catalase to prevent inhibition by H2O2.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Method_9055882207821409057">
  <data key="d0">Method</data>
  <data key="d1">Redox-cycling compounds were screened to identify potential IDO1 inhibitors.</data>
  <data key="d3">Redox-cycling compounds were screened to identify potential IDO1 inhibitors.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Method_805948597297295883">
  <data key="d0">Method</data>
  <data key="d1">The 2,2-diphenyl-1-picrylhydrazyl (DPPH) antioxidant assay was used to investigate redox-cycling properties of IDO1 inhibitors.</data>
  <data key="d3">The 2,2-diphenyl-1-picrylhydrazyl (DPPH) antioxidant assay was used to investigate redox-cycling properties of IDO1 inhibitors.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Method_-1823932813714502215">
  <data key="d0">Method</data>
  <data key="d1">HPLC was used to precisely monitor the amount of L-Trp breakdown by quantifying kynurenine and L-Trp after acidification and hydrolysis of NFK.</data>
  <data key="d3">HPLC was used to precisely monitor the amount of L-Trp breakdown by quantifying kynurenine and L-Trp after acidification and hydrolysis of NFK.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Method_-3336356305181547916">
  <data key="d0">Method</data>
  <data key="d1">Spectroscopic detection without prior separation was used to detect NFK or kynurenine.</data>
  <data key="d3">Spectroscopic detection without prior separation was used to detect NFK or kynurenine.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Method_-5482894651495804418">
  <data key="d0">Method</data>
  <data key="d1">Kynurenine was reacted with p-dimethylaminobenzaldehyde (pDMAB), also called Ehrlich's reagent, to produce a compound with an absorption maximum at 480 nm.</data>
  <data key="d3">Kynurenine was reacted with p-dimethylaminobenzaldehyde (pDMAB), also called Ehrlich's reagent, to produce a compound with an absorption maximum at 480 nm.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Method_-5703729735610551584">
  <data key="d0">Method</data>
  <data key="d1">Cellular assays were performed to assess IDO1 inhibition in a cellular context.</data>
  <data key="d3">Cellular assays were performed to assess IDO1 inhibition in a cellular context.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Method_-9073987393270922306">
  <data key="d0">Method</data>
  <data key="d1">Cell viability was measured using tetrazolium reduction assays with MTT or MTS.</data>
  <data key="d3">Cell viability was measured using tetrazolium reduction assays with MTT or MTS.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Method_-6087577049620300557">
  <data key="d0">Method</data>
  <data key="d1">Alternative tests such as the trypan blue exclusion assay, the lactate dehydrogenase (LDH) assay, the sulforhodamine B (SRB) assay, and an ATP assay were used to validate cellular dose-response curves on IDO1.</data>
  <data key="d3">Alternative tests such as the trypan blue exclusion assay, the lactate dehydrogenase (LDH) assay, the sulforhodamine B (SRB) assay, and an ATP assay were used to validate cellular dose-response curves on IDO1.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Method_-3080344647673332069">
  <data key="d0">Method</data>
  <data key="d1">Structure-based in silico design of IDO1 inhibitors was performed based on crystal structures.</data>
  <data key="d3">Structure-based in silico design of IDO1 inhibitors was performed based on crystal structures.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Method_-7413824123133422542">
  <data key="d0">Method</data>
  <data key="d1">Docking studies were conducted to predict binding modes of IDO1 inhibitors.</data>
  <data key="d3">Docking studies were conducted to predict binding modes of IDO1 inhibitors.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Method_2768604988970750107">
  <data key="d0">Method</data>
  <data key="d1">High throughput screening (HTS) was used to discover new IDO1 inhibitor scaffolds.</data>
  <data key="d3">High throughput screening (HTS) was used to discover new IDO1 inhibitor scaffolds.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Method_4202996321749210489">
  <data key="d0">Method</data>
  <data key="d1">Differential scanning fluorimetry was used to screen for IDO1 binding.</data>
  <data key="d3">Differential scanning fluorimetry was used to screen for IDO1 binding.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Method_-7476481780943625109">
  <data key="d0">Method</data>
  <data key="d1">Yeast growth assays were used to identify IDO1 inhibitors.</data>
  <data key="d3">Yeast growth assays were used to identify IDO1 inhibitors.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Result_2019945866185237103">
  <data key="d0">Result</data>
  <data key="d1">Many compounds showed IDO1 inhibitory activity through unspecific mechanisms.</data>
  <data key="d3">Many compounds showed IDO1 inhibitory activity through unspecific mechanisms.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Result_607836368851484092">
  <data key="d0">Result</data>
  <data key="d1">Isothiazolinone derivatives probably inhibit IDO1 through covalent modification of nucleophilic amino acid side chains.</data>
  <data key="d3">Isothiazolinone derivatives probably inhibit IDO1 through covalent modification of nucleophilic amino acid side chains.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Result_-4673995192671679884">
  <data key="d0">Result</data>
  <data key="d1">The binding of the selenic compound ebselen to cysteine residues of IDO1 shifts the Soret band of ferric IDO1.</data>
  <data key="d3">The binding of the selenic compound ebselen to cysteine residues of IDO1 shifts the Soret band of ferric IDO1.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Result_-1450192277327488715">
  <data key="d0">Result</data>
  <data key="d1">IDO1 activity is modulated by antioxidants both at the transcriptional level and posttranslationally by limiting the availability of heme.</data>
  <data key="d3">IDO1 activity is modulated by antioxidants both at the transcriptional level and posttranslationally by limiting the availability of heme.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Result_-258544749106952487">
  <data key="d0">Result</data>
  <data key="d1">Some quinones and iminoquinones display cellular IC50 values much higher than their enzymatic IC50 values and close to their LD50 values, suggesting that the prevention of L-Trp to NFK oxidation could result from perturbing the cells' redox state instead of specific inhibition of IDO1.</data>
  <data key="d3">Some quinones and iminoquinones display cellular IC50 values much higher than their enzymatic IC50 values and close to their LD50 values, suggesting that the prevention of L-Trp to NFK oxidation could result from perturbing the cells' redox state instead of specific inhibition of IDO1.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Result_-1260085640156065862">
  <data key="d0">Result</data>
  <data key="d1">For N-hydroxyamidines or 4-phenyl-1,2,3-triazoles, cellular IC50 values were somewhat lower than the corresponding enzymatic values.</data>
  <data key="d3">For N-hydroxyamidines or 4-phenyl-1,2,3-triazoles, cellular IC50 values were somewhat lower than the corresponding enzymatic values.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Result_3182651631102266101">
  <data key="d0">Result</data>
  <data key="d1">High side chain and backbone flexibility lead to different active site conformations of IDO1.</data>
  <data key="d3">High side chain and backbone flexibility lead to different active site conformations of IDO1.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Result_3539517018661627335">
  <data key="d0">Result</data>
  <data key="d1">Conflicting binding modes have been reported for L-Trp, 2-mercapto-benzothiazole, and 4-phenyl-1,2,3-triazole.</data>
  <data key="d3">Conflicting binding modes have been reported for L-Trp, 2-mercapto-benzothiazole, and 4-phenyl-1,2,3-triazole.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Conclusion_679698040799210895">
  <data key="d0">Conclusion</data>
  <data key="d1">Kinetic measurements with variable L-Trp concentrations do not yield direct information if a compound binds to the IDO1 active site or not.</data>
  <data key="d3">Kinetic measurements with variable L-Trp concentrations do not yield direct information if a compound binds to the IDO1 active site or not.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_9_Conclusion_9195966159291304153">
  <data key="d0">Conclusion</data>
  <data key="d1">Caution should be used when interpreting docking results, taking into account that protein flexibility and heme interactions could be ill-described within the chosen approach.</data>
  <data key="d3">Caution should be used when interpreting docking results, taking into account that protein flexibility and heme interactions could be ill-described within the chosen approach.</data>
  <data key="d4">PDF_9</data>
</node>
<node id="PDF_10">
  <data key="d0">Paper</data>
  <data key="d1">Here is the complete text from the scientific PDF you provided, with all sections included as requested:

**The Journal of Clinical Investigation**

**RESEARCH ARTICLE**

**The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss**

Anna Secher,¹ Jacob Jelsing,¹ Arian F. Baquero,³ Jacob Hecksher-Sørensen,¹ Michael A. Cowley, Louise S. Dalbøge,2
Gitte Hansen,² Kevin L. Grove, Charles Pyke,¹ Kirsten Raun,¹ Lauge Schäffer,¹ Mads Tang-Christensen,¹ Saurabh Verma,³
Brent </data>
  <data key="d2">2024</data>
</node>
<node id="PDF_10_Hypothesis_1118222127013157452">
  <data key="d0">Hypothesis</data>
  <data key="d1">GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
  <data key="d3">GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
  <data key="d4">PDF_10</data>
</node>
<node id="PDF_10_Method_-5097182521296068159">
  <data key="d0">Method</data>
  <data key="d1">Peripheral injection of fluorescently labeled liraglutide in mice revealed the presence of the drug in the circumventricular organs.</data>
  <data key="d3">Peripheral injection of fluorescently labeled liraglutide in mice revealed the presence of the drug in the circumventricular organs.</data>
  <data key="d4">PDF_10</data>
</node>
<node id="PDF_10_Method_4648609706086463165">
  <data key="d0">Method</data>
  <data key="d1">Electrophysiological measurements of murine brain slices revealed that GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling.</data>
  <data key="d3">Electrophysiological measurements of murine brain slices revealed that GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling.</data>
  <data key="d4">PDF_10</data>
</node>
<node id="Compound_GLP-1">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">GLP-1</data>
  <data key="d7">GLP-1</data>
</node>
<node id="Compound_GABA">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">GABA</data>
  <data key="d7">GABA</data>
</node>
<node id="PDF_10_Result_676263553865618409">
  <data key="d0">Result</data>
  <data key="d1">Liraglutide treatment significantly increased the mean Cart mRNA levels in the ARC 1.6-fold compared with both vehicle-treated, ad libitum-fed rats and weight-matched rats (P&lt;0.001, liraglutide vs. vehicle and vs. weight-matched), whereas Pomc expression was unaffected.</data>
  <data key="d3">Liraglutide treatment significantly increased the mean Cart mRNA levels in the ARC 1.6-fold compared with both vehicle-treated, ad libitum-fed rats and weight-matched rats (P&lt;0.001, liraglutide vs. vehicle and vs. weight-matched), whereas Pomc expression was unaffected.</data>
  <data key="d4">PDF_10</data>
</node>
<node id="PDF_10_Result_3012633037109734960">
  <data key="d0">Result</data>
  <data key="d1">A 1.4-fold increase in Npy mRNA levels and a 1.7-fold increase in Agrp mRNA levels were observed in weight-matched rats, while levels were unaltered following treatment with liraglutide (P &lt; 0.05, weight matched vs. vehicle and vs. liraglutide, Figure 2B), suggesting an ability of liraglutide to suppress the food-deprived hunger signals observed in the weight-matched control group.</data>
  <data key="d3">A 1.4-fold increase in Npy mRNA levels and a 1.7-fold increase in Agrp mRNA levels were observed in weight-matched rats, while levels were unaltered following treatment with liraglutide (P &lt; 0.05, weight matched vs. vehicle and vs. liraglutide, Figure 2B), suggesting an ability of liraglutide to suppress the food-deprived hunger signals observed in the weight-matched control group.</data>
  <data key="d4">PDF_10</data>
</node>
<node id="PDF_10_Result_-4375520179359696923">
  <data key="d0">Result</data>
  <data key="d1">GLP-1(7-36)amide (10 nM) caused a substantial outward current in NPY cells</data>
  <data key="d3">GLP-1(7-36)amide (10 nM) caused a substantial outward current in NPY cells</data>
  <data key="d4">PDF_10</data>
</node>
<node id="PDF_10_Result_4000361962435329222">
  <data key="d0">Result</data>
  <data key="d1">GLP-1(7-36)amide failed to change the current in the presence of bicuculline, demonstrating that GABA-A receptor activation was likely responsible for the inhibitory effects of GLP-1(7-36)amide on NPY neurons.</data>
  <data key="d3">GLP-1(7-36)amide failed to change the current in the presence of bicuculline, demonstrating that GABA-A receptor activation was likely responsible for the inhibitory effects of GLP-1(7-36)amide on NPY neurons.</data>
  <data key="d4">PDF_10</data>
</node>
<node id="Protein_GABA-A">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">GABA-A</data>
  <data key="d7">GABA-A</data>
</node>
<node id="PDF_10_Result_-4888990278513477082">
  <data key="d0">Result</data>
  <data key="d1">administration of liraglutide750 (s.c. 400 µg/kg) to Glp1r-/- mice revealed a loss of these nuclei-specific signals, demonstrating that the accumulation of the liraglutide750 signal entirely depends on binding of liraglutide750 to the GLP-1R.</data>
  <data key="d3">administration of liraglutide750 (s.c. 400 µg/kg) to Glp1r-/- mice revealed a loss of these nuclei-specific signals, demonstrating that the accumulation of the liraglutide750 signal entirely depends on binding of liraglutide750 to the GLP-1R.</data>
  <data key="d4">PDF_10</data>
</node>
<node id="PDF_10_Result_-8052761423405053473">
  <data key="d0">Result</data>
  <data key="d1">In hypothalamic ARC neurons, liraglutide appeared to be internalized, as in pancreatic ẞ cells</data>
  <data key="d3">In hypothalamic ARC neurons, liraglutide appeared to be internalized, as in pancreatic ẞ cells</data>
  <data key="d4">PDF_10</data>
</node>
<node id="PDF_10_Result_-2631523302642105631">
  <data key="d0">Result</data>
  <data key="d1">GLP-1R were expressed on virtually all POMC/CART neurons</data>
  <data key="d3">GLP-1R were expressed on virtually all POMC/CART neurons</data>
  <data key="d4">PDF_10</data>
</node>
<node id="PDF_10_Result_-61111773155434910">
  <data key="d0">Result</data>
  <data key="d1">Stimulation with GLP-1(7-36)amide dose dependently depolarized POMC neurons (5.3 ± 0.7 mV and 8.4 ± 1.4 mV for 10 and 100 nM, respectively) and increased the frequency of action potentials in 7 of 7 cells from 2 animals</data>
  <data key="d3">Stimulation with GLP-1(7-36)amide dose dependently depolarized POMC neurons (5.3 ± 0.7 mV and 8.4 ± 1.4 mV for 10 and 100 nM, respectively) and increased the frequency of action potentials in 7 of 7 cells from 2 animals</data>
  <data key="d4">PDF_10</data>
</node>
<node id="PDF_10_Conclusion_-7323234921176164086">
  <data key="d0">Conclusion</data>
  <data key="d1">the long-acting GLP-1R ago- nist liraglutide, when injected peripherally, targets hypothalamic GLP-1Rs located on ARC neurons and that these neurons are likely mediators of liraglutide-induced weight loss</data>
  <data key="d3">the long-acting GLP-1R ago- nist liraglutide, when injected peripherally, targets hypothalamic GLP-1Rs located on ARC neurons and that these neurons are likely mediators of liraglutide-induced weight loss</data>
  <data key="d4">PDF_10</data>
</node>
<node id="PDF_10_Conclusion_7228628183724661220">
  <data key="d0">Conclusion</data>
  <data key="d1">Our data collectively indicate that GLP-1Rs in the ARC could play an important role as mediators of the long-term body weight- lowering effects of a peripherally administered long-acting GLP-1 analog-in this case liraglutide</data>
  <data key="d3">Our data collectively indicate that GLP-1Rs in the ARC could play an important role as mediators of the long-term body weight- lowering effects of a peripherally administered long-acting GLP-1 analog-in this case liraglutide</data>
  <data key="d4">PDF_10</data>
</node>
<node id="PDF_5">
  <data key="d0">Paper</data>
  <data key="d1">Here is the complete text from the scientific PDF, as requested:

www.nature.com/scientificreports

scientific reports
OPEN A GLP1 receptor agonist
Check for updates
diabetes drug ameliorates
neurodegeneration in a mouse
model of infantile neurometabolic
disease
L. Poupon-Bejuit1,2, M. P. Hughes1,2, W. Liu¹, A. Geard¹, N. Faour-Slika¹, S. Whaler¹,
G. Massaro1 &amp; A. A. Rahim1
Infantile neuroaxonal dystrophy (INAD) is a rare paediatric neurodegenerative condition caused by
mutations in the PLA2G6 g</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_5_Hypothesis_3983644344882168355">
  <data key="d0">Hypothesis</data>
  <data key="d1">GLP-1R agonist diabetes drug can ameliorate neurodegeneration in a mouse model of infantile neurometabolic disease.</data>
  <data key="d3">GLP-1R agonist diabetes drug can ameliorate neurodegeneration in a mouse model of infantile neurometabolic disease.</data>
  <data key="d4">PDF_5</data>
</node>
<node id="PDF_5_Method_-7437006454939263303">
  <data key="d0">Method</data>
  <data key="d1">Semaglutide was administered systemically at a high dose weekly to juvenile INAD mice.</data>
  <data key="d3">Semaglutide was administered systemically at a high dose weekly to juvenile INAD mice.</data>
  <data key="d4">PDF_5</data>
</node>
<node id="PDF_5_Result_486879588226485803">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide treatment significantly increased levels of key neuroprotective molecules while decreasing those involved in pro-neurodegenerative pathways.</data>
  <data key="d3">Semaglutide treatment significantly increased levels of key neuroprotective molecules while decreasing those involved in pro-neurodegenerative pathways.</data>
  <data key="d4">PDF_5</data>
</node>
<node id="PDF_5_Result_-2859336671449135130">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide treatment extended lifespan and rescued locomotor functions in a mouse model of INAD.</data>
  <data key="d3">Semaglutide treatment extended lifespan and rescued locomotor functions in a mouse model of INAD.</data>
  <data key="d4">PDF_5</data>
</node>
<node id="PDF_5_Result_-6195138621265668278">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide treatment resulted in a significant increase in GLP-1R expression in Pla2g6-/- mice.</data>
  <data key="d3">Semaglutide treatment resulted in a significant increase in GLP-1R expression in Pla2g6-/- mice.</data>
  <data key="d4">PDF_5</data>
</node>
<node id="Gene_PLA2G6">
  <data key="d0">Entity</data>
  <data key="d5">Gene</data>
  <data key="d6">PLA2G6</data>
  <data key="d7">PLA2G6</data>
</node>
<node id="PDF_5_Result_-6716606027273492474">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide treatment resulted in a significant reduction in mRNA levels of ATF-3 compared to untreated Pla2g6-/- mice.</data>
  <data key="d3">Semaglutide treatment resulted in a significant reduction in mRNA levels of ATF-3 compared to untreated Pla2g6-/- mice.</data>
  <data key="d4">PDF_5</data>
</node>
<node id="Protein_ATF-3">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">ATF-3</data>
  <data key="d7">ATF-3</data>
</node>
<node id="PDF_5_Result_-8964148140503980180">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide treatment ameliorated levels of GSK3β to those measured in wild-type controls and showed a significant difference compared to age-matched untreated Pla2g6-/- mice.</data>
  <data key="d3">Semaglutide treatment ameliorated levels of GSK3β to those measured in wild-type controls and showed a significant difference compared to age-matched untreated Pla2g6-/- mice.</data>
  <data key="d4">PDF_5</data>
</node>
<node id="Protein_GSK3B">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">GSK3B</data>
  <data key="d7">GSK3B</data>
</node>
<node id="PDF_5_Result_2212965905093549929">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide treatment significantly increased CREB mRNA levels compared to untreated Pla2g6-/- mice and restored expression levels to those observed in the wild-type controls.</data>
  <data key="d3">Semaglutide treatment significantly increased CREB mRNA levels compared to untreated Pla2g6-/- mice and restored expression levels to those observed in the wild-type controls.</data>
  <data key="d4">PDF_5</data>
</node>
<node id="Protein_CREB">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">CREB</data>
  <data key="d7">CREB</data>
</node>
<node id="PDF_5_Result_924721623483609916">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide treatment resulted in amelioration of neuronal loss, with significantly higher numbers of neurons observed in the treated group compared to untreated controls in the cortex (S1BF).</data>
  <data key="d3">Semaglutide treatment resulted in amelioration of neuronal loss, with significantly higher numbers of neurons observed in the treated group compared to untreated controls in the cortex (S1BF).</data>
  <data key="d4">PDF_5</data>
</node>
<node id="PDF_5_Result_-1603145797845319656">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide treatment increased levels of BClxL to those found in the wild-type controls and statistically significantly increased in comparison to untreated Pla2g6-/- mice.</data>
  <data key="d3">Semaglutide treatment increased levels of BClxL to those found in the wild-type controls and statistically significantly increased in comparison to untreated Pla2g6-/- mice.</data>
  <data key="d4">PDF_5</data>
</node>
<node id="Protein_BCLXL">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">BCLXL</data>
  <data key="d7">BClxL</data>
</node>
<node id="PDF_5_Result_8763054309734859190">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide treatment increased levels of BCl2 to those found in the wild-type controls and significantly increased in comparison to untreated Pla2g6-/- mice.</data>
  <data key="d3">Semaglutide treatment increased levels of BCl2 to those found in the wild-type controls and significantly increased in comparison to untreated Pla2g6-/- mice.</data>
  <data key="d4">PDF_5</data>
</node>
<node id="Protein_BCL2">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">BCL2</data>
  <data key="d7">BCl2</data>
</node>
<node id="PDF_5_Result_7669237552842980219">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide treatment showed a protective effect in Pla2g6-/- mice through significantly reduced Bax expression compared to age-matched untreated Pla2g6-/- mice.</data>
  <data key="d3">Semaglutide treatment showed a protective effect in Pla2g6-/- mice through significantly reduced Bax expression compared to age-matched untreated Pla2g6-/- mice.</data>
  <data key="d4">PDF_5</data>
</node>
<node id="Protein_BAX">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">BAX</data>
  <data key="d7">Bax</data>
</node>
<node id="PDF_5_Result_-6567360113983550527">
  <data key="d0">Result</data>
  <data key="d1">RIP3 was significantly reduced in weekly 0.5 µg/g semaglutide treated mice compared to untreated Pla2g6-/- mice.</data>
  <data key="d3">RIP3 was significantly reduced in weekly 0.5 µg/g semaglutide treated mice compared to untreated Pla2g6-/- mice.</data>
  <data key="d4">PDF_5</data>
</node>
<node id="Protein_RIP3">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">RIP3</data>
  <data key="d7">RIP3</data>
</node>
<node id="PDF_5_Result_551580069177254747">
  <data key="d0">Result</data>
  <data key="d1">Microglial activation was significantly reduced by weekly 0.5 µg/g semaglutide treatment in Pla2g6-/- mice compared to the untreated controls.</data>
  <data key="d3">Microglial activation was significantly reduced by weekly 0.5 µg/g semaglutide treatment in Pla2g6-/- mice compared to the untreated controls.</data>
  <data key="d4">PDF_5</data>
</node>
<node id="PDF_5_Result_3564476496712209234">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide treatment significantly reduced the CD68 immunoreactivity in all the affected areas compared to untreated Pla2g6-/- mice.</data>
  <data key="d3">Semaglutide treatment significantly reduced the CD68 immunoreactivity in all the affected areas compared to untreated Pla2g6-/- mice.</data>
  <data key="d4">PDF_5</data>
</node>
<node id="Protein_CD68">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">CD68</data>
  <data key="d7">CD68</data>
</node>
<node id="PDF_5_Result_793911901043520945">
  <data key="d0">Result</data>
  <data key="d1">Astrogliosis was significantly ameliorated following semaglutide treatment compared to the untreated Pla2g6-/- controls.</data>
  <data key="d3">Astrogliosis was significantly ameliorated following semaglutide treatment compared to the untreated Pla2g6-/- controls.</data>
  <data key="d4">PDF_5</data>
</node>
<node id="PDF_5_Result_-8257945448189805228">
  <data key="d0">Result</data>
  <data key="d1">High-dose semaglutide treatment significantly reduced the number of vacuoles compared to untreated Pla2g6-/- mice in the cortex.</data>
  <data key="d3">High-dose semaglutide treatment significantly reduced the number of vacuoles compared to untreated Pla2g6-/- mice in the cortex.</data>
  <data key="d4">PDF_5</data>
</node>
<node id="PDF_5_Conclusion_1340985672363221141">
  <data key="d0">Conclusion</data>
  <data key="d1">Semaglutide treatment administered once a week to a mouse model of INAD is neuroprotective, ameliorates neuroinflammation and reduces cell death pathways, resulting in significant improvements to locomotor function and lifespan.</data>
  <data key="d3">Semaglutide treatment administered once a week to a mouse model of INAD is neuroprotective, ameliorates neuroinflammation and reduces cell death pathways, resulting in significant improvements to locomotor function and lifespan.</data>
  <data key="d4">PDF_5</data>
</node>
<node id="Disease_INAD">
  <data key="d0">Entity</data>
  <data key="d5">Disease</data>
  <data key="d6">INAD</data>
  <data key="d7">INAD</data>
</node>
<node id="PDF_19">
  <data key="d0">Paper</data>
  <data key="d1">www.nature.com/scientificreports
scientific reports
OPEN A pro-oxidant combination
of resveratrol and copper
down-regulates multiple
biological hallmarks of ageing
and neurodegeneration in mice
Kavita Pal1,2,3, Gorantla V. Raghuram1,2,3, Jenevieve Dsouza¹,2, Sushma Shinde1,2,
Vishalkumar Jadhav¹,2, Alfina Shaikh¹,2, Bhagyeshri Rane¹,2, Harshali Tandel 1,2,
Dipali Kondhalkar¹,2, Shahid Chaudhary¹,2 &amp; Indraneel Mittra (1,2
Check for updates
Billions of cells die in the body every day, and cell-fre</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_19_Hypothesis_5289388398369228207">
  <data key="d0">Hypothesis</data>
  <data key="d1">Lifelong assault on healthy cells by cfChPs is the underlying cause of ageing, and that ageing could be retarded by deactivating extra-cellular cfChPs.</data>
  <data key="d3">Lifelong assault on healthy cells by cfChPs is the underlying cause of ageing, and that ageing could be retarded by deactivating extra-cellular cfChPs.</data>
  <data key="d4">PDF_19</data>
</node>
<node id="Compound_CFCHPS">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">CFCHPS</data>
  <data key="d7">cfChPs</data>
</node>
<node id="PDF_19_Method_850012236976339227">
  <data key="d0">Method</data>
  <data key="d1">C57BL/6 mice were divided into 3 equal groups; one group was sacrificed at age 3 months, and which acted as young controls. The remaining mice were allowed to age, and at age 10 months the experimental ageing group was given R-Cu by oral gavage twice daily for further 12 months at a dose of 1 mg/kg of R and 0.1 µg/kg of Cu.</data>
  <data key="d3">C57BL/6 mice were divided into 3 equal groups; one group was sacrificed at age 3 months, and which acted as young controls. The remaining mice were allowed to age, and at age 10 months the experimental ageing group was given R-Cu by oral gavage twice daily for further 12 months at a dose of 1 mg/kg of R and 0.1 µg/kg of Cu.</data>
  <data key="d4">PDF_19</data>
</node>
<node id="Gene_C57BL/6">
  <data key="d0">Entity</data>
  <data key="d5">Gene</data>
  <data key="d6">C57BL/6</data>
  <data key="d7">C57BL/6</data>
</node>
<node id="Compound_R-CU">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">R-CU</data>
  <data key="d7">R-Cu</data>
</node>
<node id="Compound_R">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">R</data>
  <data key="d7">R</data>
</node>
<node id="Compound_CU">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">CU</data>
  <data key="d7">Cu</data>
</node>
<node id="PDF_19_Result_366711149377926412">
  <data key="d0">Result</data>
  <data key="d1">R-Cu treatment led to reduction of several biological hallmarks of ageing in brain cells which included telomere attrition, amyloid deposition, DNA damage, apoptosis, inflammation, senescence, aneuploidy and mitochondrial dysfunction.</data>
  <data key="d3">R-Cu treatment led to reduction of several biological hallmarks of ageing in brain cells which included telomere attrition, amyloid deposition, DNA damage, apoptosis, inflammation, senescence, aneuploidy and mitochondrial dysfunction.</data>
  <data key="d4">PDF_19</data>
</node>
<node id="PDF_19_Result_-1638143175366158459">
  <data key="d0">Result</data>
  <data key="d1">R-Cu treatment also led to significant reduction in blood levels of glucose, cholesterol and C-reactive protein.</data>
  <data key="d3">R-Cu treatment also led to significant reduction in blood levels of glucose, cholesterol and C-reactive protein.</data>
  <data key="d4">PDF_19</data>
</node>
<node id="PDF_19_Result_6667101106283799368">
  <data key="d0">Result</data>
  <data key="d1">ageing mice showed significant reduction in SOD levels in brain cells</data>
  <data key="d3">ageing mice showed significant reduction in SOD levels in brain cells</data>
  <data key="d4">PDF_19</data>
</node>
<node id="Protein_SOD">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">SOD</data>
  <data key="d7">SOD</data>
</node>
<node id="PDF_19_Result_-152527027810759783">
  <data key="d0">Result</data>
  <data key="d1">R-Cu treatment led to marked increase in SOD levels that were similar to that detected in young control mice</data>
  <data key="d3">R-Cu treatment led to marked increase in SOD levels that were similar to that detected in young control mice</data>
  <data key="d4">PDF_19</data>
</node>
<node id="PDF_19_Result_4844417600976532472">
  <data key="d0">Result</data>
  <data key="d1">R-Cu treatment did lead to an increase in SOD activity in serum of ageing mice, restoring them to levels similar to those seen in young control mice</data>
  <data key="d3">R-Cu treatment did lead to an increase in SOD activity in serum of ageing mice, restoring them to levels similar to those seen in young control mice</data>
  <data key="d4">PDF_19</data>
</node>
<node id="PDF_19_Result_2136482510085313533">
  <data key="d0">Result</data>
  <data key="d1">copious presence of cfChPs (yellow fluorescent signals) were detected in the extracellular spaces of brain of ageing mice. cfChPs were virtually eliminated following R-Cu treatment for one-year.</data>
  <data key="d3">copious presence of cfChPs (yellow fluorescent signals) were detected in the extracellular spaces of brain of ageing mice. cfChPs were virtually eliminated following R-Cu treatment for one-year.</data>
  <data key="d4">PDF_19</data>
</node>
<node id="PDF_19_Result_3330498275100582759">
  <data key="d0">Result</data>
  <data key="d1">R-Cu treatment restored telomere length to a significant degree in female mice</data>
  <data key="d3">R-Cu treatment restored telomere length to a significant degree in female mice</data>
  <data key="d4">PDF_19</data>
</node>
<node id="PDF_19_Result_-9174667434230489420">
  <data key="d0">Result</data>
  <data key="d1">a reduction was seen in ageing mice of both sexes (p&lt;0.01 in both sexes), which was again significantly restored following R-Cu treatment in female (p&lt;0.01) but not in male mice</data>
  <data key="d3">a reduction was seen in ageing mice of both sexes (p&lt;0.01 in both sexes), which was again significantly restored following R-Cu treatment in female (p&lt;0.01) but not in male mice</data>
  <data key="d4">PDF_19</data>
</node>
<node id="PDF_19_Result_-4112474976594474053">
  <data key="d0">Result</data>
  <data key="d1">amyloid deposition in the form of amyloid fibrils in ageing mice. The latter was remarkably reduced following one year of R-Cu treatment</data>
  <data key="d3">amyloid deposition in the form of amyloid fibrils in ageing mice. The latter was remarkably reduced following one year of R-Cu treatment</data>
  <data key="d4">PDF_19</data>
</node>
<node id="Protein_AMYLOID">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">AMYLOID</data>
  <data key="d7">amyloid</data>
</node>
<node id="PDF_19_Result_8095632726691338850">
  <data key="d0">Result</data>
  <data key="d1">Brain derived neurotrophic factor (BDNF), which plays an important role in neuronal survival and growth 36, was greatly reduced in sera of ageing mice of both sexes as measured by ELISA (p&lt;0.01 and p&lt;0.05 in female and male mice, respectively) (Fig. 4B). R-Cu treatment for one year resorted serum BDNF levels nearly to those seen in young mice in both sexes (p&lt;0.05 and p&lt;0.001 in female and male mice, respectively) (Fig. 4B).</data>
  <data key="d3">Brain derived neurotrophic factor (BDNF), which plays an important role in neuronal survival and growth 36, was greatly reduced in sera of ageing mice of both sexes as measured by ELISA (p&lt;0.01 and p&lt;0.05 in female and male mice, respectively) (Fig. 4B). R-Cu treatment for one year resorted serum BDNF levels nearly to those seen in young mice in both sexes (p&lt;0.05 and p&lt;0.001 in female and male mice, respectively) (Fig. 4B).</data>
  <data key="d4">PDF_19</data>
</node>
<node id="Protein_BDNF">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">BDNF</data>
  <data key="d7">BDNF</data>
</node>
<node id="PDF_19_Result_-1690465482618680369">
  <data key="d0">Result</data>
  <data key="d1">DNA damage was examined using phosphorylation of H2AX as a marker of dsDNA breaks40. y-H2AX levels were markedly increased in ageing mice (p&lt;0.001 and p&lt;0.0001 in female and male mice, respectively). R-Cu treatment reduced y-H2AX levels (p&lt;0.01 and p&lt;0.05 in female and male mice, respectively) (Fig. 5A, left &amp; right hand panels).</data>
  <data key="d3">DNA damage was examined using phosphorylation of H2AX as a marker of dsDNA breaks40. y-H2AX levels were markedly increased in ageing mice (p&lt;0.001 and p&lt;0.0001 in female and male mice, respectively). R-Cu treatment reduced y-H2AX levels (p&lt;0.01 and p&lt;0.05 in female and male mice, respectively) (Fig. 5A, left &amp; right hand panels).</data>
  <data key="d4">PDF_19</data>
</node>
<node id="Protein_H2AX">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">H2AX</data>
  <data key="d7">H2AX</data>
</node>
<node id="Compound_DNA">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">DNA</data>
  <data key="d7">DNA</data>
</node>
<node id="PDF_19_Result_884761514541857341">
  <data key="d0">Result</data>
  <data key="d1">Highly significant increase in apoptosis in ageing brain cells was seen in both sexes (p&lt;0.0001). R-Cu treatment significantly reduced the degree of apoptosis in mice of both sexes (p&lt;0.01 and p&lt;0.0001 in female and male mice, respectively) (Fig. 5B, left &amp; right hand panels).</data>
  <data key="d3">Highly significant increase in apoptosis in ageing brain cells was seen in both sexes (p&lt;0.0001). R-Cu treatment significantly reduced the degree of apoptosis in mice of both sexes (p&lt;0.01 and p&lt;0.0001 in female and male mice, respectively) (Fig. 5B, left &amp; right hand panels).</data>
  <data key="d4">PDF_19</data>
</node>
<node id="Process_APOPTOSIS">
  <data key="d0">Entity</data>
  <data key="d5">Process</data>
  <data key="d6">APOPTOSIS</data>
  <data key="d7">apoptosis</data>
</node>
<node id="PDF_19_Result_-7697977620803994591">
  <data key="d0">Result</data>
  <data key="d1">The latter was highly significantly elevated in ageing mice of both sexes (p &lt; 0.0001). R-Cu treatment significantly reduced NF-kB levels in both sexes (p&lt;0.05 and p&lt;0.01 in female and male mice, respectively) (Fig. 5C, left &amp; right hand panels).</data>
  <data key="d3">The latter was highly significantly elevated in ageing mice of both sexes (p &lt; 0.0001). R-Cu treatment significantly reduced NF-kB levels in both sexes (p&lt;0.05 and p&lt;0.01 in female and male mice, respectively) (Fig. 5C, left &amp; right hand panels).</data>
  <data key="d4">PDF_19</data>
</node>
<node id="Protein_NF-KB">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">NF-KB</data>
  <data key="d7">NF-kB</data>
</node>
<node id="PDF_19_Result_-3213791352831985279">
  <data key="d0">Result</data>
  <data key="d1">We observed persistence of numerous co-localizing signals of y-H2AX with those of telomeres (DNA-SCARS)—a classical hallmark of senescence43—in ageing mice of both sexes (p&lt;0.001). Quantification of co-localising signals revealed a marked reduction following R-Cu treatment (p&lt;0.01 in both sexes) (Fig. 6A, upper &amp; lower panels).</data>
  <data key="d3">We observed persistence of numerous co-localizing signals of y-H2AX with those of telomeres (DNA-SCARS)—a classical hallmark of senescence43—in ageing mice of both sexes (p&lt;0.001). Quantification of co-localising signals revealed a marked reduction following R-Cu treatment (p&lt;0.01 in both sexes) (Fig. 6A, upper &amp; lower panels).</data>
  <data key="d4">PDF_19</data>
</node>
<node id="Gene_TELOMERES">
  <data key="d0">Entity</data>
  <data key="d5">Gene</data>
  <data key="d6">TELOMERES</data>
  <data key="d7">telomeres</data>
</node>
<node id="Process_SENESCENCE">
  <data key="d0">Entity</data>
  <data key="d5">Process</data>
  <data key="d6">SENESCENCE</data>
  <data key="d7">senescence</data>
</node>
<node id="PDF_19_Result_1333388756008666363">
  <data key="d0">Result</data>
  <data key="d1">the number of co-localizing signals of 53BP1 and PML were markedly increased in ageing mice of both sexes (p&lt;0.0001). Co-localising signals were significantly reduced following R-Cu treatment for 1 year (p&lt;0.05 and p&lt;0.01 in female and male mice, respectively) (Fig. 6B, left &amp; right hand panels).</data>
  <data key="d3">the number of co-localizing signals of 53BP1 and PML were markedly increased in ageing mice of both sexes (p&lt;0.0001). Co-localising signals were significantly reduced following R-Cu treatment for 1 year (p&lt;0.05 and p&lt;0.01 in female and male mice, respectively) (Fig. 6B, left &amp; right hand panels).</data>
  <data key="d4">PDF_19</data>
</node>
<node id="Protein_53BP1">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">53BP1</data>
  <data key="d7">53BP1</data>
</node>
<node id="Protein_PML">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">PML</data>
  <data key="d7">PML</data>
</node>
<node id="PDF_19_Conclusion_4385708097619144801">
  <data key="d0">Conclusion</data>
  <data key="d1">cfChPs act as global instigators of ageing and neurodegeneration, and that therapeutic use of R-Cu may help to make healthy ageing an attainable goal.</data>
  <data key="d3">cfChPs act as global instigators of ageing and neurodegeneration, and that therapeutic use of R-Cu may help to make healthy ageing an attainable goal.</data>
  <data key="d4">PDF_19</data>
</node>
<node id="PDF_3">
  <data key="d0">Paper</data>
  <data key="d1">LTH &amp; HUMAN SERVICES-US,
Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
HHS Public Access
Author manuscript
Nat Metab. Author manuscript; available in PMC 2021 August 15.
Published in final edited form as:
Nat Metab. 2021 February ; 3(2): 258–273. doi:10.1038/s42255-021-00344-4.
Central and peripheral GLP-1 systems independently suppress
eating
Daniel I. Brierley¹, Marie K. Holt2, Arashdeep Singh3,7, Alan de Araujo 3,7, Molly
McDougle 3,7, Macarena Vergara3,7, Majd H. Af</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_3_Hypothesis_-4679385473648779113">
  <data key="d0">Hypothesis</data>
  <data key="d1">peripheral GLP-1 signals to the brain to suppress eating via vagal and/or endocrine activation of central GLP-1-producing preproglucagon (PPG) neurons, i.e. that peripheral and central GLP-1 systems comprise a unified, directly connected gut-brain satiation circuit</data>
  <data key="d3">peripheral GLP-1 signals to the brain to suppress eating via vagal and/or endocrine activation of central GLP-1-producing preproglucagon (PPG) neurons, i.e. that peripheral and central GLP-1 systems comprise a unified, directly connected gut-brain satiation circuit</data>
  <data key="d4">PDF_3</data>
</node>
<node id="Gene_PPG">
  <data key="d0">Entity</data>
  <data key="d5">Gene</data>
  <data key="d6">PPG</data>
  <data key="d7">PPG</data>
</node>
<node id="PDF_3_Method_-6051751568582498301">
  <data key="d0">Method</data>
  <data key="d1">viral ablation of PPGNTS neurons, using AAV-mediated selective expression of diptheria toxin subunit A (DTA)</data>
  <data key="d3">viral ablation of PPGNTS neurons, using AAV-mediated selective expression of diptheria toxin subunit A (DTA)</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Method_816710081986762244">
  <data key="d0">Method</data>
  <data key="d1">chemogenetic inhibition of PPGNTS neurons on termination of large solid and liquid meals, using the inhibitory hM4Di Designer Receptor Exclusively Activated by Designer Drugs (DREADD)</data>
  <data key="d3">chemogenetic inhibition of PPGNTS neurons on termination of large solid and liquid meals, using the inhibitory hM4Di Designer Receptor Exclusively Activated by Designer Drugs (DREADD)</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Method_-5394029100478570223">
  <data key="d0">Method</data>
  <data key="d1">chemogenetic activation of PPGNTS neurons with hM3Dq DREADD</data>
  <data key="d3">chemogenetic activation of PPGNTS neurons with hM3Dq DREADD</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Method_5912197178049720103">
  <data key="d0">Method</data>
  <data key="d1">optogenetic activation of the central axon terminals of Glp1r VANS with the excitatory opsin ChR2</data>
  <data key="d3">optogenetic activation of the central axon terminals of Glp1r VANS with the excitatory opsin ChR2</data>
  <data key="d4">PDF_3</data>
</node>
<node id="Gene_GLP-1R">
  <data key="d0">Entity</data>
  <data key="d5">Gene</data>
  <data key="d6">GLP-1R</data>
  <data key="d7">GLP-1R</data>
</node>
<node id="PDF_3_Method_4679292067826613729">
  <data key="d0">Method</data>
  <data key="d1">Cre-dependent monosynaptic retrograde rabies virus tracing in combination with RNAscope fluorescence in situ hybridisation in nodose ganglia for Glp1rand oxytocin receptor gene (Oxtr) expression</data>
  <data key="d3">Cre-dependent monosynaptic retrograde rabies virus tracing in combination with RNAscope fluorescence in situ hybridisation in nodose ganglia for Glp1rand oxytocin receptor gene (Oxtr) expression</data>
  <data key="d4">PDF_3</data>
</node>
<node id="Gene_OXTR">
  <data key="d0">Entity</data>
  <data key="d5">Gene</data>
  <data key="d6">OXTR</data>
  <data key="d7">Oxtr</data>
</node>
<node id="PDF_3_Method_1930217671267736327">
  <data key="d0">Method</data>
  <data key="d1">ex vivo calcium imaging using coronal brainstem slices from transgenic mice expressing GCaMP3 in PPGNTS neurons</data>
  <data key="d3">ex vivo calcium imaging using coronal brainstem slices from transgenic mice expressing GCaMP3 in PPGNTS neurons</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Method_1200006301349517513">
  <data key="d0">Method</data>
  <data key="d1">quantifying cFos expression in the PPG-YFP mouse line</data>
  <data key="d3">quantifying cFos expression in the PPG-YFP mouse line</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Result_-2436540140130895462">
  <data key="d0">Result</data>
  <data key="d1">PPGNTS neuron inhibition increased fasting-induced pellet refeeding during hour 1 in a sex-independent manner, and this effect was driven by increased meal size, rather than frequency</data>
  <data key="d3">PPGNTS neuron inhibition increased fasting-induced pellet refeeding during hour 1 in a sex-independent manner, and this effect was driven by increased meal size, rather than frequency</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Result_3277555210032171539">
  <data key="d0">Result</data>
  <data key="d1">Ensure intake was increased by PPGNTS neuron inhibition, and, consistent with effects on pellet intake in the FED system, this increase was driven by increased duration of Ensure eating</data>
  <data key="d3">Ensure intake was increased by PPGNTS neuron inhibition, and, consistent with effects on pellet intake in the FED system, this increase was driven by increased duration of Ensure eating</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Result_3542628263517594065">
  <data key="d0">Result</data>
  <data key="d1">PPGNTS activation reduced intake by ~40% in the first 24 hours</data>
  <data key="d3">PPGNTS activation reduced intake by ~40% in the first 24 hours</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Result_-4585105860993238033">
  <data key="d0">Result</data>
  <data key="d1">PPGNTS neuron activation advanced the point of satiation by ~15 minutes</data>
  <data key="d3">PPGNTS neuron activation advanced the point of satiation by ~15 minutes</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Result_-7076444585394845266">
  <data key="d0">Result</data>
  <data key="d1">chemogenetic activation of Glp1rVANs using the excitatory hM3Dq DREADD in ad libitum eating mice suppressed eating during the dark but not subsequent light phase</data>
  <data key="d3">chemogenetic activation of Glp1rVANs using the excitatory hM3Dq DREADD in ad libitum eating mice suppressed eating during the dark but not subsequent light phase</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Result_-3807290741009570591">
  <data key="d0">Result</data>
  <data key="d1">Optogenetic activation of Glp1r terminals within the NTS conditioned avoidance of the paired flavour</data>
  <data key="d3">Optogenetic activation of Glp1r terminals within the NTS conditioned avoidance of the paired flavour</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Result_-6195899216514636334">
  <data key="d0">Result</data>
  <data key="d1">33% of all PPGNTS neuron-innervating VANs express Oxtralone, and 21% of VANs which express Oxtralone synapse onto PPGNTS neurons</data>
  <data key="d3">33% of all PPGNTS neuron-innervating VANs express Oxtralone, and 21% of VANs which express Oxtralone synapse onto PPGNTS neurons</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Result_3230802158087093871">
  <data key="d0">Result</data>
  <data key="d1">oxytocin activated 84% of glutamate-responsive PPGNTS neurons</data>
  <data key="d3">oxytocin activated 84% of glutamate-responsive PPGNTS neurons</data>
  <data key="d4">PDF_3</data>
</node>
<node id="Compound_OXYTOCIN">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">OXYTOCIN</data>
  <data key="d7">oxytocin</data>
</node>
<node id="PDF_3_Result_-157677116027046846">
  <data key="d0">Result</data>
  <data key="d1">oxytocin acutely suppressed eating in ad libitum eating control mice, this effect was completely abolished in mice in which PPGNTS neurons had been virally ablated by DTA expression</data>
  <data key="d3">oxytocin acutely suppressed eating in ad libitum eating control mice, this effect was completely abolished in mice in which PPGNTS neurons had been virally ablated by DTA expression</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Result_1762540584757598420">
  <data key="d0">Result</data>
  <data key="d1">Liraglutide robustly suppressed intake and bodyweight over 24 hours in ad libitum eating eGFP-transduced control mice, however DTA ablation of PPGNTS neurons had no effect on the magnitude of eating suppression at any timepoint</data>
  <data key="d3">Liraglutide robustly suppressed intake and bodyweight over 24 hours in ad libitum eating eGFP-transduced control mice, however DTA ablation of PPGNTS neurons had no effect on the magnitude of eating suppression at any timepoint</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Result_-1210487380892098746">
  <data key="d0">Result</data>
  <data key="d1">Semaglutide suppressed eating to an even greater extent than liraglutide, and similarly PPGNTS neuron ablation had no impact on acute or delayed eating suppression, or on bodyweight loss</data>
  <data key="d3">Semaglutide suppressed eating to an even greater extent than liraglutide, and similarly PPGNTS neuron ablation had no impact on acute or delayed eating suppression, or on bodyweight loss</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Result_4648796894935863897">
  <data key="d0">Result</data>
  <data key="d1">less than 3% of PPGNTS neurons were activated by semaglutide</data>
  <data key="d3">less than 3% of PPGNTS neurons were activated by semaglutide</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Result_6167789673436234015">
  <data key="d0">Result</data>
  <data key="d1">either manipulation alone suppressed eating over the first 24 hours, with semaglutide eliciting the stronger effect. Crucially, their combined effect was significantly greater than that of semaglutide alone throughout the duration of acute chemogenetic activation</data>
  <data key="d3">either manipulation alone suppressed eating over the first 24 hours, with semaglutide eliciting the stronger effect. Crucially, their combined effect was significantly greater than that of semaglutide alone throughout the duration of acute chemogenetic activation</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Conclusion_-1497665836386122097">
  <data key="d0">Conclusion</data>
  <data key="d1">PPGNTS neurons are recruited to encode physiological satiation, specifically by ingestion of large meals</data>
  <data key="d3">PPGNTS neurons are recruited to encode physiological satiation, specifically by ingestion of large meals</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Conclusion_-3129359784067431577">
  <data key="d0">Conclusion</data>
  <data key="d1">PPGNTS neurons have translational potential as a pharmacological target for obesity treatment</data>
  <data key="d3">PPGNTS neurons have translational potential as a pharmacological target for obesity treatment</data>
  <data key="d4">PDF_3</data>
</node>
<node id="Disease_OBESITY">
  <data key="d0">Entity</data>
  <data key="d5">Disease</data>
  <data key="d6">OBESITY</data>
  <data key="d7">obesity</data>
</node>
<node id="PDF_3_Conclusion_816397274048116659">
  <data key="d0">Conclusion</data>
  <data key="d1">Oxtr- rather than Glp1r-expressing VANs are the primary source of gastrointestinal distension signals driving PPGNTS neuron-mediated satiation</data>
  <data key="d3">Oxtr- rather than Glp1r-expressing VANs are the primary source of gastrointestinal distension signals driving PPGNTS neuron-mediated satiation</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Conclusion_-1948668734909414417">
  <data key="d0">Conclusion</data>
  <data key="d1">PPGNTS neurons as a necessary component of the gut-brain circuit recruited by peripheral oxytocin to suppress eating</data>
  <data key="d3">PPGNTS neurons as a necessary component of the gut-brain circuit recruited by peripheral oxytocin to suppress eating</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Conclusion_2321696407336075315">
  <data key="d0">Conclusion</data>
  <data key="d1">PPGNTS neurons are not necessary for GLP-1RA-induced suppression of eating</data>
  <data key="d3">PPGNTS neurons are not necessary for GLP-1RA-induced suppression of eating</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Conclusion_4209648061107124474">
  <data key="d0">Conclusion</data>
  <data key="d1">PPGNTS neurons suppress eating via circuits which are anatomically and functionally distinct from those recruited by peripheral endogenous GLP-1 and peripherally administered GLP-1RAs</data>
  <data key="d3">PPGNTS neurons suppress eating via circuits which are anatomically and functionally distinct from those recruited by peripheral endogenous GLP-1 and peripherally administered GLP-1RAs</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Conclusion_-5221819320897875189">
  <data key="d0">Conclusion</data>
  <data key="d1">the unified peripheral to central GLP-1 satiation circuit hypothesis cannot be supported, but that the peripheral and central GLP-1 systems are rather components of functionally and anatomically independent eating control circuits</data>
  <data key="d3">the unified peripheral to central GLP-1 satiation circuit hypothesis cannot be supported, but that the peripheral and central GLP-1 systems are rather components of functionally and anatomically independent eating control circuits</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_3_Conclusion_-4419455904112913995">
  <data key="d0">Conclusion</data>
  <data key="d1">Activation of PPGNTS neurons, either alone or in combination with GLP-1RAs, thus represents a rational strategy for obesity treatment</data>
  <data key="d3">Activation of PPGNTS neurons, either alone or in combination with GLP-1RAs, thus represents a rational strategy for obesity treatment</data>
  <data key="d4">PDF_3</data>
</node>
<node id="PDF_12">
  <data key="d0">Paper</data>
  <data key="d1">Drugs 1996; 52 Suppl. 3: 39-47
Pharmacology and Clinical Experience
with Tramadol in Osteoarthritis
Warren A. Katz
University of Pennsylvania Health System, Presbyterian Medical Center, Philadelphia,
Pennsylvania, USA

Tramadol is a centrally acting analgesic that has been shown to be effective
in a variety of acute and chronic pain states. Unlike other centrally acting anal-
gesics, it exerts a dual action by binding to the opioid receptor site in the central
nervous system and by weakly inhibi</data>
  <data key="d2">2024</data>
</node>
<node id="PDF_12_Result_6135624927386232844">
  <data key="d0">Result</data>
  <data key="d1">Tramadol is a centrally acting analgesic effective in acute and chronic pain states, exerting a dual action by binding to opioid receptors and weakly inhibiting biogenic amine reuptake.</data>
  <data key="d3">Tramadol is a centrally acting analgesic effective in acute and chronic pain states, exerting a dual action by binding to opioid receptors and weakly inhibiting biogenic amine reuptake.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="Compound_TRAMADOL">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">TRAMADOL</data>
  <data key="d7">Tramadol</data>
</node>
<node id="PDF_12_Result_-7189104412129414113">
  <data key="d0">Result</data>
  <data key="d1">Tramadol is rapidly absorbed with action onset within 1 hour; sustained release is advantageous for chronic pain like osteoarthritis.</data>
  <data key="d3">Tramadol is rapidly absorbed with action onset within 1 hour; sustained release is advantageous for chronic pain like osteoarthritis.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="Disease_OSTEOARTHRITIS">
  <data key="d0">Entity</data>
  <data key="d5">Disease</data>
  <data key="d6">OSTEOARTHRITIS</data>
  <data key="d7">Osteoarthritis</data>
</node>
<node id="PDF_12_Result_229012398668281384">
  <data key="d0">Result</data>
  <data key="d1">Tramadol appears useful in elderly with osteoarthritis, avoiding hypertension, heart failure aggravation, and peptic ulcers, unlike NSAIDs; it also induces less respiratory depression, constipation, and abuse potential than narcotics.</data>
  <data key="d3">Tramadol appears useful in elderly with osteoarthritis, avoiding hypertension, heart failure aggravation, and peptic ulcers, unlike NSAIDs; it also induces less respiratory depression, constipation, and abuse potential than narcotics.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="PDF_12_Result_-2805374894381281088">
  <data key="d0">Result</data>
  <data key="d1">Tramadol binds to u opioid receptor site in the central nervous system, with a binding affinity 6000 times less than that of morphine.</data>
  <data key="d3">Tramadol binds to u opioid receptor site in the central nervous system, with a binding affinity 6000 times less than that of morphine.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="Compound_MORPHINE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">MORPHINE</data>
  <data key="d7">morphine</data>
</node>
<node id="PDF_12_Result_-3184145757421236057">
  <data key="d0">Result</data>
  <data key="d1">Tramadol-mediated analgesia is only partially reduced by the opioid antagonist, naloxone, thus suggesting an important nonopioid mechanism of action.</data>
  <data key="d3">Tramadol-mediated analgesia is only partially reduced by the opioid antagonist, naloxone, thus suggesting an important nonopioid mechanism of action.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="Compound_NALOXONE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">NALOXONE</data>
  <data key="d7">naloxone</data>
</node>
<node id="PDF_12_Result_7762534828733437259">
  <data key="d0">Result</data>
  <data key="d1">Reuptake inhibitory effects on noradrenaline (norepinephrine) and serotonin (5-hydroxytryptamine; 5-HT) contributed to the analgesic effects of tramadol by inhibiting pain transmission in the spinal cord.</data>
  <data key="d3">Reuptake inhibitory effects on noradrenaline (norepinephrine) and serotonin (5-hydroxytryptamine; 5-HT) contributed to the analgesic effects of tramadol by inhibiting pain transmission in the spinal cord.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="Compound_NORADRENALINE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">NORADRENALINE</data>
  <data key="d7">noradrenaline</data>
</node>
<node id="Compound_SEROTONIN">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">SEROTONIN</data>
  <data key="d7">serotonin</data>
</node>
<node id="PDF_12_Result_6359609731107884522">
  <data key="d0">Result</data>
  <data key="d1">The (+) enantiomer has a weakly preferential effect at u opioid receptors and in inhibiting the reuptake of serotonin, whereas the (-) enantiomer preferentially inhibits the reuptake of noradrenaline.</data>
  <data key="d3">The (+) enantiomer has a weakly preferential effect at u opioid receptors and in inhibiting the reuptake of serotonin, whereas the (-) enantiomer preferentially inhibits the reuptake of noradrenaline.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="PDF_12_Result_7898330476481306524">
  <data key="d0">Result</data>
  <data key="d1">Mono-O-desmethyl-tramadol (M1), the one active metabolite of tramadol, has a greater opioid receptor affinity than the parent compound.</data>
  <data key="d3">Mono-O-desmethyl-tramadol (M1), the one active metabolite of tramadol, has a greater opioid receptor affinity than the parent compound.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="PDF_12_Result_-8915652742990526202">
  <data key="d0">Result</data>
  <data key="d1">Codeine has 10 times greater affinity for the u opioid receptor than tramadol.</data>
  <data key="d3">Codeine has 10 times greater affinity for the u opioid receptor than tramadol.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="Compound_CODEINE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">CODEINE</data>
  <data key="d7">Codeine</data>
</node>
<node id="PDF_12_Result_-3082237975900150399">
  <data key="d0">Result</data>
  <data key="d1">The reuptake inhibitory effects of tramadol on noradrenaline and serotonin are 100 to 1000 times weaker than those of imipramine.</data>
  <data key="d3">The reuptake inhibitory effects of tramadol on noradrenaline and serotonin are 100 to 1000 times weaker than those of imipramine.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="Compound_IMIPRAMINE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">IMIPRAMINE</data>
  <data key="d7">imipramine</data>
</node>
<node id="PDF_12_Result_-971115072939932909">
  <data key="d0">Result</data>
  <data key="d1">Tramadol is rapidly and almost completely absorbed, with an onset of action occurring within 1 hour of oral administration.</data>
  <data key="d3">Tramadol is rapidly and almost completely absorbed, with an onset of action occurring within 1 hour of oral administration.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="PDF_12_Result_1565443364262036202">
  <data key="d0">Result</data>
  <data key="d1">Tramadol is extensively metabolised by the liver; only the O-demethylated metabolite has pharmacological activity.</data>
  <data key="d3">Tramadol is extensively metabolised by the liver; only the O-demethylated metabolite has pharmacological activity.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="PDF_12_Result_-4748601598772986517">
  <data key="d0">Result</data>
  <data key="d1">The drug and its metabolites are eliminated primarily by the kidney (90%), with 30% of an oral dose excreted unchanged in the urine.</data>
  <data key="d3">The drug and its metabolites are eliminated primarily by the kidney (90%), with 30% of an oral dose excreted unchanged in the urine.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="PDF_12_Result_-2925905954577225094">
  <data key="d0">Result</data>
  <data key="d1">The plasma terminal elimination half-life of tramadol is 6.3 hours after a single 100mg dose.</data>
  <data key="d3">The plasma terminal elimination half-life of tramadol is 6.3 hours after a single 100mg dose.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="PDF_12_Result_-925196915687677708">
  <data key="d0">Result</data>
  <data key="d1">Coadministration of tramadol with cimetidine increases the terminal elimination half-life of tramadol; however, these changes are not clinically significant and do not necessitate an adjustment of the tramadol dose.</data>
  <data key="d3">Coadministration of tramadol with cimetidine increases the terminal elimination half-life of tramadol; however, these changes are not clinically significant and do not necessitate an adjustment of the tramadol dose.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="Compound_CIMETIDINE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">CIMETIDINE</data>
  <data key="d7">cimetidine</data>
</node>
<node id="PDF_12_Result_1896818659557132719">
  <data key="d0">Result</data>
  <data key="d1">Concomitant administration of oral tramadol and oral quinidine in humans had no effect on tramadol-induced analgesia.</data>
  <data key="d3">Concomitant administration of oral tramadol and oral quinidine in humans had no effect on tramadol-induced analgesia.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="Compound_QUINIDINE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">QUINIDINE</data>
  <data key="d7">quinidine</data>
</node>
<node id="PDF_12_Result_-8608051912689437436">
  <data key="d0">Result</data>
  <data key="d1">Coadministration of carbamazepine resulted in a decrease in the half-life of tramadol.</data>
  <data key="d3">Coadministration of carbamazepine resulted in a decrease in the half-life of tramadol.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="Compound_CARBAMAZEPINE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">CARBAMAZEPINE</data>
  <data key="d7">carbamazepine</data>
</node>
<node id="PDF_12_Result_-2006356274132936653">
  <data key="d0">Result</data>
  <data key="d1">Because tramadol inhibits the uptake of noradrenaline and serotonin, it should be used with caution in patients taking MAO inhibitors.</data>
  <data key="d3">Because tramadol inhibits the uptake of noradrenaline and serotonin, it should be used with caution in patients taking MAO inhibitors.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="PDF_12_Result_-5568255116895183618">
  <data key="d0">Result</data>
  <data key="d1">Tramadol at a dose of 150mg was significantly better than dextropropoxyphene.</data>
  <data key="d3">Tramadol at a dose of 150mg was significantly better than dextropropoxyphene.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="Compound_DEXTROPROPOXYPHENE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">DEXTROPROPOXYPHENE</data>
  <data key="d7">dextropropoxyphene</data>
</node>
<node id="PDF_12_Result_-5453686403668738889">
  <data key="d0">Result</data>
  <data key="d1">Tramadol 75 and 150mg were found to be as effective as paracetamol 650mg plus dextropropoxyphene 100mg in patients with postcaesarean section pain.</data>
  <data key="d3">Tramadol 75 and 150mg were found to be as effective as paracetamol 650mg plus dextropropoxyphene 100mg in patients with postcaesarean section pain.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="Compound_PARACETAMOL">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">PARACETAMOL</data>
  <data key="d7">paracetamol</data>
</node>
<node id="PDF_12_Result_4065359506097667417">
  <data key="d0">Result</data>
  <data key="d1">Tramadol 100mg was the optimal single dose treatment for acute pain, and tramadol 50mg showed similar analgesic efficacy to that of codeine 60mg.</data>
  <data key="d3">Tramadol 100mg was the optimal single dose treatment for acute pain, and tramadol 50mg showed similar analgesic efficacy to that of codeine 60mg.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="PDF_12_Result_5114278779626160691">
  <data key="d0">Result</data>
  <data key="d1">At the end of the 6-week study, 9 of 10 tramadol-treated patients and 6 of 11 control patients indicated satisfactory to excellent responses for postherpetic neuralgia.</data>
  <data key="d3">At the end of the 6-week study, 9 of 10 tramadol-treated patients and 6 of 11 control patients indicated satisfactory to excellent responses for postherpetic neuralgia.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="Disease_POSTHERPETIC NEURALGIA">
  <data key="d0">Entity</data>
  <data key="d5">Disease</data>
  <data key="d6">POSTHERPETIC NEURALGIA</data>
  <data key="d7">postherpetic neuralgia</data>
</node>
<node id="PDF_12_Result_-7152261828659858270">
  <data key="d0">Result</data>
  <data key="d1">Tramadol provided analgesia comparable to that of paracetamol plus codeine in chronic nonmalignant pain.</data>
  <data key="d3">Tramadol provided analgesia comparable to that of paracetamol plus codeine in chronic nonmalignant pain.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="PDF_12_Result_7667186950944966518">
  <data key="d0">Result</data>
  <data key="d1">An average daily dosage of 245mg tramadol was significantly more effective than placebo in reducing the severity of the pain at rest from osteoarthritis treated with NSAIDs</data>
  <data key="d3">An average daily dosage of 245mg tramadol was significantly more effective than placebo in reducing the severity of the pain at rest from osteoarthritis treated with NSAIDs</data>
  <data key="d4">PDF_12</data>
</node>
<node id="PDF_12_Result_1599930704965880782">
  <data key="d0">Result</data>
  <data key="d1">Total daily pain scores were lower for patients receiving tramadol than for those receiving pentazocine in patients with painful arthritis of the hip and/or knee.</data>
  <data key="d3">Total daily pain scores were lower for patients receiving tramadol than for those receiving pentazocine in patients with painful arthritis of the hip and/or knee.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="Compound_PENTAZOCINE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">PENTAZOCINE</data>
  <data key="d7">pentazocine</data>
</node>
<node id="Disease_ARTHRITIS">
  <data key="d0">Entity</data>
  <data key="d5">Disease</data>
  <data key="d6">ARTHRITIS</data>
  <data key="d7">arthritis</data>
</node>
<node id="PDF_12_Result_-5647623402321451362">
  <data key="d0">Result</data>
  <data key="d1">In 40 patients with osteoarthritis of the hip or knee, tramadol 50mg 3 times daily for 3 weeks was slightly more effective than dextropropoxyphene in relieving pain.</data>
  <data key="d3">In 40 patients with osteoarthritis of the hip or knee, tramadol 50mg 3 times daily for 3 weeks was slightly more effective than dextropropoxyphene in relieving pain.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="PDF_12_Result_-8582382207447656538">
  <data key="d0">Result</data>
  <data key="d1">Both diclofenac and tramadol drugs showed comparable efficacy after 4 weeks in patients with osteoarthritis of the hip and/or knee</data>
  <data key="d3">Both diclofenac and tramadol drugs showed comparable efficacy after 4 weeks in patients with osteoarthritis of the hip and/or knee</data>
  <data key="d4">PDF_12</data>
</node>
<node id="Compound_DICLOFENAC">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">DICLOFENAC</data>
  <data key="d7">diclofenac</data>
</node>
<node id="PDF_12_Result_-6930284550770577579">
  <data key="d0">Result</data>
  <data key="d1">Mean daily tramadol dose of 160mg produced overall ‘satisfactory' pain relief in approximately 86% of patients</data>
  <data key="d3">Mean daily tramadol dose of 160mg produced overall ‘satisfactory' pain relief in approximately 86% of patients</data>
  <data key="d4">PDF_12</data>
</node>
<node id="PDF_12_Result_6724487634730754546">
  <data key="d0">Result</data>
  <data key="d1">Both ibuprofen and tramadol drugs demonstrated equivalent efficacy in patients with hip or knee osteoarthritis.</data>
  <data key="d3">Both ibuprofen and tramadol drugs demonstrated equivalent efficacy in patients with hip or knee osteoarthritis.</data>
  <data key="d4">PDF_12</data>
</node>
<node id="Compound_IBUPROFEN">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">IBUPROFEN</data>
  <data key="d7">ibuprofen</data>
</node>
<node id="PDF_11">
  <data key="d0">Paper</data>
  <data key="d1">DRUG EVALUATION
Drugs 42 (1): 90-114, 1991
0012-6667/91/0007-0090/$12.50/0
Adis International Limited. All rights reserved.
DRE1 15
Perindopril
A Review of its Pharmacological Properties and Therapeutic Use in
Cardiovascular Disorders
Peter A. Todd and Andrew Fitton
Adis International Limited, Auckland, New Zealand
Various sections of the manuscript reviewed by: A. Breckenridge, Department of Pharmacology and Therapeutics,
University of Liverpool, Liverpool, England; K. Dickstein, Department of </data>
  <data key="d2">2024</data>
</node>
<node id="PDF_11_Result_4698747440489162178">
  <data key="d0">Result</data>
  <data key="d1">Perindopril 4 to 8mg once daily is usually effective for blood pressure control in patients with mild to moderate essential hypertension.</data>
  <data key="d3">Perindopril 4 to 8mg once daily is usually effective for blood pressure control in patients with mild to moderate essential hypertension.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-2918929946762459002">
  <data key="d0">Result</data>
  <data key="d1">Those patients who do not respond adequately to monotherapy with perindopril usually respond with the addition of a second agent, such as a thiazide diuretic.</data>
  <data key="d3">Those patients who do not respond adequately to monotherapy with perindopril usually respond with the addition of a second agent, such as a thiazide diuretic.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-1264326948666588695">
  <data key="d0">Result</data>
  <data key="d1">Preliminary results indicate that perindopril may also be effective in patients with severe hypertension or congestive heart failure.</data>
  <data key="d3">Preliminary results indicate that perindopril may also be effective in patients with severe hypertension or congestive heart failure.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-452162685896198458">
  <data key="d0">Result</data>
  <data key="d1">Perindopril is generally well tolerated and has an adverse effect profile similar to that of other ACE inhibitors.</data>
  <data key="d3">Perindopril is generally well tolerated and has an adverse effect profile similar to that of other ACE inhibitors.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-2895694798426260474">
  <data key="d0">Result</data>
  <data key="d1">After oral administration of perindopril, potent inhibition of ACE, and consequently angiotensin II formation, is achieved in plasma and most tissues.</data>
  <data key="d3">After oral administration of perindopril, potent inhibition of ACE, and consequently angiotensin II formation, is achieved in plasma and most tissues.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="Protein_ANGIOTENSIN II">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">ANGIOTENSIN II</data>
  <data key="d7">angiotensin II</data>
</node>
<node id="PDF_11_Result_-2433814731328786998">
  <data key="d0">Result</data>
  <data key="d1">The blood pressure lowering effect of perindopril has been shown in animal models of spontaneous and renovascular hypertension.</data>
  <data key="d3">The blood pressure lowering effect of perindopril has been shown in animal models of spontaneous and renovascular hypertension.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_917555633588458259">
  <data key="d0">Result</data>
  <data key="d1">Perindopril 4 to 8mg once daily significantly reduces supine and standing blood pressure in patients with essential hypertension.</data>
  <data key="d3">Perindopril 4 to 8mg once daily significantly reduces supine and standing blood pressure in patients with essential hypertension.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-8468138155765780383">
  <data key="d0">Result</data>
  <data key="d1">Perindopril also improves arterial structure and reduces left ventricular hypertrophy in hypertensive patients.</data>
  <data key="d3">Perindopril also improves arterial structure and reduces left ventricular hypertrophy in hypertensive patients.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-7007323564526676114">
  <data key="d0">Result</data>
  <data key="d1">Beneficial acute haemodynamic effects comprising a reduction in preload and afterload with only a slight reduction in heart rate, and increased renal blood flow are seen after oral administration of perindopril 2 to 4mg in patients with congestive heart failure.</data>
  <data key="d3">Beneficial acute haemodynamic effects comprising a reduction in preload and afterload with only a slight reduction in heart rate, and increased renal blood flow are seen after oral administration of perindopril 2 to 4mg in patients with congestive heart failure.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-8412380112980374188">
  <data key="d0">Result</data>
  <data key="d1">In this indication oral administration of perindopril 4 to 8mg once daily reduces supine and standing systolic and diastolic blood pressure by about 5 to 15%, and adequate diastolic blood pressure control (&lt;90mm Hg) is attained in about 50 to 70% of patients with monotherapy.</data>
  <data key="d3">In this indication oral administration of perindopril 4 to 8mg once daily reduces supine and standing systolic and diastolic blood pressure by about 5 to 15%, and adequate diastolic blood pressure control (&lt;90mm Hg) is attained in about 50 to 70% of patients with monotherapy.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-8843911614121635976">
  <data key="d0">Result</data>
  <data key="d1">Limited information in patients with congestive heart failure has indicated beneficial haemodynamic effects with perindopril.</data>
  <data key="d3">Limited information in patients with congestive heart failure has indicated beneficial haemodynamic effects with perindopril.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-1048354603491960383">
  <data key="d0">Result</data>
  <data key="d1">Perindopril has been well tolerated in clinical trials involving patients with mild to moderate essential hypertension.</data>
  <data key="d3">Perindopril has been well tolerated in clinical trials involving patients with mild to moderate essential hypertension.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_1361837061015144963">
  <data key="d0">Result</data>
  <data key="d1">Large-scale clinical trials indicate that perindopril is at least as well tolerated as captopril, atenolol and hydrochlorothiazide plus amiloride in patients with essential hypertension.</data>
  <data key="d3">Large-scale clinical trials indicate that perindopril is at least as well tolerated as captopril, atenolol and hydrochlorothiazide plus amiloride in patients with essential hypertension.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="Compound_CAPTOPRIL">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">CAPTOPRIL</data>
  <data key="d7">captopril</data>
</node>
<node id="Compound_ATENOLOL">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">ATENOLOL</data>
  <data key="d7">atenolol</data>
</node>
<node id="Compound_HYDROCHLOROTHIAZIDE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">HYDROCHLOROTHIAZIDE</data>
  <data key="d7">hydrochlorothiazide</data>
</node>
<node id="Compound_AMILORIDE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">AMILORIDE</data>
  <data key="d7">amiloride</data>
</node>
<node id="PDF_11_Result_-2253920903812482562">
  <data key="d0">Result</data>
  <data key="d1">The usual effective dosage of perindopril is 2 to 8mg once daily in patients with mild to moderate essential hypertension.</data>
  <data key="d3">The usual effective dosage of perindopril is 2 to 8mg once daily in patients with mild to moderate essential hypertension.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_5812999850210364681">
  <data key="d0">Result</data>
  <data key="d1">Limited experience in patients with congestive heart failure suggests that 4mg once daily is an effective dosage</data>
  <data key="d3">Limited experience in patients with congestive heart failure suggests that 4mg once daily is an effective dosage</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_5521930659563623561">
  <data key="d0">Result</data>
  <data key="d1">The active metabolite per- indoprilat is, however, a potent in vitro ACE in- hibitor</data>
  <data key="d3">The active metabolite per- indoprilat is, however, a potent in vitro ACE in- hibitor</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_8305297351042134455">
  <data key="d0">Result</data>
  <data key="d1">Oral administration of perindopril produces dose-dependent inhibition of plasma ACE activity in normotensive and hypertensive animals , healthy human subjects , hyperten- sive patients and patients with congestive heart failure</data>
  <data key="d3">Oral administration of perindopril produces dose-dependent inhibition of plasma ACE activity in normotensive and hypertensive animals , healthy human subjects , hyperten- sive patients and patients with congestive heart failure</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-3108081169811871539">
  <data key="d0">Result</data>
  <data key="d1">As a con- sequence of this ACE inhibition, a decrease in plasma angiotensin II levels occurs, as well as in- creases in plasma renin activity and plasma angio- tensin I levels mediated by negative feedback, and a somewhat variable but frequent decrease in plasma aldosterone levels.</data>
  <data key="d3">As a con- sequence of this ACE inhibition, a decrease in plasma angiotensin II levels occurs, as well as in- creases in plasma renin activity and plasma angio- tensin I levels mediated by negative feedback, and a somewhat variable but frequent decrease in plasma aldosterone levels.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_5816630019852456634">
  <data key="d0">Result</data>
  <data key="d1">Animal studies have indicated that perindopril produces significant ACE inhibition in most tissues, includ- ing lung parenchyma, pulmonary vessels, heart, aortic wall, adrenal glands, proximal renal tubules, glomerular mesangium, renal vessels, brain cortex and pituitary glands, but not in the testes, medulla oblongata or hypothalamus</data>
  <data key="d3">Animal studies have indicated that perindopril produces significant ACE inhibition in most tissues, includ- ing lung parenchyma, pulmonary vessels, heart, aortic wall, adrenal glands, proximal renal tubules, glomerular mesangium, renal vessels, brain cortex and pituitary glands, but not in the testes, medulla oblongata or hypothalamus</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-2111090754358233878">
  <data key="d0">Result</data>
  <data key="d1">It should also be noted that administration of per- indopril to pregnant animals leads to significant fe- tal ACE inhibition, indicating placental transfer of perindopril and/or perindoprilat</data>
  <data key="d3">It should also be noted that administration of per- indopril to pregnant animals leads to significant fe- tal ACE inhibition, indicating placental transfer of perindopril and/or perindoprilat</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_2887498797745895915">
  <data key="d0">Result</data>
  <data key="d1">While intravenously administered perindopril potentiates exogenous bradykinin-induced femoral artery vasodilatation in dogs , the effect of perindopril on endogenous bradykinin and prostaglandin levels has not been reported.</data>
  <data key="d3">While intravenously administered perindopril potentiates exogenous bradykinin-induced femoral artery vasodilatation in dogs , the effect of perindopril on endogenous bradykinin and prostaglandin levels has not been reported.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="Protein_BRADYKININ">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">BRADYKININ</data>
  <data key="d7">bradykinin</data>
</node>
<node id="Compound_PROSTAGLANDINS">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">PROSTAGLANDINS</data>
  <data key="d7">prostaglandins</data>
</node>
<node id="PDF_11_Result_1658112093970035645">
  <data key="d0">Result</data>
  <data key="d1">Animal studies by Lo et al. (1990) have shown that most of the cardiovascular effects of long term per- indopril administration are similar to those of anti- renin immunisation, indicating that blockade of the renin-angiotensin system accounts for most of the effects of perindopril.</data>
  <data key="d3">Animal studies by Lo et al. (1990) have shown that most of the cardiovascular effects of long term per- indopril administration are similar to those of anti- renin immunisation, indicating that blockade of the renin-angiotensin system accounts for most of the effects of perindopril.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_5446436163520006439">
  <data key="d0">Result</data>
  <data key="d1">Perindopril has been reported to normalise the increased plasma atrial natriuretic factor levels in rats with myocardial infarction experimentally in- duced by coronary artery ligation</data>
  <data key="d3">Perindopril has been reported to normalise the increased plasma atrial natriuretic factor levels in rats with myocardial infarction experimentally in- duced by coronary artery ligation</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-2688218205457220709">
  <data key="d0">Result</data>
  <data key="d1">Mean plasma atrial natriuretic factor levels were decreased from 90 to 63 ng/L (p = 0.05) after 15 days' treatment with perindopril 4mg daily in 10 hypertensive patients with chronic nephropathy, an effect which was correlated with the fractional excretion of sodium</data>
  <data key="d3">Mean plasma atrial natriuretic factor levels were decreased from 90 to 63 ng/L (p = 0.05) after 15 days' treatment with perindopril 4mg daily in 10 hypertensive patients with chronic nephropathy, an effect which was correlated with the fractional excretion of sodium</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-4469746774708237442">
  <data key="d0">Result</data>
  <data key="d1">Numerous studies have demonstrated the anti- hypertensive effects of perindopril in animal models of both spontaneous (genetic) and renovascular hypertension</data>
  <data key="d3">Numerous studies have demonstrated the anti- hypertensive effects of perindopril in animal models of both spontaneous (genetic) and renovascular hypertension</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-7235482679999002366">
  <data key="d0">Result</data>
  <data key="d1">The antihypertensive effect of perindopril was more pronounced in sodium-depleted animals , presumably because of their increased dependence on the renin-angiotensin system for maintenance of blood pressure.</data>
  <data key="d3">The antihypertensive effect of perindopril was more pronounced in sodium-depleted animals , presumably because of their increased dependence on the renin-angiotensin system for maintenance of blood pressure.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_2563765306779389364">
  <data key="d0">Result</data>
  <data key="d1">An additive antihypertensive effect was noted when perindopril and nitrendipine were administered concomitantly in the spontaneously hypertensive rat</data>
  <data key="d3">An additive antihypertensive effect was noted when perindopril and nitrendipine were administered concomitantly in the spontaneously hypertensive rat</data>
  <data key="d4">PDF_11</data>
</node>
<node id="Compound_NITRENDIPINE">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">NITRENDIPINE</data>
  <data key="d7">nitrendipine</data>
</node>
<node id="PDF_11_Result_4559622370633345913">
  <data key="d0">Result</data>
  <data key="d1">The reduction in blood pressure produced by perindopril in animals with spontaneous or reno- vascular hypertension was associated with a de- crease in peripheral vascular resistance with no sig- nificant change in heart rate or cardiac output</data>
  <data key="d3">The reduction in blood pressure produced by perindopril in animals with spontaneous or reno- vascular hypertension was associated with a de- crease in peripheral vascular resistance with no sig- nificant change in heart rate or cardiac output</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-3891733967867274678">
  <data key="d0">Result</data>
  <data key="d1">Recently, Muller et al. (1990) found that perindopril normalised the elevated cerebrovascular resistance normally associated with untreated renovascular hypertension in the rat.</data>
  <data key="d3">Recently, Muller et al. (1990) found that perindopril normalised the elevated cerebrovascular resistance normally associated with untreated renovascular hypertension in the rat.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_4691117518972233469">
  <data key="d0">Result</data>
  <data key="d1">Perindopril in- hibited and even prevented development of card- iac hypertrophy in the rat; this was also associated with reversal of the isoenzyme shift of myocardial myosin and improvement in coronary blood flow and papillary muscle mechanical per- formance.</data>
  <data key="d3">Perindopril in- hibited and even prevented development of card- iac hypertrophy in the rat; this was also associated with reversal of the isoenzyme shift of myocardial myosin and improvement in coronary blood flow and papillary muscle mechanical per- formance.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_4436157426692650895">
  <data key="d0">Result</data>
  <data key="d1">In addition, perindopril im- proved large artery (carotid and aorta) and small resistance artery (mesenteric) structure, tending to normalise arterial wall thickness as well as collagen and elastin content, and thereby enhance arterial compliance</data>
  <data key="d3">In addition, perindopril im- proved large artery (carotid and aorta) and small resistance artery (mesenteric) structure, tending to normalise arterial wall thickness as well as collagen and elastin content, and thereby enhance arterial compliance</data>
  <data key="d4">PDF_11</data>
</node>
<node id="Protein_COLLAGEN">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">COLLAGEN</data>
  <data key="d7">collagen</data>
</node>
<node id="Protein_ELASTIN">
  <data key="d0">Entity</data>
  <data key="d5">Protein</data>
  <data key="d6">ELASTIN</data>
  <data key="d7">elastin</data>
</node>
<node id="PDF_11_Result_-8823070298879714663">
  <data key="d0">Result</data>
  <data key="d1">Coronary artery ligation in the rat leads to card- iac hypertrophy and electrophysiological changes, and may be used as a model to study myocardial infarction, left ventricular failure and ventricular arrhythmias. Long term perindopril administra- tion either prevented or inhibited development of experimental cardiac hypertrophy</data>
  <data key="d3">Coronary artery ligation in the rat leads to card- iac hypertrophy and electrophysiological changes, and may be used as a model to study myocardial infarction, left ventricular failure and ventricular arrhythmias. Long term perindopril administra- tion either prevented or inhibited development of experimental cardiac hypertrophy</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-8805107246137760054">
  <data key="d0">Result</data>
  <data key="d1">High doses of perindopril in the perfusate pre- vented these arrhythmias but did not affect nor- adrenaline release in vitro</data>
  <data key="d3">High doses of perindopril in the perfusate pre- vented these arrhythmias but did not affect nor- adrenaline release in vitro</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_7324330300928826471">
  <data key="d0">Result</data>
  <data key="d1">Acute administration of perindopril shortly before coronary artery ligation in vivo significantly re- duced mortality and the severity of ventricular tachycardia and fibrillation</data>
  <data key="d3">Acute administration of perindopril shortly before coronary artery ligation in vivo significantly re- duced mortality and the severity of ventricular tachycardia and fibrillation</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-6656925133536417044">
  <data key="d0">Result</data>
  <data key="d1">Oral administration of single or repeated once daily doses of perindopril 1 to 16mg to normoten- sive subjects either had no significant effect on blood pressure or caused a slight, but significant, blood pressure decrease, particularly with higher doses</data>
  <data key="d3">Oral administration of single or repeated once daily doses of perindopril 1 to 16mg to normoten- sive subjects either had no significant effect on blood pressure or caused a slight, but significant, blood pressure decrease, particularly with higher doses</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-1067514607605544875">
  <data key="d0">Result</data>
  <data key="d1">Ajayi et al. (1986) found that a single oral dose of perindopril 8mg did not affect blood pressure and heart rate responses to dynamic exercise, fore- arm isometric exercise, the cold pressor test or Val- salva's manoeuvre, but enhanced the vagally me- diated sinus arrhythmia associated with deep breathing.</data>
  <data key="d3">Ajayi et al. (1986) found that a single oral dose of perindopril 8mg did not affect blood pressure and heart rate responses to dynamic exercise, fore- arm isometric exercise, the cold pressor test or Val- salva's manoeuvre, but enhanced the vagally me- diated sinus arrhythmia associated with deep breathing.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_4561285386901556600">
  <data key="d0">Result</data>
  <data key="d1">Single oral doses of perindopril 4, 8 and 16mg caused a dose-depend- ent increase in brachial and carotid artery diameter and blood flow with a decrease in forearm vascular resistance, as measured by the pulsed Doppler technique.</data>
  <data key="d3">Single oral doses of perindopril 4, 8 and 16mg caused a dose-depend- ent increase in brachial and carotid artery diameter and blood flow with a decrease in forearm vascular resistance, as measured by the pulsed Doppler technique.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-5950082456397010265">
  <data key="d0">Result</data>
  <data key="d1">Appropriate acute reductions in systolic and diastolic blood pressure have been demonstrated with single oral doses of perindopril 4 to 16mg in patients with essential hypertension</data>
  <data key="d3">Appropriate acute reductions in systolic and diastolic blood pressure have been demonstrated with single oral doses of perindopril 4 to 16mg in patients with essential hypertension</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-8150012407422805875">
  <data key="d0">Result</data>
  <data key="d1">Therapeutic trials have confirmed that 4 to 8mg once daily produces an adequate reduction in systolic and diastolic blood pressure over 24 hours , although pressure reduction may be progressive over several weeks</data>
  <data key="d3">Therapeutic trials have confirmed that 4 to 8mg once daily produces an adequate reduction in systolic and diastolic blood pressure over 24 hours , although pressure reduction may be progressive over several weeks</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_3681192080723752934">
  <data key="d0">Result</data>
  <data key="d1">After 6 weeks' treatment with perindopril 8mg once daily, haemodynamic responses to Valsalva's man- oeuvre, tilt, isometric forearm exercise and cold pressor testing were unaltered, while there was a significant increase in bradycardia during facial immersion; a resetting of the sino-aortic barore- ceptor reflex occurred within 2 hours after the first dose.</data>
  <data key="d3">After 6 weeks' treatment with perindopril 8mg once daily, haemodynamic responses to Valsalva's man- oeuvre, tilt, isometric forearm exercise and cold pressor testing were unaltered, while there was a significant increase in bradycardia during facial immersion; a resetting of the sino-aortic barore- ceptor reflex occurred within 2 hours after the first dose.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_1721636786537021481">
  <data key="d0">Result</data>
  <data key="d1">There was a statistically significant increase in resting forearm blood flow and a tendency for echocardiographically estimated left ventricular mass to decrease (from 192 to 166g, p = 0.12) after 6 weeks' treatment. Regression of left ventricular hypertrophy on long term therapy (3 to 12 months) with perindopril 4 to 8mg daily has been con- firmed in other studies in patients with essential hypertension</data>
  <data key="d3">There was a statistically significant increase in resting forearm blood flow and a tendency for echocardiographically estimated left ventricular mass to decrease (from 192 to 166g, p = 0.12) after 6 weeks' treatment. Regression of left ventricular hypertrophy on long term therapy (3 to 12 months) with perindopril 4 to 8mg daily has been con- firmed in other studies in patients with essential hypertension</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_-5222279738855471904">
  <data key="d0">Result</data>
  <data key="d1">Investigation of the effect of perindopril 2 to 8mg daily on the elastic properties of the brachial artery in 15 patients with essential hypertension re- vealed that it increased arterial compliance (as- sessed by a pulsed Doppler technique) by 42%, de- creased pulsed wave velocity (an indicator of arterial stiffness) by 13% and reduced arterial impedance by 29% after 3 months' treatment</data>
  <data key="d3">Investigation of the effect of perindopril 2 to 8mg daily on the elastic properties of the brachial artery in 15 patients with essential hypertension re- vealed that it increased arterial compliance (as- sessed by a pulsed Doppler technique) by 42%, de- creased pulsed wave velocity (an indicator of arterial stiffness) by 13% and reduced arterial impedance by 29% after 3 months' treatment</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_5436875052255904408">
  <data key="d0">Result</data>
  <data key="d1">The acute haemodynamic effects of single oral doses of perindopril 2 to 4mg have been deter- mined in patients with congestive heart failure of varying severity (NYHA classes II to IV) using in- vasive monitoring (table I). Overall, there was a reduction in preload and afterload, with a slight reduction in heart rate.</data>
  <data key="d3">The acute haemodynamic effects of single oral doses of perindopril 2 to 4mg have been deter- mined in patients with congestive heart failure of varying severity (NYHA classes II to IV) using in- vasive monitoring (table I). Overall, there was a reduction in preload and afterload, with a slight reduction in heart rate.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_3661870917759909080">
  <data key="d0">Result</data>
  <data key="d1">Although hepatic blood flow was unchanged, brachial (+130%) and renal (+34%) blood flows were sig- nificantly increased . A fa- vourable redistribution in regional blood flow thus occurred which was even significant for the renal vascular bed as it exceeded the increase in cardiac output.</data>
  <data key="d3">Although hepatic blood flow was unchanged, brachial (+130%) and renal (+34%) blood flows were sig- nificantly increased . A fa- vourable redistribution in regional blood flow thus occurred which was even significant for the renal vascular bed as it exceeded the increase in cardiac output.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_7944410958009257752">
  <data key="d0">Result</data>
  <data key="d1">Concomitant with the increase in brachial blood flow there was a decrease in forearm vas- cular resistance (approximately halved) and an in- crease in brachial artery diameter (about 15%), the latter reaching values close to those seen in healthy subjects.</data>
  <data key="d3">Concomitant with the increase in brachial blood flow there was a decrease in forearm vas- cular resistance (approximately halved) and an in- crease in brachial artery diameter (about 15%), the latter reaching values close to those seen in healthy subjects.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_7378990707650912457">
  <data key="d0">Result</data>
  <data key="d1">The maximal decrease in mean arterial pressure with perindopril (-15%) did not differ from that with placebo (-16%), while both captopril (-22%) and enalapril (-26%) produced significantly greater decreases (p = 0.012).</data>
  <data key="d3">The maximal decrease in mean arterial pressure with perindopril (-15%) did not differ from that with placebo (-16%), while both captopril (-22%) and enalapril (-26%) produced significantly greater decreases (p = 0.012).</data>
  <data key="d4">PDF_11</data>
</node>
<node id="Compound_ENALAPRIL">
  <data key="d0">Entity</data>
  <data key="d5">Compound</data>
  <data key="d6">ENALAPRIL</data>
  <data key="d7">enalapril</data>
</node>
<node id="PDF_11_Result_2816071552959862711">
  <data key="d0">Result</data>
  <data key="d1">These results might suggest a differential response between ACE inhibitors with respect to their first-dose hypotensive effects.</data>
  <data key="d3">These results might suggest a differential response between ACE inhibitors with respect to their first-dose hypotensive effects.</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_4858937553636521488">
  <data key="d0">Result</data>
  <data key="d1">The renal histological changes in rats with ex- perimentally induced renovascular hypertension were prevented by administration of perindopril for 5 weeks</data>
  <data key="d3">The renal histological changes in rats with ex- perimentally induced renovascular hypertension were prevented by administration of perindopril for 5 weeks</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_1210638954632113027">
  <data key="d0">Result</data>
  <data key="d1">Renal blood flow and glomerular filtration rate were increased in normotensive and spontaneously hypertensive rats during 1 to 12 weeks' administration of perindopril</data>
  <data key="d3">Renal blood flow and glomerular filtration rate were increased in normotensive and spontaneously hypertensive rats during 1 to 12 weeks' administration of perindopril</data>
  <data key="d4">PDF_11</data>
</node>
<node id="PDF_11_Result_6849486154197006296">
  <data key="d0">Result</data>
  <data key="d1">After administration of a single oral dose of per- indopril 8mg to 11 healthy subjects, 24-hour ur- inary output of sodium and chloride were in- creased by about 25% (p &lt; 0.02) and their renal clearance</data>
  <data key="d3">After administration of a single oral dose of per- indopril 8mg to 11 healthy subjects, 24-hour ur- inary output of sodium and chloride were in- creased by about 25% (p &lt; 0.02) and their renal clearance</data>
  <data key="d4">PDF_11</data>
</node>
<edge source="PDF_16" target="PDF_16_Hypothesis_-1001928361261613389">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_16" target="PDF_16_Method_1405357716690634200">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_16" target="PDF_16_Result_-4603631527809478861">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_16" target="PDF_16_Result_-4860963387706469022">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_16" target="PDF_16_Conclusion_6611930757598402587">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_16_Hypothesis_-1001928361261613389" target="Gene_ACE">
  <data key="d8">MENTIONS</data>
  <data key="d9">ACE inhibitors may have direct effects on skeletal muscle.</data>
</edge>
<edge source="PDF_16_Hypothesis_-1001928361261613389" target="Process_SKELETAL MUSCLE">
  <data key="d8">MENTIONS</data>
  <data key="d9">ACE inhibitors may have direct effects on skeletal muscle.</data>
</edge>
<edge source="PDF_16_Method_1405357716690634200" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Participants aged 65 years and older who had problems with mobility or functional impairment were randomly assigned to receive either perindopril or placebo for 20 weeks.</data>
</edge>
<edge source="PDF_16_Result_-4603631527809478861" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">At 20 weeks, the mean 6-minute walking distance was significantly improved in the perindopril group relative to the placebo group</data>
</edge>
<edge source="PDF_16_Result_-4860963387706469022" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">quality of life was maintained in the perindopril group</data>
</edge>
<edge source="PDF_16_Conclusion_6611930757598402587" target="Gene_ACE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Use of the ACE inhibitor perindopril improved exercise capacity in functionally impaired elderly people who had no heart failure and maintained health-related quality of life.</data>
</edge>
<edge source="PDF_16_Conclusion_6611930757598402587" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Use of the ACE inhibitor perindopril improved exercise capacity in functionally impaired elderly people who had no heart failure and maintained health-related quality of life.</data>
</edge>
<edge source="PDF_16_Conclusion_6611930757598402587" target="Disease_HEART FAILURE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Use of the ACE inhibitor perindopril improved exercise capacity in functionally impaired elderly people who had no heart failure and maintained health-related quality of life.</data>
</edge>
<edge source="PDF_17" target="PDF_17_Hypothesis_-660013291876930389">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_17" target="PDF_17_Method_-7388902424420068180">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_17" target="PDF_17_Result_5344063052469787024">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_17" target="PDF_17_Conclusion_4691730757618169805">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_17_Hypothesis_-660013291876930389" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">To evaluate the effects of the angiotensin converting enzyme inhibitor perindopril on six minute walking distance and quality of life in very old patients with left ventricular systolic dysfunction.</data>
</edge>
<edge source="PDF_17_Method_-7388902424420068180" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Prospective, double blind placebo controlled trial with 66 patients (average age 81) with left ventricular systolic dysfunction identified by echocardiography. Treatment with titrated doses of perindopril or placebo for 10 weeks.</data>
</edge>
<edge source="PDF_17_Conclusion_4691730757618169805" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Six minute walking distance is improved considerably by treatment with perindopril in older patients with heart failure caused by left ventricular systolic dysfunction.</data>
</edge>
<edge source="PDF_14" target="PDF_14_Result_-7955122279640508438">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_14" target="PDF_14_Conclusion_-1068359777605661893">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_14" target="PDF_14_Method_-1294717443288242483">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_14_Result_-7955122279640508438" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril resulted in significantly fewer patients reaching the primary endpoint versus all other ACEIs combined. The results were consistent for myocardial infarction, stroke and mortality (5 vs 11%, p = 0.0001).</data>
</edge>
<edge source="PDF_14_Result_-7955122279640508438" target="Disease_MYOCARDIAL INFARCTION">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril resulted in significantly fewer patients reaching the primary endpoint versus all other ACEIs combined. The results were consistent for myocardial infarction, stroke and mortality (5 vs 11%, p = 0.0001).</data>
</edge>
<edge source="PDF_14_Result_-7955122279640508438" target="Disease_STROKE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril resulted in significantly fewer patients reaching the primary endpoint versus all other ACEIs combined. The results were consistent for myocardial infarction, stroke and mortality (5 vs 11%, p = 0.0001).</data>
</edge>
<edge source="PDF_14_Conclusion_-1068359777605661893" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril alone or as part of combination therapy in clinical trials seemed to deliver clear and consistent outcome differences compared to other ACEI trials. In the presence of positive outcomes from robust randomised, controlled trials for perindopril, one cannot assume a class effect for all ACEIs.</data>
</edge>
<edge source="PDF_13" target="PDF_13_Method_5818618468528436876">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_13" target="PDF_13_Result_-7821153563378710597">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_13" target="PDF_13_Result_9070215760168419076">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_13" target="PDF_13_Conclusion_5059259856092741698">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_13_Method_5818618468528436876" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">This prospective cohort study included primary care patients with essential hypertension.</data>
</edge>
<edge source="PDF_13_Result_-7821153563378710597" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">In the great majority of the study patients (more than 96%) perindopril was effective as monotherapy, achieving a significant reduction in both systolic and diastolic blood pressure, and in three-quarters of the study patients it normalized both systolic and diastolic blood pressure.</data>
</edge>
<edge source="PDF_13_Result_9070215760168419076" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">The effectiveness of perindopril was shown in both patients with previously and newly diagnosed hypertension, adverse events were mild and rare, even hyperkalemia was encountered less often than before the onset of the therapy with perindopril.</data>
</edge>
<edge source="PDF_13_Result_9070215760168419076" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">The effectiveness of perindopril was shown in both patients with previously and newly diagnosed hypertension, adverse events were mild and rare, even hyperkalemia was encountered less often than before the onset of the therapy with perindopril.</data>
</edge>
<edge source="PDF_13_Conclusion_5059259856092741698" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Our study confirmed excellent effectiveness of perindopril in the treatment of essential hypertension and its remarkable safety.</data>
</edge>
<edge source="PDF_13_Conclusion_5059259856092741698" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">Our study confirmed excellent effectiveness of perindopril in the treatment of essential hypertension and its remarkable safety.</data>
</edge>
<edge source="PDF_15" target="PDF_15_Hypothesis_6165205839212340986">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_15" target="PDF_15_Method_-3745470565031048406">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_15" target="PDF_15_Result_-2010676726385772421">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_15" target="PDF_15_Result_-5701829914027310010">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_15" target="PDF_15_Conclusion_3200986636981088749">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_15" target="PDF_15_Conclusion_8062723024005871718">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_15_Hypothesis_6165205839212340986" target="Protein_ACE">
  <data key="d8">MENTIONS</data>
  <data key="d9">To assess the antihypertensive efficacy of the angiotensin-converting enzyme (ACE)-inhibitor, perindopril, in the elderly.</data>
</edge>
<edge source="PDF_15_Hypothesis_6165205839212340986" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">To assess the antihypertensive efficacy of the angiotensin-converting enzyme (ACE)-inhibitor, perindopril, in the elderly.</data>
</edge>
<edge source="PDF_15_Hypothesis_6165205839212340986" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">To assess the antihypertensive efficacy of the angiotensin-converting enzyme (ACE)-inhibitor, perindopril, in the elderly.</data>
</edge>
<edge source="PDF_15_Method_-3745470565031048406" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">patients &gt;65 years of age with supine diastolic blood pressure (BP) ≥90 and ≤110 mm Hg at the end of a 4-week placebo washout period were treated with perindopril 4-8 mg/daily vs placebo using a multi-centre, randomised, double-blind, parallel group design.</data>
</edge>
<edge source="PDF_15_Method_-3745470565031048406" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">patients &gt;65 years of age with supine diastolic blood pressure (BP) ≥90 and ≤110 mm Hg at the end of a 4-week placebo washout period were treated with perindopril 4-8 mg/daily vs placebo using a multi-centre, randomised, double-blind, parallel group design.</data>
</edge>
<edge source="PDF_15_Result_-2010676726385772421" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">In the perindopril-group, diastolic BP decreased by 6-7 mm Hg and systolic BP by 10-13 mm Hg (both P &lt; 0.01 vs placebo).</data>
</edge>
<edge source="PDF_15_Result_-5701829914027310010" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril caused additional decreases in diastolic BP by about 2 mm Hg, and in systolic BP by 4-5 mm Hg.</data>
</edge>
<edge source="PDF_15_Conclusion_3200986636981088749" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">the present double-blind, placebo-controlled study shows a significant antihypertensive effect of placebo, and additional effect of perindopril in an elderly population.</data>
</edge>
<edge source="PDF_15_Conclusion_3200986636981088749" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">the present double-blind, placebo-controlled study shows a significant antihypertensive effect of placebo, and additional effect of perindopril in an elderly population.</data>
</edge>
<edge source="PDF_15_Conclusion_8062723024005871718" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">The extent of this effect may be less than observed in middle-aged hypertensives.</data>
</edge>
<edge source="PDF_1" target="PDF_1_Result_-8454390891778832376">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_1" target="PDF_1_Result_3026515512155509167">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_1" target="PDF_1_Result_587467621871043712">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_1" target="PDF_1_Result_-2587084149367949985">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_1" target="PDF_1_Result_-2651618173839202636">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_1" target="PDF_1_Result_-60329191782281013">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_1_Result_-8454390891778832376" target="Compound_HBA1C">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide induced a larger reduction in HbA1c levels than dapagliflozin, with a pronounced effect in those with SIDD.</data>
</edge>
<edge source="PDF_1_Result_-8454390891778832376" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide induced a larger reduction in HbA1c levels than dapagliflozin, with a pronounced effect in those with SIDD.</data>
</edge>
<edge source="PDF_1_Result_-8454390891778832376" target="Compound_DAPAGLIFLOZIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide induced a larger reduction in HbA1c levels than dapagliflozin, with a pronounced effect in those with SIDD.</data>
</edge>
<edge source="PDF_1_Result_-8454390891778832376" target="Disease_TYPE 2 DIABETES MELLITUS">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide induced a larger reduction in HbA1c levels than dapagliflozin, with a pronounced effect in those with SIDD.</data>
</edge>
<edge source="PDF_1_Result_3026515512155509167" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Participants on semaglutide had larger improvements in fasting and postprandial glucose, insulin secretion and BMI than those on dapagliflozin.</data>
</edge>
<edge source="PDF_1_Result_3026515512155509167" target="Compound_DAPAGLIFLOZIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">Participants on semaglutide had larger improvements in fasting and postprandial glucose, insulin secretion and BMI than those on dapagliflozin.</data>
</edge>
<edge source="PDF_1_Result_587467621871043712" target="Compound_DAPAGLIFLOZIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">Dapagliflozin treatment improved the homoeostasis model assessment 2 estimate of insulin resistance (HOMA2-IR) compared with semaglutide treatment.</data>
</edge>
<edge source="PDF_1_Result_587467621871043712" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Dapagliflozin treatment improved the homoeostasis model assessment 2 estimate of insulin resistance (HOMA2-IR) compared with semaglutide treatment.</data>
</edge>
<edge source="PDF_1_Result_587467621871043712" target="Process_INSULIN RESISTANCE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Dapagliflozin treatment improved the homoeostasis model assessment 2 estimate of insulin resistance (HOMA2-IR) compared with semaglutide treatment.</data>
</edge>
<edge source="PDF_1_Result_-2587084149367949985" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide was found to result in greater reductions in fasting glucose, glucose at 2 h of the oral glucose tolerance test (OGTT) and average glucose concentration during continuous monitoring, as well as a higher time in range in participants with SIDD than in those with SIRD.</data>
</edge>
<edge source="PDF_1_Result_-2587084149367949985" target="Disease_TYPE 2 DIABETES MELLITUS">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide was found to result in greater reductions in fasting glucose, glucose at 2 h of the oral glucose tolerance test (OGTT) and average glucose concentration during continuous monitoring, as well as a higher time in range in participants with SIDD than in those with SIRD.</data>
</edge>
<edge source="PDF_1_Result_-2651618173839202636" target="Compound_DAPAGLIFLOZIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">Dapagliflozin resulted in a significantly larger improvement in 2-h glucose and a tendency for greater improvements in fasting glucose and HOMA2-IR in participants with SIDD than in those with SIRD.</data>
</edge>
<edge source="PDF_1_Result_-2651618173839202636" target="Disease_TYPE 2 DIABETES MELLITUS">
  <data key="d8">MENTIONS</data>
  <data key="d9">Dapagliflozin resulted in a significantly larger improvement in 2-h glucose and a tendency for greater improvements in fasting glucose and HOMA2-IR in participants with SIDD than in those with SIRD.</data>
</edge>
<edge source="PDF_6" target="PDF_6_Result_7807270647179962157">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_6" target="PDF_6_Result_-7733577376683516890">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_6" target="PDF_6_Result_-3766554712485558065">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_6" target="PDF_6_Result_1450101461538820557">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_6" target="PDF_6_Result_-5543974218509804172">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_6" target="PDF_6_Result_7097652081495334130">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_6" target="PDF_6_Result_1226396694637456463">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_6" target="PDF_6_Result_3901098566409783361">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_6" target="PDF_6_Result_39484958943931859">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_6" target="PDF_6_Conclusion_-2120543418135045177">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_6" target="PDF_6_Conclusion_-5975492430483773805">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_6" target="PDF_6_Conclusion_-4228870845903613936">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_6_Result_7807270647179962157" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide improves glycemic control with automated insulin delivery compared to placebo.</data>
</edge>
<edge source="PDF_6_Result_-7733577376683516890" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide increased time in the target glucose range by a mean 4.8 (s.d. = 7.6) percentage points compared to placebo.</data>
</edge>
<edge source="PDF_6_Result_-3766554712485558065" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide reduces glycated hemoglobin (HbA1c).</data>
</edge>
<edge source="PDF_6_Result_1450101461538820557" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide reduces weight.</data>
</edge>
<edge source="PDF_6_Result_-5543974218509804172" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide reduces insulin requirements.</data>
</edge>
<edge source="PDF_6_Result_7097652081495334130" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">High-density lipoprotein (HDL) cholesterol was lower with semaglutide than placebo.</data>
</edge>
<edge source="PDF_6_Result_1226396694637456463" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Weight was reduced by 5.3 (2.9) kg with semaglutide compared to placebo.</data>
</edge>
<edge source="PDF_6_Result_3901098566409783361" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Daily insulin use was reduced by 11.3 units with semaglutide compared to placebo.</data>
</edge>
<edge source="PDF_6_Result_39484958943931859" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Daily carbohydrate intake was also reduced by 36 g with semaglutide compared to placebo.</data>
</edge>
<edge source="PDF_6_Conclusion_-2120543418135045177" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide improved glycemic control, with lower insulin requirements, in adults with T1D when used with AID.</data>
</edge>
<edge source="PDF_6_Conclusion_-5975492430483773805" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide also reduced carbohydrate intake, body weight, BMI and waist and hip circumferences compared to placebo.</data>
</edge>
<edge source="PDF_18" target="PDF_18_Hypothesis_-6096125481521144220">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_18" target="PDF_18_Method_5193417751340496414">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_18" target="PDF_18_Result_-407893529333615044">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_18" target="PDF_18_Result_-6385519272228046690">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_18" target="PDF_18_Result_1089460308327150157">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_18" target="PDF_18_Conclusion_8827001182071805207">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_18" target="PDF_18_Conclusion_-8389163720824783125">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_18" target="PDF_18_Result_8810086388341940152">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_18" target="PDF_18_Result_-4438071127433426661">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_18" target="PDF_18_Result_491250402134037445">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_18_Hypothesis_-6096125481521144220" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">We hypothesize that long-term supplementation with intermediate dose of RSV (i.e. 200 mg/kg.day¯¹) affects health and lifespan of the grey mouse lemur.</data>
</edge>
<edge source="PDF_18_Method_5193417751340496414" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Longitudinal monitoring of cognitive and motor performances, occurrence of age-related pathologies, age-related brain atrophy and mortality was performed from adulthood to death in a cohort of male grey mouse lemurs receiving RSV (200 mg.kg¯¹ body weight.day¯¹).</data>
</edge>
<edge source="PDF_18_Result_-407893529333615044" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">RSV supplementation improved cognitive and motor performance at middle age as compared to control animals.</data>
</edge>
<edge source="PDF_18_Result_-6385519272228046690" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Median-lifespan was greater in RSV-fed animals (7.9 years compared to 6.4 years for CTL) but long-term RSV supplementation did not significantly affect all-cause nor age-related mortality.</data>
</edge>
<edge source="PDF_18_Result_1089460308327150157" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Brain grey matter atrophy accelerated in the RSV group at old age as compared to the CTL group.</data>
</edge>
<edge source="PDF_18_Conclusion_8827001182071805207" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Long-term RSV supplementation procures health benefits at middle-age in male mouse lemurs but has limited long-term effects on health and longevity and might even impair brain integrity at older ages.</data>
</edge>
<edge source="PDF_18_Conclusion_-8389163720824783125" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Long-term RSV supplementation does not mimic the lifespan extension provided by chronic CR, and does not reduce either the risk of age-associated diseases or age-associated mortality.</data>
</edge>
<edge source="PDF_18_Result_8810086388341940152" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">RSV animals exhibited better motor abilities than the CTL group</data>
</edge>
<edge source="PDF_18_Result_-4438071127433426661" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">In RSV animals, an age-related grey matter atrophy occurred in the amygdala as well as in Brodmann areas 13-16, 1-3 (primary somato-sensory area), and to a lesser extent in area 24 (anterior cingulate cortex)</data>
</edge>
<edge source="PDF_18_Result_491250402134037445" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">White matter areas from posterior brain regions presented a marked atrophy in RSV</data>
</edge>
<edge source="PDF_2" target="PDF_2_Hypothesis_-2070621026036629826">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_2" target="PDF_2_Method_8186109347083392772">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_2" target="PDF_2_Result_-3239342030352855854">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_2" target="PDF_2_Result_7307697403183768988">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_2" target="PDF_2_Result_7724462909747946980">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_2" target="PDF_2_Result_-5511250891358556857">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_2" target="PDF_2_Result_5262244793152732578">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_2" target="PDF_2_Result_5363330739030996411">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_2" target="PDF_2_Result_-5931998345472062457">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_2" target="PDF_2_Result_509783133794400544">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_2" target="PDF_2_Result_-3638402075649209858">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_2" target="PDF_2_Result_-6642779959515258451">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_2" target="PDF_2_Conclusion_2992662053797503356">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_2" target="PDF_2_Conclusion_-5766293106915615546">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_2_Hypothesis_-2070621026036629826" target="Protein_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1RAs may reduce food intake and BW through distributed effects in the CNS, rather than through a specific localized population of GLP-1Rs.</data>
</edge>
<edge source="PDF_2_Method_8186109347083392772" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">DIO mice and rats fed a high-fat diet received semaglutide, administered subchronically, and the effects on food intake and BW were evaluated.</data>
</edge>
<edge source="PDF_2_Result_-3239342030352855854" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide dose-dependently reduced BW and suppressed food intake in DIO mice.</data>
</edge>
<edge source="PDF_2_Result_7307697403183768988" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide transiently reduced dark phase EE until day 6 of treatment.</data>
</edge>
<edge source="PDF_2_Result_7724462909747946980" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide decreased chocolate intake compared with vehicle.</data>
</edge>
<edge source="PDF_2_Result_-5511250891358556857" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">SemaglutideVT750 was observed in the choroid plexus</data>
</edge>
<edge source="PDF_2_Result_5262244793152732578" target="Protein_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1R was coexpressed with CART in the ARH.</data>
</edge>
<edge source="PDF_2_Result_5262244793152732578" target="Gene_CART">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1R was coexpressed with CART in the ARH.</data>
</edge>
<edge source="PDF_2_Result_5363330739030996411" target="Protein_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1R was highly coexpressed with somatostatin in the ARH and the LSc.</data>
</edge>
<edge source="PDF_2_Result_5363330739030996411" target="Protein_SOMATOSTATIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1R was highly coexpressed with somatostatin in the ARH and the LSc.</data>
</edge>
<edge source="PDF_2_Result_-5931998345472062457" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide colocalized with GLP-1R, CART, SST, and TH in the ARH.</data>
</edge>
<edge source="PDF_2_Result_-5931998345472062457" target="Protein_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide colocalized with GLP-1R, CART, SST, and TH in the ARH.</data>
</edge>
<edge source="PDF_2_Result_-5931998345472062457" target="Gene_CART">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide colocalized with GLP-1R, CART, SST, and TH in the ARH.</data>
</edge>
<edge source="PDF_2_Result_-5931998345472062457" target="Gene_SOMATOSTATIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide colocalized with GLP-1R, CART, SST, and TH in the ARH.</data>
</edge>
<edge source="PDF_2_Result_-5931998345472062457" target="Gene_TH">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide colocalized with GLP-1R, CART, SST, and TH in the ARH.</data>
</edge>
<edge source="PDF_2_Result_509783133794400544" target="Gene_POMC">
  <data key="d8">MENTIONS</data>
  <data key="d9">POMC/CART neurons were depolarized in response to semaglutide.</data>
</edge>
<edge source="PDF_2_Result_509783133794400544" target="Gene_CART">
  <data key="d8">MENTIONS</data>
  <data key="d9">POMC/CART neurons were depolarized in response to semaglutide.</data>
</edge>
<edge source="PDF_2_Result_509783133794400544" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">POMC/CART neurons were depolarized in response to semaglutide.</data>
</edge>
<edge source="PDF_2_Result_-3638402075649209858" target="Gene_NPY">
  <data key="d8">MENTIONS</data>
  <data key="d9">NPY/AgRP neurons elicited membrane hyperpolarization and became inactivated in response to semaglutide.</data>
</edge>
<edge source="PDF_2_Result_-3638402075649209858" target="Gene_AGRP">
  <data key="d8">MENTIONS</data>
  <data key="d9">NPY/AgRP neurons elicited membrane hyperpolarization and became inactivated in response to semaglutide.</data>
</edge>
<edge source="PDF_2_Result_-3638402075649209858" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">NPY/AgRP neurons elicited membrane hyperpolarization and became inactivated in response to semaglutide.</data>
</edge>
<edge source="PDF_2_Result_-6642779959515258451" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Increased c-Fos activity was observed in the bed nuclei of the stria terminalis, central amygdala nucleus, OV, parasubthalamic nucleus, SFO, midline group of the dorsal thalamus, PB, AP, DMX, and NTS after acute s.c. semaglutide</data>
</edge>
<edge source="PDF_2_Result_-6642779959515258451" target="Protein_C-FOS">
  <data key="d8">MENTIONS</data>
  <data key="d9">Increased c-Fos activity was observed in the bed nuclei of the stria terminalis, central amygdala nucleus, OV, parasubthalamic nucleus, SFO, midline group of the dorsal thalamus, PB, AP, DMX, and NTS after acute s.c. semaglutide</data>
</edge>
<edge source="PDF_2_Conclusion_2992662053797503356" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide lowers body weight by direct interaction with diverse GLP-1R populations and by directly and indirectly affecting the activity of neural pathways involved in food intake, reward, and energy expenditure.</data>
</edge>
<edge source="PDF_2_Conclusion_2992662053797503356" target="Protein_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide lowers body weight by direct interaction with diverse GLP-1R populations and by directly and indirectly affecting the activity of neural pathways involved in food intake, reward, and energy expenditure.</data>
</edge>
<edge source="PDF_2_Conclusion_-5766293106915615546" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">These data demonstrate that peripherally injected semaglutide enters GLP-1R-positive neurons, which likely interface with central appetite regulation pathways.</data>
</edge>
<edge source="PDF_2_Conclusion_-5766293106915615546" target="Protein_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">These data demonstrate that peripherally injected semaglutide enters GLP-1R-positive neurons, which likely interface with central appetite regulation pathways.</data>
</edge>
<edge source="PDF_8" target="PDF_8_Hypothesis_-2155207627074218973">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_8" target="PDF_8_Method_1964857229919188915">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_8" target="PDF_8_Method_9032079059677385326">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_8" target="PDF_8_Method_-4829911658522364862">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_8" target="PDF_8_Result_3531943023714543105">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_8" target="PDF_8_Result_-9175753306507436856">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_8" target="PDF_8_Result_-575873265780513373">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_8" target="PDF_8_Result_-1490347002616043120">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_8" target="PDF_8_Result_-5185130707825005661">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_8" target="PDF_8_Result_-1244192531941085761">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_8" target="PDF_8_Conclusion_5848802722130182223">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_8_Hypothesis_-2155207627074218973" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Peptides known as GLP-1 protectors are predicted to increase the half-life of GLP-1 in vivo.</data>
</edge>
<edge source="PDF_8_Method_1964857229919188915" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1 and protecting peptides (peptide 1 or peptide 2) were mixed at various ratios and then incubated at 25 °C for 5 min.</data>
</edge>
<edge source="PDF_8_Method_9032079059677385326" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Sprague Dawley rats (n = 5 per group, male) were subcutaneously injected with GLP-1/peptide 1 (1:10, containing of 750 µg GLP-1/kg body weight) and GLP-1/peptide 2 (1:10, containing of 750 µg GLP-1/kg body weight), respectively.</data>
</edge>
<edge source="PDF_8_Method_-4829911658522364862" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Male Zucker Diabetic Fatty (ZDF) rats (n = 6 per group) were treated with GLP-1/peptide 1 complex (GLP-1 ~300 µg/kg/4 days), exenatide (100 µg/kg/12 h) and liraglutide (300 µg/kg/ daily) for 28 days.</data>
</edge>
<edge source="PDF_8_Method_-4829911658522364862" target="Compound_EXENATIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Male Zucker Diabetic Fatty (ZDF) rats (n = 6 per group) were treated with GLP-1/peptide 1 complex (GLP-1 ~300 µg/kg/4 days), exenatide (100 µg/kg/12 h) and liraglutide (300 µg/kg/ daily) for 28 days.</data>
</edge>
<edge source="PDF_8_Method_-4829911658522364862" target="Compound_LIRAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Male Zucker Diabetic Fatty (ZDF) rats (n = 6 per group) were treated with GLP-1/peptide 1 complex (GLP-1 ~300 µg/kg/4 days), exenatide (100 µg/kg/12 h) and liraglutide (300 µg/kg/ daily) for 28 days.</data>
</edge>
<edge source="PDF_8_Result_3531943023714543105" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">The HPLC results predicted that the visible peak with a retention time of 18.8 min might be the GLP-1/ peptide 1 complex.</data>
</edge>
<edge source="PDF_8_Result_-9175753306507436856" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">The half-life of GLP-1 inside the GLP-1/peptide 1 complex was 90 h and inside the GLP-1/peptide 2 complex was 75 h in human serum. However, the half-life of the GLP-1 monomer was only 2.5 min.</data>
</edge>
<edge source="PDF_8_Result_-575873265780513373" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Data in Fig. 3B demonstrated that after a single dose administration in Sprague Dawley rats,there was a significant increase in the concentration of GLP-1.</data>
</edge>
<edge source="PDF_8_Result_-1490347002616043120" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">The concentration of GLP-1 reached a plateau at 10 h and gradually decreased but remained detectable until 150 h.</data>
</edge>
<edge source="PDF_8_Result_-5185130707825005661" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">The secreted insulin level was dramatically raised to 956.7 37.84 pmol/l (GLP-1/peptide 1) and 827.9 31.40 pmol/l (GLP-1/peptide 2).</data>
</edge>
<edge source="PDF_8_Result_-5185130707825005661" target="Protein_INSULIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">The secreted insulin level was dramatically raised to 956.7 37.84 pmol/l (GLP-1/peptide 1) and 827.9 31.40 pmol/l (GLP-1/peptide 2).</data>
</edge>
<edge source="PDF_8_Result_-1244192531941085761" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Compared to GLP-1 treated rats, there were 1.6-fold increases in the AUCglucose value of GLP-1/peptide complex treated rats (GLP-1/peptide and GLP-1/peptide 2, Fig. 5B).</data>
</edge>
<edge source="PDF_8_Conclusion_5848802722130182223" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Based upon these results, it is suggested that the GLP-1/peptide 1 complex might be utilized as a possible potent anti-diabetic drug in the treatment of type 2 diabetes mellitus.</data>
</edge>
<edge source="PDF_8_Conclusion_5848802722130182223" target="Disease_TYPE 2 DIABETES MELLITUS">
  <data key="d8">MENTIONS</data>
  <data key="d9">Based upon these results, it is suggested that the GLP-1/peptide 1 complex might be utilized as a possible potent anti-diabetic drug in the treatment of type 2 diabetes mellitus.</data>
</edge>
<edge source="PDF_20" target="PDF_20_Hypothesis_-5301540700550017463">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_20" target="PDF_20_Method_6161906745008828660">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_20" target="PDF_20_Result_6101583909347351880">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_20" target="PDF_20_Result_-6598078894435798902">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_20" target="PDF_20_Conclusion_-7391324592977041247">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_20" target="PDF_20_Result_-1236927307856544601">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_20" target="PDF_20_Result_-3905280296332344895">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_20" target="PDF_20_Result_-5082324705917866817">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_20" target="PDF_20_Result_-2458969671575563981">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_20" target="PDF_20_Result_1639635215569233018">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_20" target="PDF_20_Result_5320510106815831434">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_20" target="PDF_20_Result_-2312552359889964690">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_20" target="PDF_20_Method_7481165225366016652">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_20" target="PDF_20_Result_2005892203652200507">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_20_Hypothesis_-5301540700550017463" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Resveratrol can counteract age-related memory and mood impairments and the associated detrimental changes in the hippocampus.</data>
</edge>
<edge source="PDF_20_Method_6161906745008828660" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Two groups of male F344 rats in late middle-age having similar learning and memory abilities were chosen and treated with resveratrol or vehicle for four weeks.</data>
</edge>
<edge source="PDF_20_Result_6101583909347351880" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Analyses at ~25 months of age uncovered improved learning, memory and mood function in resveratrol-treated animals but impairments in vehicle-treated animals.</data>
</edge>
<edge source="PDF_20_Result_-6598078894435798902" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Resveratrol-treated animals also displayed increased net neurogenesis and microvasculature, and diminished astrocyte hypertrophy and microglial activation in the hippocampus.</data>
</edge>
<edge source="PDF_20_Conclusion_-7391324592977041247" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Resveratrol treatment in late middle age is efficacious for improving memory and mood function in old age.</data>
</edge>
<edge source="PDF_20_Result_-1236927307856544601" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">RESV treatment enhanced net neurogenesis in the hippocampus of aged rats.</data>
</edge>
<edge source="PDF_20_Result_-3905280296332344895" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">RESV treatment promoted increased neurogenesis in aged rats for prolonged periods.</data>
</edge>
<edge source="PDF_20_Result_-5082324705917866817" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">RESV treatment enhanced microvasculature in the hippocampus of aged rats.</data>
</edge>
<edge source="PDF_20_Result_-2458969671575563981" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">RESV treatment reduced the hypertrophy of astrocytes in aged rats.</data>
</edge>
<edge source="PDF_20_Result_1639635215569233018" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">RESV treatment reduced activation of microglia in aged rats.</data>
</edge>
<edge source="PDF_20_Result_5320510106815831434" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">RESV treatment did not alter the volume of hippocampus.</data>
</edge>
<edge source="PDF_20_Result_-2312552359889964690" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">RESV treatment improved mood function in aged rats.</data>
</edge>
<edge source="PDF_20_Method_7481165225366016652" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Analyses of immobility (or floating) time in a forced swim test (FST) was used as a measure of depressive-like behavior in VEH and RESV treated rats</data>
</edge>
<edge source="PDF_20_Result_2005892203652200507" target="Compound_RESVERATROL">
  <data key="d8">MENTIONS</data>
  <data key="d9">RESV treatment enhanced net neurogenesis in the last week of RESV treatment, and maintained increased neurogenesis and microvasculature when examined at ~25 months of age (i.e. ~6 weeks after the termination of RESV treatment).</data>
</edge>
<edge source="PDF_7" target="PDF_7_Result_-3090687357896771049">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_7" target="PDF_7_Result_4746371245348940570">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_7" target="PDF_7_Result_7075294896616740654">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_7" target="PDF_7_Result_7945670712715370278">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_7" target="PDF_7_Result_-4324159728268611067">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_7" target="PDF_7_Result_-2500740769242565691">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_7" target="PDF_7_Result_-181240583450137585">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_7" target="PDF_7_Result_8316280004690137734">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_7" target="PDF_7_Conclusion_-163162194050676099">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_7" target="PDF_7_Conclusion_5799145113198410169">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_7_Result_-3090687357896771049" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">After 68 weeks of treatment, 495 protein targets (438 unique proteins) were identified to be significantly affected by semaglutide treatment (compared with placebo) in STEP 1 (P &lt;0.05, after Holm-Bonferroni correction for the 7,289 aptamers tested). In the STEP 2 trial, the relative abundance of 277 protein targets (244 unique proteins) was changed significantly in response to semaglutide treatment relative to placebo.</data>
</edge>
<edge source="PDF_7_Result_4746371245348940570" target="Protein_MTORC1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment downregulated proteins involved in key biological pathways governing xenobiotic metabolism, fatty acid metabolism and mammalian target of rapamycin complex 1 (MTORC1) signaling, among others.</data>
</edge>
<edge source="PDF_7_Result_4746371245348940570" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment downregulated proteins involved in key biological pathways governing xenobiotic metabolism, fatty acid metabolism and mammalian target of rapamycin complex 1 (MTORC1) signaling, among others.</data>
</edge>
<edge source="PDF_7_Result_7075294896616740654" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Levels of digestive enzymes secreted from the exocrine pancreas were increased by semaglutide.</data>
</edge>
<edge source="PDF_7_Result_7945670712715370278" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Adjusting for body weight and HbA1c changes at the end of treatment identified 47 (38 unique proteins) and 15 (14 unique proteins) protein targets significantly altered by semaglutide treatment in STEP 1 and STEP 2, respectively.</data>
</edge>
<edge source="PDF_7_Result_-4324159728268611067" target="Protein_TNC">
  <data key="d8">MENTIONS</data>
  <data key="d9">Significantly downregulated proteins when adjusting for body weight effects in STEP 1 known to be associated with CVD risk included tenascin C (TNC), NT-proBNP, thrombospondin 2 (THBS2), complement component C1q receptor (cluster of differentiation 93 (CD93)), macrophage scavenger receptor 1-extra- cellular domain (MSR1) and angiopoietin-2 (ANGPT2).</data>
</edge>
<edge source="PDF_7_Result_-4324159728268611067" target="Protein_THBS2">
  <data key="d8">MENTIONS</data>
  <data key="d9">Significantly downregulated proteins when adjusting for body weight effects in STEP 1 known to be associated with CVD risk included tenascin C (TNC), NT-proBNP, thrombospondin 2 (THBS2), complement component C1q receptor (cluster of differentiation 93 (CD93)), macrophage scavenger receptor 1-extra- cellular domain (MSR1) and angiopoietin-2 (ANGPT2).</data>
</edge>
<edge source="PDF_7_Result_-4324159728268611067" target="Protein_ANGPT2">
  <data key="d8">MENTIONS</data>
  <data key="d9">Significantly downregulated proteins when adjusting for body weight effects in STEP 1 known to be associated with CVD risk included tenascin C (TNC), NT-proBNP, thrombospondin 2 (THBS2), complement component C1q receptor (cluster of differentiation 93 (CD93)), macrophage scavenger receptor 1-extra- cellular domain (MSR1) and angiopoietin-2 (ANGPT2).</data>
</edge>
<edge source="PDF_7_Result_-2500740769242565691" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">The final trained signature included 30 aptamers (Extended Data Fig. 4a). The signature included proteins implicated in biological processes related to obesity and T2D (for example, adipogenesis, fatty acid metabolism, glycolysis and signaling pathways), consistent with the protein set analysis described above (Extended Data Fig. 2a), along with proteins related to fat mass and function, weight loss, CVD, endothelial function, lipid metabolism, pancreatic endocrine and exocrine function, inflammation and possibly cancer risk. The STEP 1 signature had a high classification performance (internal nested cross-validation area under the curve (AUC) = 0.94), showing that semaglutide treatment results in a specific serum proteomic signature.</data>
</edge>
<edge source="PDF_7_Result_-181240583450137585" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Using data from STEP 1 and STEP 2, we found that semaglutide treatment reduced this CVD risk score compared with placebo</data>
</edge>
<edge source="PDF_7_Result_8316280004690137734" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Proteins that were significantly elevated with higher genetic risk for increased BMI or T2D in the deCODE population were significantly downregulated by semaglutide and vice versa.</data>
</edge>
<edge source="PDF_7_Conclusion_-163162194050676099" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide might lower CVD risk, even in populations without established CVD.</data>
</edge>
<edge source="PDF_7_Conclusion_5799145113198410169" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Analyses of the clinical trial data also support effects of semaglutide beyond those that can be explained by the observed weight loss and HbA1c reductions.</data>
</edge>
<edge source="PDF_9" target="PDF_9_Method_-1688702638989591655">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Method_375044847436254170">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Method_9055882207821409057">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Method_805948597297295883">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Method_-1823932813714502215">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Method_-3336356305181547916">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Method_-5482894651495804418">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Method_-5703729735610551584">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Method_-9073987393270922306">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Method_-6087577049620300557">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Method_-3080344647673332069">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Method_-7413824123133422542">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Method_2768604988970750107">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Method_4202996321749210489">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Method_-7476481780943625109">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Result_2019945866185237103">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Result_607836368851484092">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Result_-4673995192671679884">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Result_-1450192277327488715">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Result_-258544749106952487">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Result_-1260085640156065862">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Result_3182651631102266101">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Result_3539517018661627335">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Conclusion_679698040799210895">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9" target="PDF_9_Conclusion_9195966159291304153">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_9_Method_-1688702638989591655" target="Protein_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Enzymatic assays were performed to determine IDO1 inhibitory activity of small organic molecules using a specific incubation medium composition.</data>
</edge>
<edge source="PDF_9_Method_375044847436254170" target="Protein_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">IDO1 inhibition was assessed using purified ferric IDO1 reduced by ascorbic acid, with methylene blue as an electron carrier and catalase to prevent inhibition by H2O2.</data>
</edge>
<edge source="PDF_9_Method_9055882207821409057" target="Protein_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Redox-cycling compounds were screened to identify potential IDO1 inhibitors.</data>
</edge>
<edge source="PDF_9_Method_805948597297295883" target="Protein_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">The 2,2-diphenyl-1-picrylhydrazyl (DPPH) antioxidant assay was used to investigate redox-cycling properties of IDO1 inhibitors.</data>
</edge>
<edge source="PDF_9_Method_-5703729735610551584" target="Protein_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Cellular assays were performed to assess IDO1 inhibition in a cellular context.</data>
</edge>
<edge source="PDF_9_Method_-6087577049620300557" target="Protein_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Alternative tests such as the trypan blue exclusion assay, the lactate dehydrogenase (LDH) assay, the sulforhodamine B (SRB) assay, and an ATP assay were used to validate cellular dose-response curves on IDO1.</data>
</edge>
<edge source="PDF_9_Method_-3080344647673332069" target="Protein_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Structure-based in silico design of IDO1 inhibitors was performed based on crystal structures.</data>
</edge>
<edge source="PDF_9_Method_-7413824123133422542" target="Protein_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Docking studies were conducted to predict binding modes of IDO1 inhibitors.</data>
</edge>
<edge source="PDF_9_Method_2768604988970750107" target="Protein_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">High throughput screening (HTS) was used to discover new IDO1 inhibitor scaffolds.</data>
</edge>
<edge source="PDF_9_Method_4202996321749210489" target="Protein_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Differential scanning fluorimetry was used to screen for IDO1 binding.</data>
</edge>
<edge source="PDF_9_Method_-7476481780943625109" target="Protein_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Yeast growth assays were used to identify IDO1 inhibitors.</data>
</edge>
<edge source="PDF_9_Result_2019945866185237103" target="Protein_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Many compounds showed IDO1 inhibitory activity through unspecific mechanisms.</data>
</edge>
<edge source="PDF_9_Result_607836368851484092" target="Protein_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Isothiazolinone derivatives probably inhibit IDO1 through covalent modification of nucleophilic amino acid side chains.</data>
</edge>
<edge source="PDF_9_Result_-4673995192671679884" target="Protein_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">The binding of the selenic compound ebselen to cysteine residues of IDO1 shifts the Soret band of ferric IDO1.</data>
</edge>
<edge source="PDF_9_Result_-1450192277327488715" target="Protein_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">IDO1 activity is modulated by antioxidants both at the transcriptional level and posttranslationally by limiting the availability of heme.</data>
</edge>
<edge source="PDF_9_Result_-258544749106952487" target="Protein_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Some quinones and iminoquinones display cellular IC50 values much higher than their enzymatic IC50 values and close to their LD50 values, suggesting that the prevention of L-Trp to NFK oxidation could result from perturbing the cells' redox state instead of specific inhibition of IDO1.</data>
</edge>
<edge source="PDF_9_Result_3182651631102266101" target="Protein_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">High side chain and backbone flexibility lead to different active site conformations of IDO1.</data>
</edge>
<edge source="PDF_9_Conclusion_679698040799210895" target="Protein_IDO1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Kinetic measurements with variable L-Trp concentrations do not yield direct information if a compound binds to the IDO1 active site or not.</data>
</edge>
<edge source="PDF_10" target="PDF_10_Hypothesis_1118222127013157452">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10" target="PDF_10_Method_-5097182521296068159">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10" target="PDF_10_Method_4648609706086463165">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10" target="PDF_10_Result_676263553865618409">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10" target="PDF_10_Result_3012633037109734960">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10" target="PDF_10_Result_-4375520179359696923">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10" target="PDF_10_Result_4000361962435329222">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10" target="PDF_10_Result_-4888990278513477082">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10" target="PDF_10_Result_-8052761423405053473">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10" target="PDF_10_Result_-2631523302642105631">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10" target="PDF_10_Result_-61111773155434910">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10" target="PDF_10_Conclusion_-7323234921176164086">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10" target="PDF_10_Conclusion_7228628183724661220">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_10_Hypothesis_1118222127013157452" target="Protein_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
</edge>
<edge source="PDF_10_Hypothesis_1118222127013157452" target="Gene_POMC">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
</edge>
<edge source="PDF_10_Hypothesis_1118222127013157452" target="Gene_CART">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
</edge>
<edge source="PDF_10_Hypothesis_1118222127013157452" target="Compound_LIRAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.</data>
</edge>
<edge source="PDF_10_Method_-5097182521296068159" target="Compound_LIRAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Peripheral injection of fluorescently labeled liraglutide in mice revealed the presence of the drug in the circumventricular organs.</data>
</edge>
<edge source="PDF_10_Method_4648609706086463165" target="Compound_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Electrophysiological measurements of murine brain slices revealed that GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling.</data>
</edge>
<edge source="PDF_10_Method_4648609706086463165" target="Gene_POMC">
  <data key="d8">MENTIONS</data>
  <data key="d9">Electrophysiological measurements of murine brain slices revealed that GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling.</data>
</edge>
<edge source="PDF_10_Method_4648609706086463165" target="Gene_CART">
  <data key="d8">MENTIONS</data>
  <data key="d9">Electrophysiological measurements of murine brain slices revealed that GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling.</data>
</edge>
<edge source="PDF_10_Method_4648609706086463165" target="Gene_NPY">
  <data key="d8">MENTIONS</data>
  <data key="d9">Electrophysiological measurements of murine brain slices revealed that GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling.</data>
</edge>
<edge source="PDF_10_Method_4648609706086463165" target="Gene_AGRP">
  <data key="d8">MENTIONS</data>
  <data key="d9">Electrophysiological measurements of murine brain slices revealed that GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling.</data>
</edge>
<edge source="PDF_10_Method_4648609706086463165" target="Compound_GABA">
  <data key="d8">MENTIONS</data>
  <data key="d9">Electrophysiological measurements of murine brain slices revealed that GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling.</data>
</edge>
<edge source="PDF_10_Result_676263553865618409" target="Gene_CART">
  <data key="d8">MENTIONS</data>
  <data key="d9">Liraglutide treatment significantly increased the mean Cart mRNA levels in the ARC 1.6-fold compared with both vehicle-treated, ad libitum-fed rats and weight-matched rats (P&lt;0.001, liraglutide vs. vehicle and vs. weight-matched), whereas Pomc expression was unaffected.</data>
</edge>
<edge source="PDF_10_Result_676263553865618409" target="Gene_POMC">
  <data key="d8">MENTIONS</data>
  <data key="d9">Liraglutide treatment significantly increased the mean Cart mRNA levels in the ARC 1.6-fold compared with both vehicle-treated, ad libitum-fed rats and weight-matched rats (P&lt;0.001, liraglutide vs. vehicle and vs. weight-matched), whereas Pomc expression was unaffected.</data>
</edge>
<edge source="PDF_10_Result_676263553865618409" target="Compound_LIRAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Liraglutide treatment significantly increased the mean Cart mRNA levels in the ARC 1.6-fold compared with both vehicle-treated, ad libitum-fed rats and weight-matched rats (P&lt;0.001, liraglutide vs. vehicle and vs. weight-matched), whereas Pomc expression was unaffected.</data>
</edge>
<edge source="PDF_10_Result_3012633037109734960" target="Gene_NPY">
  <data key="d8">MENTIONS</data>
  <data key="d9">A 1.4-fold increase in Npy mRNA levels and a 1.7-fold increase in Agrp mRNA levels were observed in weight-matched rats, while levels were unaltered following treatment with liraglutide (P &lt; 0.05, weight matched vs. vehicle and vs. liraglutide, Figure 2B), suggesting an ability of liraglutide to suppress the food-deprived hunger signals observed in the weight-matched control group.</data>
</edge>
<edge source="PDF_10_Result_3012633037109734960" target="Gene_AGRP">
  <data key="d8">MENTIONS</data>
  <data key="d9">A 1.4-fold increase in Npy mRNA levels and a 1.7-fold increase in Agrp mRNA levels were observed in weight-matched rats, while levels were unaltered following treatment with liraglutide (P &lt; 0.05, weight matched vs. vehicle and vs. liraglutide, Figure 2B), suggesting an ability of liraglutide to suppress the food-deprived hunger signals observed in the weight-matched control group.</data>
</edge>
<edge source="PDF_10_Result_3012633037109734960" target="Compound_LIRAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">A 1.4-fold increase in Npy mRNA levels and a 1.7-fold increase in Agrp mRNA levels were observed in weight-matched rats, while levels were unaltered following treatment with liraglutide (P &lt; 0.05, weight matched vs. vehicle and vs. liraglutide, Figure 2B), suggesting an ability of liraglutide to suppress the food-deprived hunger signals observed in the weight-matched control group.</data>
</edge>
<edge source="PDF_10_Result_-4375520179359696923" target="Compound_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1(7-36)amide (10 nM) caused a substantial outward current in NPY cells</data>
</edge>
<edge source="PDF_10_Result_-4375520179359696923" target="Gene_NPY">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1(7-36)amide (10 nM) caused a substantial outward current in NPY cells</data>
</edge>
<edge source="PDF_10_Result_4000361962435329222" target="Compound_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1(7-36)amide failed to change the current in the presence of bicuculline, demonstrating that GABA-A receptor activation was likely responsible for the inhibitory effects of GLP-1(7-36)amide on NPY neurons.</data>
</edge>
<edge source="PDF_10_Result_4000361962435329222" target="Protein_GABA-A">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1(7-36)amide failed to change the current in the presence of bicuculline, demonstrating that GABA-A receptor activation was likely responsible for the inhibitory effects of GLP-1(7-36)amide on NPY neurons.</data>
</edge>
<edge source="PDF_10_Result_4000361962435329222" target="Gene_NPY">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1(7-36)amide failed to change the current in the presence of bicuculline, demonstrating that GABA-A receptor activation was likely responsible for the inhibitory effects of GLP-1(7-36)amide on NPY neurons.</data>
</edge>
<edge source="PDF_10_Result_-4888990278513477082" target="Compound_LIRAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">administration of liraglutide750 (s.c. 400 µg/kg) to Glp1r-/- mice revealed a loss of these nuclei-specific signals, demonstrating that the accumulation of the liraglutide750 signal entirely depends on binding of liraglutide750 to the GLP-1R.</data>
</edge>
<edge source="PDF_10_Result_-4888990278513477082" target="Protein_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">administration of liraglutide750 (s.c. 400 µg/kg) to Glp1r-/- mice revealed a loss of these nuclei-specific signals, demonstrating that the accumulation of the liraglutide750 signal entirely depends on binding of liraglutide750 to the GLP-1R.</data>
</edge>
<edge source="PDF_10_Result_-8052761423405053473" target="Compound_LIRAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">In hypothalamic ARC neurons, liraglutide appeared to be internalized, as in pancreatic ẞ cells</data>
</edge>
<edge source="PDF_10_Result_-2631523302642105631" target="Protein_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1R were expressed on virtually all POMC/CART neurons</data>
</edge>
<edge source="PDF_10_Result_-2631523302642105631" target="Gene_POMC">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1R were expressed on virtually all POMC/CART neurons</data>
</edge>
<edge source="PDF_10_Result_-2631523302642105631" target="Gene_CART">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1R were expressed on virtually all POMC/CART neurons</data>
</edge>
<edge source="PDF_10_Result_-61111773155434910" target="Compound_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">Stimulation with GLP-1(7-36)amide dose dependently depolarized POMC neurons (5.3 ± 0.7 mV and 8.4 ± 1.4 mV for 10 and 100 nM, respectively) and increased the frequency of action potentials in 7 of 7 cells from 2 animals</data>
</edge>
<edge source="PDF_10_Result_-61111773155434910" target="Gene_POMC">
  <data key="d8">MENTIONS</data>
  <data key="d9">Stimulation with GLP-1(7-36)amide dose dependently depolarized POMC neurons (5.3 ± 0.7 mV and 8.4 ± 1.4 mV for 10 and 100 nM, respectively) and increased the frequency of action potentials in 7 of 7 cells from 2 animals</data>
</edge>
<edge source="PDF_10_Conclusion_-7323234921176164086" target="Protein_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">the long-acting GLP-1R ago- nist liraglutide, when injected peripherally, targets hypothalamic GLP-1Rs located on ARC neurons and that these neurons are likely mediators of liraglutide-induced weight loss</data>
</edge>
<edge source="PDF_10_Conclusion_-7323234921176164086" target="Compound_LIRAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">the long-acting GLP-1R ago- nist liraglutide, when injected peripherally, targets hypothalamic GLP-1Rs located on ARC neurons and that these neurons are likely mediators of liraglutide-induced weight loss</data>
</edge>
<edge source="PDF_10_Conclusion_7228628183724661220" target="Protein_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">Our data collectively indicate that GLP-1Rs in the ARC could play an important role as mediators of the long-term body weight- lowering effects of a peripherally administered long-acting GLP-1 analog-in this case liraglutide</data>
</edge>
<edge source="PDF_10_Conclusion_7228628183724661220" target="Compound_LIRAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Our data collectively indicate that GLP-1Rs in the ARC could play an important role as mediators of the long-term body weight- lowering effects of a peripherally administered long-acting GLP-1 analog-in this case liraglutide</data>
</edge>
<edge source="PDF_5" target="PDF_5_Hypothesis_3983644344882168355">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Method_-7437006454939263303">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Result_486879588226485803">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Result_-2859336671449135130">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Result_-6195138621265668278">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Result_-6716606027273492474">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Result_-8964148140503980180">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Result_2212965905093549929">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Result_924721623483609916">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Result_-1603145797845319656">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Result_8763054309734859190">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Result_7669237552842980219">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Result_-6567360113983550527">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Result_551580069177254747">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Result_3564476496712209234">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Result_793911901043520945">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Result_-8257945448189805228">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5" target="PDF_5_Conclusion_1340985672363221141">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_5_Hypothesis_3983644344882168355" target="Protein_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">GLP-1R agonist diabetes drug can ameliorate neurodegeneration in a mouse model of infantile neurometabolic disease.</data>
</edge>
<edge source="PDF_5_Method_-7437006454939263303" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide was administered systemically at a high dose weekly to juvenile INAD mice.</data>
</edge>
<edge source="PDF_5_Result_486879588226485803" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment significantly increased levels of key neuroprotective molecules while decreasing those involved in pro-neurodegenerative pathways.</data>
</edge>
<edge source="PDF_5_Result_-2859336671449135130" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment extended lifespan and rescued locomotor functions in a mouse model of INAD.</data>
</edge>
<edge source="PDF_5_Result_-6195138621265668278" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment resulted in a significant increase in GLP-1R expression in Pla2g6-/- mice.</data>
</edge>
<edge source="PDF_5_Result_-6195138621265668278" target="Protein_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment resulted in a significant increase in GLP-1R expression in Pla2g6-/- mice.</data>
</edge>
<edge source="PDF_5_Result_-6195138621265668278" target="Gene_PLA2G6">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment resulted in a significant increase in GLP-1R expression in Pla2g6-/- mice.</data>
</edge>
<edge source="PDF_5_Result_-6716606027273492474" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment resulted in a significant reduction in mRNA levels of ATF-3 compared to untreated Pla2g6-/- mice.</data>
</edge>
<edge source="PDF_5_Result_-6716606027273492474" target="Protein_ATF-3">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment resulted in a significant reduction in mRNA levels of ATF-3 compared to untreated Pla2g6-/- mice.</data>
</edge>
<edge source="PDF_5_Result_-6716606027273492474" target="Gene_PLA2G6">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment resulted in a significant reduction in mRNA levels of ATF-3 compared to untreated Pla2g6-/- mice.</data>
</edge>
<edge source="PDF_5_Result_-8964148140503980180" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment ameliorated levels of GSK3β to those measured in wild-type controls and showed a significant difference compared to age-matched untreated Pla2g6-/- mice.</data>
</edge>
<edge source="PDF_5_Result_-8964148140503980180" target="Protein_GSK3B">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment ameliorated levels of GSK3β to those measured in wild-type controls and showed a significant difference compared to age-matched untreated Pla2g6-/- mice.</data>
</edge>
<edge source="PDF_5_Result_-8964148140503980180" target="Gene_PLA2G6">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment ameliorated levels of GSK3β to those measured in wild-type controls and showed a significant difference compared to age-matched untreated Pla2g6-/- mice.</data>
</edge>
<edge source="PDF_5_Result_2212965905093549929" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment significantly increased CREB mRNA levels compared to untreated Pla2g6-/- mice and restored expression levels to those observed in the wild-type controls.</data>
</edge>
<edge source="PDF_5_Result_2212965905093549929" target="Protein_CREB">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment significantly increased CREB mRNA levels compared to untreated Pla2g6-/- mice and restored expression levels to those observed in the wild-type controls.</data>
</edge>
<edge source="PDF_5_Result_2212965905093549929" target="Gene_PLA2G6">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment significantly increased CREB mRNA levels compared to untreated Pla2g6-/- mice and restored expression levels to those observed in the wild-type controls.</data>
</edge>
<edge source="PDF_5_Result_924721623483609916" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment resulted in amelioration of neuronal loss, with significantly higher numbers of neurons observed in the treated group compared to untreated controls in the cortex (S1BF).</data>
</edge>
<edge source="PDF_5_Result_-1603145797845319656" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment increased levels of BClxL to those found in the wild-type controls and statistically significantly increased in comparison to untreated Pla2g6-/- mice.</data>
</edge>
<edge source="PDF_5_Result_-1603145797845319656" target="Protein_BCLXL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment increased levels of BClxL to those found in the wild-type controls and statistically significantly increased in comparison to untreated Pla2g6-/- mice.</data>
</edge>
<edge source="PDF_5_Result_-1603145797845319656" target="Gene_PLA2G6">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment increased levels of BClxL to those found in the wild-type controls and statistically significantly increased in comparison to untreated Pla2g6-/- mice.</data>
</edge>
<edge source="PDF_5_Result_8763054309734859190" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment increased levels of BCl2 to those found in the wild-type controls and significantly increased in comparison to untreated Pla2g6-/- mice.</data>
</edge>
<edge source="PDF_5_Result_8763054309734859190" target="Protein_BCL2">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment increased levels of BCl2 to those found in the wild-type controls and significantly increased in comparison to untreated Pla2g6-/- mice.</data>
</edge>
<edge source="PDF_5_Result_8763054309734859190" target="Gene_PLA2G6">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment increased levels of BCl2 to those found in the wild-type controls and significantly increased in comparison to untreated Pla2g6-/- mice.</data>
</edge>
<edge source="PDF_5_Result_7669237552842980219" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment showed a protective effect in Pla2g6-/- mice through significantly reduced Bax expression compared to age-matched untreated Pla2g6-/- mice.</data>
</edge>
<edge source="PDF_5_Result_7669237552842980219" target="Protein_BAX">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment showed a protective effect in Pla2g6-/- mice through significantly reduced Bax expression compared to age-matched untreated Pla2g6-/- mice.</data>
</edge>
<edge source="PDF_5_Result_7669237552842980219" target="Gene_PLA2G6">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment showed a protective effect in Pla2g6-/- mice through significantly reduced Bax expression compared to age-matched untreated Pla2g6-/- mice.</data>
</edge>
<edge source="PDF_5_Result_-6567360113983550527" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">RIP3 was significantly reduced in weekly 0.5 µg/g semaglutide treated mice compared to untreated Pla2g6-/- mice.</data>
</edge>
<edge source="PDF_5_Result_-6567360113983550527" target="Protein_RIP3">
  <data key="d8">MENTIONS</data>
  <data key="d9">RIP3 was significantly reduced in weekly 0.5 µg/g semaglutide treated mice compared to untreated Pla2g6-/- mice.</data>
</edge>
<edge source="PDF_5_Result_-6567360113983550527" target="Gene_PLA2G6">
  <data key="d8">MENTIONS</data>
  <data key="d9">RIP3 was significantly reduced in weekly 0.5 µg/g semaglutide treated mice compared to untreated Pla2g6-/- mice.</data>
</edge>
<edge source="PDF_5_Result_551580069177254747" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Microglial activation was significantly reduced by weekly 0.5 µg/g semaglutide treatment in Pla2g6-/- mice compared to the untreated controls.</data>
</edge>
<edge source="PDF_5_Result_551580069177254747" target="Gene_PLA2G6">
  <data key="d8">MENTIONS</data>
  <data key="d9">Microglial activation was significantly reduced by weekly 0.5 µg/g semaglutide treatment in Pla2g6-/- mice compared to the untreated controls.</data>
</edge>
<edge source="PDF_5_Result_3564476496712209234" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment significantly reduced the CD68 immunoreactivity in all the affected areas compared to untreated Pla2g6-/- mice.</data>
</edge>
<edge source="PDF_5_Result_3564476496712209234" target="Protein_CD68">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment significantly reduced the CD68 immunoreactivity in all the affected areas compared to untreated Pla2g6-/- mice.</data>
</edge>
<edge source="PDF_5_Result_3564476496712209234" target="Gene_PLA2G6">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment significantly reduced the CD68 immunoreactivity in all the affected areas compared to untreated Pla2g6-/- mice.</data>
</edge>
<edge source="PDF_5_Result_793911901043520945" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Astrogliosis was significantly ameliorated following semaglutide treatment compared to the untreated Pla2g6-/- controls.</data>
</edge>
<edge source="PDF_5_Result_793911901043520945" target="Gene_PLA2G6">
  <data key="d8">MENTIONS</data>
  <data key="d9">Astrogliosis was significantly ameliorated following semaglutide treatment compared to the untreated Pla2g6-/- controls.</data>
</edge>
<edge source="PDF_5_Result_-8257945448189805228" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">High-dose semaglutide treatment significantly reduced the number of vacuoles compared to untreated Pla2g6-/- mice in the cortex.</data>
</edge>
<edge source="PDF_5_Result_-8257945448189805228" target="Gene_PLA2G6">
  <data key="d8">MENTIONS</data>
  <data key="d9">High-dose semaglutide treatment significantly reduced the number of vacuoles compared to untreated Pla2g6-/- mice in the cortex.</data>
</edge>
<edge source="PDF_5_Conclusion_1340985672363221141" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment administered once a week to a mouse model of INAD is neuroprotective, ameliorates neuroinflammation and reduces cell death pathways, resulting in significant improvements to locomotor function and lifespan.</data>
</edge>
<edge source="PDF_5_Conclusion_1340985672363221141" target="Disease_INAD">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide treatment administered once a week to a mouse model of INAD is neuroprotective, ameliorates neuroinflammation and reduces cell death pathways, resulting in significant improvements to locomotor function and lifespan.</data>
</edge>
<edge source="PDF_19" target="PDF_19_Hypothesis_5289388398369228207">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Method_850012236976339227">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Result_366711149377926412">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Result_-1638143175366158459">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Result_6667101106283799368">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Result_-152527027810759783">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Result_4844417600976532472">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Result_2136482510085313533">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Result_3330498275100582759">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Result_-9174667434230489420">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Result_-4112474976594474053">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Result_8095632726691338850">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Result_-1690465482618680369">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Result_884761514541857341">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Result_-7697977620803994591">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Result_-3213791352831985279">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Result_1333388756008666363">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19" target="PDF_19_Conclusion_4385708097619144801">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_19_Hypothesis_5289388398369228207" target="Compound_CFCHPS">
  <data key="d8">MENTIONS</data>
  <data key="d9">Lifelong assault on healthy cells by cfChPs is the underlying cause of ageing, and that ageing could be retarded by deactivating extra-cellular cfChPs.</data>
</edge>
<edge source="PDF_19_Method_850012236976339227" target="Gene_C57BL/6">
  <data key="d8">MENTIONS</data>
  <data key="d9">C57BL/6 mice were divided into 3 equal groups; one group was sacrificed at age 3 months, and which acted as young controls. The remaining mice were allowed to age, and at age 10 months the experimental ageing group was given R-Cu by oral gavage twice daily for further 12 months at a dose of 1 mg/kg of R and 0.1 µg/kg of Cu.</data>
</edge>
<edge source="PDF_19_Method_850012236976339227" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">C57BL/6 mice were divided into 3 equal groups; one group was sacrificed at age 3 months, and which acted as young controls. The remaining mice were allowed to age, and at age 10 months the experimental ageing group was given R-Cu by oral gavage twice daily for further 12 months at a dose of 1 mg/kg of R and 0.1 µg/kg of Cu.</data>
</edge>
<edge source="PDF_19_Method_850012236976339227" target="Compound_R">
  <data key="d8">MENTIONS</data>
  <data key="d9">C57BL/6 mice were divided into 3 equal groups; one group was sacrificed at age 3 months, and which acted as young controls. The remaining mice were allowed to age, and at age 10 months the experimental ageing group was given R-Cu by oral gavage twice daily for further 12 months at a dose of 1 mg/kg of R and 0.1 µg/kg of Cu.</data>
</edge>
<edge source="PDF_19_Method_850012236976339227" target="Compound_CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">C57BL/6 mice were divided into 3 equal groups; one group was sacrificed at age 3 months, and which acted as young controls. The remaining mice were allowed to age, and at age 10 months the experimental ageing group was given R-Cu by oral gavage twice daily for further 12 months at a dose of 1 mg/kg of R and 0.1 µg/kg of Cu.</data>
</edge>
<edge source="PDF_19_Result_366711149377926412" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment led to reduction of several biological hallmarks of ageing in brain cells which included telomere attrition, amyloid deposition, DNA damage, apoptosis, inflammation, senescence, aneuploidy and mitochondrial dysfunction.</data>
</edge>
<edge source="PDF_19_Result_-1638143175366158459" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment also led to significant reduction in blood levels of glucose, cholesterol and C-reactive protein.</data>
</edge>
<edge source="PDF_19_Result_6667101106283799368" target="Protein_SOD">
  <data key="d8">MENTIONS</data>
  <data key="d9">ageing mice showed significant reduction in SOD levels in brain cells</data>
</edge>
<edge source="PDF_19_Result_-152527027810759783" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment led to marked increase in SOD levels that were similar to that detected in young control mice</data>
</edge>
<edge source="PDF_19_Result_-152527027810759783" target="Protein_SOD">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment led to marked increase in SOD levels that were similar to that detected in young control mice</data>
</edge>
<edge source="PDF_19_Result_4844417600976532472" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment did lead to an increase in SOD activity in serum of ageing mice, restoring them to levels similar to those seen in young control mice</data>
</edge>
<edge source="PDF_19_Result_4844417600976532472" target="Protein_SOD">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment did lead to an increase in SOD activity in serum of ageing mice, restoring them to levels similar to those seen in young control mice</data>
</edge>
<edge source="PDF_19_Result_2136482510085313533" target="Compound_CFCHPS">
  <data key="d8">MENTIONS</data>
  <data key="d9">copious presence of cfChPs (yellow fluorescent signals) were detected in the extracellular spaces of brain of ageing mice. cfChPs were virtually eliminated following R-Cu treatment for one-year.</data>
</edge>
<edge source="PDF_19_Result_2136482510085313533" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">copious presence of cfChPs (yellow fluorescent signals) were detected in the extracellular spaces of brain of ageing mice. cfChPs were virtually eliminated following R-Cu treatment for one-year.</data>
</edge>
<edge source="PDF_19_Result_3330498275100582759" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">R-Cu treatment restored telomere length to a significant degree in female mice</data>
</edge>
<edge source="PDF_19_Result_-9174667434230489420" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">a reduction was seen in ageing mice of both sexes (p&lt;0.01 in both sexes), which was again significantly restored following R-Cu treatment in female (p&lt;0.01) but not in male mice</data>
</edge>
<edge source="PDF_19_Result_-4112474976594474053" target="Protein_AMYLOID">
  <data key="d8">MENTIONS</data>
  <data key="d9">amyloid deposition in the form of amyloid fibrils in ageing mice. The latter was remarkably reduced following one year of R-Cu treatment</data>
</edge>
<edge source="PDF_19_Result_-4112474976594474053" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">amyloid deposition in the form of amyloid fibrils in ageing mice. The latter was remarkably reduced following one year of R-Cu treatment</data>
</edge>
<edge source="PDF_19_Result_8095632726691338850" target="Protein_BDNF">
  <data key="d8">MENTIONS</data>
  <data key="d9">Brain derived neurotrophic factor (BDNF), which plays an important role in neuronal survival and growth 36, was greatly reduced in sera of ageing mice of both sexes as measured by ELISA (p&lt;0.01 and p&lt;0.05 in female and male mice, respectively) (Fig. 4B). R-Cu treatment for one year resorted serum BDNF levels nearly to those seen in young mice in both sexes (p&lt;0.05 and p&lt;0.001 in female and male mice, respectively) (Fig. 4B).</data>
</edge>
<edge source="PDF_19_Result_8095632726691338850" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">Brain derived neurotrophic factor (BDNF), which plays an important role in neuronal survival and growth 36, was greatly reduced in sera of ageing mice of both sexes as measured by ELISA (p&lt;0.01 and p&lt;0.05 in female and male mice, respectively) (Fig. 4B). R-Cu treatment for one year resorted serum BDNF levels nearly to those seen in young mice in both sexes (p&lt;0.05 and p&lt;0.001 in female and male mice, respectively) (Fig. 4B).</data>
</edge>
<edge source="PDF_19_Result_-1690465482618680369" target="Protein_H2AX">
  <data key="d8">MENTIONS</data>
  <data key="d9">DNA damage was examined using phosphorylation of H2AX as a marker of dsDNA breaks40. y-H2AX levels were markedly increased in ageing mice (p&lt;0.001 and p&lt;0.0001 in female and male mice, respectively). R-Cu treatment reduced y-H2AX levels (p&lt;0.01 and p&lt;0.05 in female and male mice, respectively) (Fig. 5A, left &amp; right hand panels).</data>
</edge>
<edge source="PDF_19_Result_-1690465482618680369" target="Compound_DNA">
  <data key="d8">MENTIONS</data>
  <data key="d9">DNA damage was examined using phosphorylation of H2AX as a marker of dsDNA breaks40. y-H2AX levels were markedly increased in ageing mice (p&lt;0.001 and p&lt;0.0001 in female and male mice, respectively). R-Cu treatment reduced y-H2AX levels (p&lt;0.01 and p&lt;0.05 in female and male mice, respectively) (Fig. 5A, left &amp; right hand panels).</data>
</edge>
<edge source="PDF_19_Result_-1690465482618680369" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">DNA damage was examined using phosphorylation of H2AX as a marker of dsDNA breaks40. y-H2AX levels were markedly increased in ageing mice (p&lt;0.001 and p&lt;0.0001 in female and male mice, respectively). R-Cu treatment reduced y-H2AX levels (p&lt;0.01 and p&lt;0.05 in female and male mice, respectively) (Fig. 5A, left &amp; right hand panels).</data>
</edge>
<edge source="PDF_19_Result_884761514541857341" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">Highly significant increase in apoptosis in ageing brain cells was seen in both sexes (p&lt;0.0001). R-Cu treatment significantly reduced the degree of apoptosis in mice of both sexes (p&lt;0.01 and p&lt;0.0001 in female and male mice, respectively) (Fig. 5B, left &amp; right hand panels).</data>
</edge>
<edge source="PDF_19_Result_884761514541857341" target="Process_APOPTOSIS">
  <data key="d8">MENTIONS</data>
  <data key="d9">Highly significant increase in apoptosis in ageing brain cells was seen in both sexes (p&lt;0.0001). R-Cu treatment significantly reduced the degree of apoptosis in mice of both sexes (p&lt;0.01 and p&lt;0.0001 in female and male mice, respectively) (Fig. 5B, left &amp; right hand panels).</data>
</edge>
<edge source="PDF_19_Result_-7697977620803994591" target="Protein_NF-KB">
  <data key="d8">MENTIONS</data>
  <data key="d9">The latter was highly significantly elevated in ageing mice of both sexes (p &lt; 0.0001). R-Cu treatment significantly reduced NF-kB levels in both sexes (p&lt;0.05 and p&lt;0.01 in female and male mice, respectively) (Fig. 5C, left &amp; right hand panels).</data>
</edge>
<edge source="PDF_19_Result_-7697977620803994591" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">The latter was highly significantly elevated in ageing mice of both sexes (p &lt; 0.0001). R-Cu treatment significantly reduced NF-kB levels in both sexes (p&lt;0.05 and p&lt;0.01 in female and male mice, respectively) (Fig. 5C, left &amp; right hand panels).</data>
</edge>
<edge source="PDF_19_Result_-3213791352831985279" target="Protein_H2AX">
  <data key="d8">MENTIONS</data>
  <data key="d9">We observed persistence of numerous co-localizing signals of y-H2AX with those of telomeres (DNA-SCARS)—a classical hallmark of senescence43—in ageing mice of both sexes (p&lt;0.001). Quantification of co-localising signals revealed a marked reduction following R-Cu treatment (p&lt;0.01 in both sexes) (Fig. 6A, upper &amp; lower panels).</data>
</edge>
<edge source="PDF_19_Result_-3213791352831985279" target="Gene_TELOMERES">
  <data key="d8">MENTIONS</data>
  <data key="d9">We observed persistence of numerous co-localizing signals of y-H2AX with those of telomeres (DNA-SCARS)—a classical hallmark of senescence43—in ageing mice of both sexes (p&lt;0.001). Quantification of co-localising signals revealed a marked reduction following R-Cu treatment (p&lt;0.01 in both sexes) (Fig. 6A, upper &amp; lower panels).</data>
</edge>
<edge source="PDF_19_Result_-3213791352831985279" target="Compound_DNA">
  <data key="d8">MENTIONS</data>
  <data key="d9">We observed persistence of numerous co-localizing signals of y-H2AX with those of telomeres (DNA-SCARS)—a classical hallmark of senescence43—in ageing mice of both sexes (p&lt;0.001). Quantification of co-localising signals revealed a marked reduction following R-Cu treatment (p&lt;0.01 in both sexes) (Fig. 6A, upper &amp; lower panels).</data>
</edge>
<edge source="PDF_19_Result_-3213791352831985279" target="Process_SENESCENCE">
  <data key="d8">MENTIONS</data>
  <data key="d9">We observed persistence of numerous co-localizing signals of y-H2AX with those of telomeres (DNA-SCARS)—a classical hallmark of senescence43—in ageing mice of both sexes (p&lt;0.001). Quantification of co-localising signals revealed a marked reduction following R-Cu treatment (p&lt;0.01 in both sexes) (Fig. 6A, upper &amp; lower panels).</data>
</edge>
<edge source="PDF_19_Result_-3213791352831985279" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">We observed persistence of numerous co-localizing signals of y-H2AX with those of telomeres (DNA-SCARS)—a classical hallmark of senescence43—in ageing mice of both sexes (p&lt;0.001). Quantification of co-localising signals revealed a marked reduction following R-Cu treatment (p&lt;0.01 in both sexes) (Fig. 6A, upper &amp; lower panels).</data>
</edge>
<edge source="PDF_19_Result_1333388756008666363" target="Protein_53BP1">
  <data key="d8">MENTIONS</data>
  <data key="d9">the number of co-localizing signals of 53BP1 and PML were markedly increased in ageing mice of both sexes (p&lt;0.0001). Co-localising signals were significantly reduced following R-Cu treatment for 1 year (p&lt;0.05 and p&lt;0.01 in female and male mice, respectively) (Fig. 6B, left &amp; right hand panels).</data>
</edge>
<edge source="PDF_19_Result_1333388756008666363" target="Protein_PML">
  <data key="d8">MENTIONS</data>
  <data key="d9">the number of co-localizing signals of 53BP1 and PML were markedly increased in ageing mice of both sexes (p&lt;0.0001). Co-localising signals were significantly reduced following R-Cu treatment for 1 year (p&lt;0.05 and p&lt;0.01 in female and male mice, respectively) (Fig. 6B, left &amp; right hand panels).</data>
</edge>
<edge source="PDF_19_Result_1333388756008666363" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">the number of co-localizing signals of 53BP1 and PML were markedly increased in ageing mice of both sexes (p&lt;0.0001). Co-localising signals were significantly reduced following R-Cu treatment for 1 year (p&lt;0.05 and p&lt;0.01 in female and male mice, respectively) (Fig. 6B, left &amp; right hand panels).</data>
</edge>
<edge source="PDF_19_Conclusion_4385708097619144801" target="Compound_CFCHPS">
  <data key="d8">MENTIONS</data>
  <data key="d9">cfChPs act as global instigators of ageing and neurodegeneration, and that therapeutic use of R-Cu may help to make healthy ageing an attainable goal.</data>
</edge>
<edge source="PDF_19_Conclusion_4385708097619144801" target="Compound_R-CU">
  <data key="d8">MENTIONS</data>
  <data key="d9">cfChPs act as global instigators of ageing and neurodegeneration, and that therapeutic use of R-Cu may help to make healthy ageing an attainable goal.</data>
</edge>
<edge source="PDF_3" target="PDF_3_Hypothesis_-4679385473648779113">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Method_-6051751568582498301">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Method_816710081986762244">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Method_-5394029100478570223">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Method_5912197178049720103">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Method_4679292067826613729">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Method_1930217671267736327">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Method_1200006301349517513">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Result_-2436540140130895462">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Result_3277555210032171539">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Result_3542628263517594065">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Result_-4585105860993238033">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Result_-7076444585394845266">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Result_-3807290741009570591">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Result_-6195899216514636334">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Result_3230802158087093871">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Result_-157677116027046846">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Result_1762540584757598420">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Result_-1210487380892098746">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Result_4648796894935863897">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Result_6167789673436234015">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Conclusion_-1497665836386122097">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Conclusion_-3129359784067431577">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Conclusion_816397274048116659">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Conclusion_-1948668734909414417">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Conclusion_2321696407336075315">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Conclusion_4209648061107124474">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Conclusion_-5221819320897875189">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3" target="PDF_3_Conclusion_-4419455904112913995">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_3_Hypothesis_-4679385473648779113" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">peripheral GLP-1 signals to the brain to suppress eating via vagal and/or endocrine activation of central GLP-1-producing preproglucagon (PPG) neurons, i.e. that peripheral and central GLP-1 systems comprise a unified, directly connected gut-brain satiation circuit</data>
</edge>
<edge source="PDF_3_Hypothesis_-4679385473648779113" target="Gene_PPG">
  <data key="d8">MENTIONS</data>
  <data key="d9">peripheral GLP-1 signals to the brain to suppress eating via vagal and/or endocrine activation of central GLP-1-producing preproglucagon (PPG) neurons, i.e. that peripheral and central GLP-1 systems comprise a unified, directly connected gut-brain satiation circuit</data>
</edge>
<edge source="PDF_3_Method_-6051751568582498301" target="Gene_PPG">
  <data key="d8">MENTIONS</data>
  <data key="d9">viral ablation of PPGNTS neurons, using AAV-mediated selective expression of diptheria toxin subunit A (DTA)</data>
</edge>
<edge source="PDF_3_Method_816710081986762244" target="Gene_PPG">
  <data key="d8">MENTIONS</data>
  <data key="d9">chemogenetic inhibition of PPGNTS neurons on termination of large solid and liquid meals, using the inhibitory hM4Di Designer Receptor Exclusively Activated by Designer Drugs (DREADD)</data>
</edge>
<edge source="PDF_3_Method_-5394029100478570223" target="Gene_PPG">
  <data key="d8">MENTIONS</data>
  <data key="d9">chemogenetic activation of PPGNTS neurons with hM3Dq DREADD</data>
</edge>
<edge source="PDF_3_Method_5912197178049720103" target="Gene_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">optogenetic activation of the central axon terminals of Glp1r VANS with the excitatory opsin ChR2</data>
</edge>
<edge source="PDF_3_Method_4679292067826613729" target="Gene_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">Cre-dependent monosynaptic retrograde rabies virus tracing in combination with RNAscope fluorescence in situ hybridisation in nodose ganglia for Glp1rand oxytocin receptor gene (Oxtr) expression</data>
</edge>
<edge source="PDF_3_Method_4679292067826613729" target="Gene_OXTR">
  <data key="d8">MENTIONS</data>
  <data key="d9">Cre-dependent monosynaptic retrograde rabies virus tracing in combination with RNAscope fluorescence in situ hybridisation in nodose ganglia for Glp1rand oxytocin receptor gene (Oxtr) expression</data>
</edge>
<edge source="PDF_3_Method_1930217671267736327" target="Gene_PPG">
  <data key="d8">MENTIONS</data>
  <data key="d9">ex vivo calcium imaging using coronal brainstem slices from transgenic mice expressing GCaMP3 in PPGNTS neurons</data>
</edge>
<edge source="PDF_3_Method_1200006301349517513" target="Gene_PPG">
  <data key="d8">MENTIONS</data>
  <data key="d9">quantifying cFos expression in the PPG-YFP mouse line</data>
</edge>
<edge source="PDF_3_Result_-2436540140130895462" target="Gene_PPG">
  <data key="d8">MENTIONS</data>
  <data key="d9">PPGNTS neuron inhibition increased fasting-induced pellet refeeding during hour 1 in a sex-independent manner, and this effect was driven by increased meal size, rather than frequency</data>
</edge>
<edge source="PDF_3_Result_3277555210032171539" target="Gene_PPG">
  <data key="d8">MENTIONS</data>
  <data key="d9">Ensure intake was increased by PPGNTS neuron inhibition, and, consistent with effects on pellet intake in the FED system, this increase was driven by increased duration of Ensure eating</data>
</edge>
<edge source="PDF_3_Result_3542628263517594065" target="Gene_PPG">
  <data key="d8">MENTIONS</data>
  <data key="d9">PPGNTS activation reduced intake by ~40% in the first 24 hours</data>
</edge>
<edge source="PDF_3_Result_-4585105860993238033" target="Gene_PPG">
  <data key="d8">MENTIONS</data>
  <data key="d9">PPGNTS neuron activation advanced the point of satiation by ~15 minutes</data>
</edge>
<edge source="PDF_3_Result_-7076444585394845266" target="Gene_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">chemogenetic activation of Glp1rVANs using the excitatory hM3Dq DREADD in ad libitum eating mice suppressed eating during the dark but not subsequent light phase</data>
</edge>
<edge source="PDF_3_Result_-3807290741009570591" target="Gene_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">Optogenetic activation of Glp1r terminals within the NTS conditioned avoidance of the paired flavour</data>
</edge>
<edge source="PDF_3_Result_-6195899216514636334" target="Gene_PPG">
  <data key="d8">MENTIONS</data>
  <data key="d9">33% of all PPGNTS neuron-innervating VANs express Oxtralone, and 21% of VANs which express Oxtralone synapse onto PPGNTS neurons</data>
</edge>
<edge source="PDF_3_Result_-6195899216514636334" target="Gene_OXTR">
  <data key="d8">MENTIONS</data>
  <data key="d9">33% of all PPGNTS neuron-innervating VANs express Oxtralone, and 21% of VANs which express Oxtralone synapse onto PPGNTS neurons</data>
</edge>
<edge source="PDF_3_Result_3230802158087093871" target="Compound_OXYTOCIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">oxytocin activated 84% of glutamate-responsive PPGNTS neurons</data>
</edge>
<edge source="PDF_3_Result_3230802158087093871" target="Gene_PPG">
  <data key="d8">MENTIONS</data>
  <data key="d9">oxytocin activated 84% of glutamate-responsive PPGNTS neurons</data>
</edge>
<edge source="PDF_3_Result_-157677116027046846" target="Compound_OXYTOCIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">oxytocin acutely suppressed eating in ad libitum eating control mice, this effect was completely abolished in mice in which PPGNTS neurons had been virally ablated by DTA expression</data>
</edge>
<edge source="PDF_3_Result_-157677116027046846" target="Gene_PPG">
  <data key="d8">MENTIONS</data>
  <data key="d9">oxytocin acutely suppressed eating in ad libitum eating control mice, this effect was completely abolished in mice in which PPGNTS neurons had been virally ablated by DTA expression</data>
</edge>
<edge source="PDF_3_Result_1762540584757598420" target="Compound_LIRAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Liraglutide robustly suppressed intake and bodyweight over 24 hours in ad libitum eating eGFP-transduced control mice, however DTA ablation of PPGNTS neurons had no effect on the magnitude of eating suppression at any timepoint</data>
</edge>
<edge source="PDF_3_Result_1762540584757598420" target="Gene_PPG">
  <data key="d8">MENTIONS</data>
  <data key="d9">Liraglutide robustly suppressed intake and bodyweight over 24 hours in ad libitum eating eGFP-transduced control mice, however DTA ablation of PPGNTS neurons had no effect on the magnitude of eating suppression at any timepoint</data>
</edge>
<edge source="PDF_3_Result_-1210487380892098746" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide suppressed eating to an even greater extent than liraglutide, and similarly PPGNTS neuron ablation had no impact on acute or delayed eating suppression, or on bodyweight loss</data>
</edge>
<edge source="PDF_3_Result_-1210487380892098746" target="Gene_PPG">
  <data key="d8">MENTIONS</data>
  <data key="d9">Semaglutide suppressed eating to an even greater extent than liraglutide, and similarly PPGNTS neuron ablation had no impact on acute or delayed eating suppression, or on bodyweight loss</data>
</edge>
<edge source="PDF_3_Result_4648796894935863897" target="Gene_PPG">
  <data key="d8">MENTIONS</data>
  <data key="d9">less than 3% of PPGNTS neurons were activated by semaglutide</data>
</edge>
<edge source="PDF_3_Result_4648796894935863897" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">less than 3% of PPGNTS neurons were activated by semaglutide</data>
</edge>
<edge source="PDF_3_Result_6167789673436234015" target="Compound_SEMAGLUTIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">either manipulation alone suppressed eating over the first 24 hours, with semaglutide eliciting the stronger effect. Crucially, their combined effect was significantly greater than that of semaglutide alone throughout the duration of acute chemogenetic activation</data>
</edge>
<edge source="PDF_3_Conclusion_-1497665836386122097" target="Gene_PPG">
  <data key="d8">MENTIONS</data>
  <data key="d9">PPGNTS neurons are recruited to encode physiological satiation, specifically by ingestion of large meals</data>
</edge>
<edge source="PDF_3_Conclusion_-3129359784067431577" target="Gene_PPG">
  <data key="d8">MENTIONS</data>
  <data key="d9">PPGNTS neurons have translational potential as a pharmacological target for obesity treatment</data>
</edge>
<edge source="PDF_3_Conclusion_-3129359784067431577" target="Disease_OBESITY">
  <data key="d8">MENTIONS</data>
  <data key="d9">PPGNTS neurons have translational potential as a pharmacological target for obesity treatment</data>
</edge>
<edge source="PDF_3_Conclusion_816397274048116659" target="Gene_OXTR">
  <data key="d8">MENTIONS</data>
  <data key="d9">Oxtr- rather than Glp1r-expressing VANs are the primary source of gastrointestinal distension signals driving PPGNTS neuron-mediated satiation</data>
</edge>
<edge source="PDF_3_Conclusion_816397274048116659" target="Gene_GLP-1R">
  <data key="d8">MENTIONS</data>
  <data key="d9">Oxtr- rather than Glp1r-expressing VANs are the primary source of gastrointestinal distension signals driving PPGNTS neuron-mediated satiation</data>
</edge>
<edge source="PDF_3_Conclusion_816397274048116659" target="Gene_PPG">
  <data key="d8">MENTIONS</data>
  <data key="d9">Oxtr- rather than Glp1r-expressing VANs are the primary source of gastrointestinal distension signals driving PPGNTS neuron-mediated satiation</data>
</edge>
<edge source="PDF_3_Conclusion_-1948668734909414417" target="Gene_PPG">
  <data key="d8">MENTIONS</data>
  <data key="d9">PPGNTS neurons as a necessary component of the gut-brain circuit recruited by peripheral oxytocin to suppress eating</data>
</edge>
<edge source="PDF_3_Conclusion_-1948668734909414417" target="Compound_OXYTOCIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">PPGNTS neurons as a necessary component of the gut-brain circuit recruited by peripheral oxytocin to suppress eating</data>
</edge>
<edge source="PDF_3_Conclusion_2321696407336075315" target="Gene_PPG">
  <data key="d8">MENTIONS</data>
  <data key="d9">PPGNTS neurons are not necessary for GLP-1RA-induced suppression of eating</data>
</edge>
<edge source="PDF_3_Conclusion_2321696407336075315" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">PPGNTS neurons are not necessary for GLP-1RA-induced suppression of eating</data>
</edge>
<edge source="PDF_3_Conclusion_4209648061107124474" target="Gene_PPG">
  <data key="d8">MENTIONS</data>
  <data key="d9">PPGNTS neurons suppress eating via circuits which are anatomically and functionally distinct from those recruited by peripheral endogenous GLP-1 and peripherally administered GLP-1RAs</data>
</edge>
<edge source="PDF_3_Conclusion_4209648061107124474" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">PPGNTS neurons suppress eating via circuits which are anatomically and functionally distinct from those recruited by peripheral endogenous GLP-1 and peripherally administered GLP-1RAs</data>
</edge>
<edge source="PDF_3_Conclusion_-5221819320897875189" target="Protein_GLP-1">
  <data key="d8">MENTIONS</data>
  <data key="d9">the unified peripheral to central GLP-1 satiation circuit hypothesis cannot be supported, but that the peripheral and central GLP-1 systems are rather components of functionally and anatomically independent eating control circuits</data>
</edge>
<edge source="PDF_3_Conclusion_-4419455904112913995" target="Gene_PPG">
  <data key="d8">MENTIONS</data>
  <data key="d9">Activation of PPGNTS neurons, either alone or in combination with GLP-1RAs, thus represents a rational strategy for obesity treatment</data>
</edge>
<edge source="PDF_3_Conclusion_-4419455904112913995" target="Disease_OBESITY">
  <data key="d8">MENTIONS</data>
  <data key="d9">Activation of PPGNTS neurons, either alone or in combination with GLP-1RAs, thus represents a rational strategy for obesity treatment</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_6135624927386232844">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_-7189104412129414113">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_229012398668281384">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_-2805374894381281088">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_-3184145757421236057">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_7762534828733437259">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_6359609731107884522">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_7898330476481306524">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_-8915652742990526202">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_-3082237975900150399">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_-971115072939932909">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_1565443364262036202">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_-4748601598772986517">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_-2925905954577225094">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_-925196915687677708">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_1896818659557132719">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_-8608051912689437436">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_-2006356274132936653">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_-5568255116895183618">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_-5453686403668738889">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_4065359506097667417">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_5114278779626160691">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_-7152261828659858270">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_7667186950944966518">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_1599930704965880782">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_-5647623402321451362">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_-8582382207447656538">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_-6930284550770577579">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12" target="PDF_12_Result_6724487634730754546">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_12_Result_6135624927386232844" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol is a centrally acting analgesic effective in acute and chronic pain states, exerting a dual action by binding to opioid receptors and weakly inhibiting biogenic amine reuptake.</data>
</edge>
<edge source="PDF_12_Result_-7189104412129414113" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol is rapidly absorbed with action onset within 1 hour; sustained release is advantageous for chronic pain like osteoarthritis.</data>
</edge>
<edge source="PDF_12_Result_-7189104412129414113" target="Disease_OSTEOARTHRITIS">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol is rapidly absorbed with action onset within 1 hour; sustained release is advantageous for chronic pain like osteoarthritis.</data>
</edge>
<edge source="PDF_12_Result_229012398668281384" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol appears useful in elderly with osteoarthritis, avoiding hypertension, heart failure aggravation, and peptic ulcers, unlike NSAIDs; it also induces less respiratory depression, constipation, and abuse potential than narcotics.</data>
</edge>
<edge source="PDF_12_Result_229012398668281384" target="Disease_OSTEOARTHRITIS">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol appears useful in elderly with osteoarthritis, avoiding hypertension, heart failure aggravation, and peptic ulcers, unlike NSAIDs; it also induces less respiratory depression, constipation, and abuse potential than narcotics.</data>
</edge>
<edge source="PDF_12_Result_-2805374894381281088" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol binds to u opioid receptor site in the central nervous system, with a binding affinity 6000 times less than that of morphine.</data>
</edge>
<edge source="PDF_12_Result_-2805374894381281088" target="Compound_MORPHINE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol binds to u opioid receptor site in the central nervous system, with a binding affinity 6000 times less than that of morphine.</data>
</edge>
<edge source="PDF_12_Result_-3184145757421236057" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol-mediated analgesia is only partially reduced by the opioid antagonist, naloxone, thus suggesting an important nonopioid mechanism of action.</data>
</edge>
<edge source="PDF_12_Result_-3184145757421236057" target="Compound_NALOXONE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol-mediated analgesia is only partially reduced by the opioid antagonist, naloxone, thus suggesting an important nonopioid mechanism of action.</data>
</edge>
<edge source="PDF_12_Result_7762534828733437259" target="Compound_NORADRENALINE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Reuptake inhibitory effects on noradrenaline (norepinephrine) and serotonin (5-hydroxytryptamine; 5-HT) contributed to the analgesic effects of tramadol by inhibiting pain transmission in the spinal cord.</data>
</edge>
<edge source="PDF_12_Result_7762534828733437259" target="Compound_SEROTONIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">Reuptake inhibitory effects on noradrenaline (norepinephrine) and serotonin (5-hydroxytryptamine; 5-HT) contributed to the analgesic effects of tramadol by inhibiting pain transmission in the spinal cord.</data>
</edge>
<edge source="PDF_12_Result_7762534828733437259" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Reuptake inhibitory effects on noradrenaline (norepinephrine) and serotonin (5-hydroxytryptamine; 5-HT) contributed to the analgesic effects of tramadol by inhibiting pain transmission in the spinal cord.</data>
</edge>
<edge source="PDF_12_Result_6359609731107884522" target="Compound_SEROTONIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">The (+) enantiomer has a weakly preferential effect at u opioid receptors and in inhibiting the reuptake of serotonin, whereas the (-) enantiomer preferentially inhibits the reuptake of noradrenaline.</data>
</edge>
<edge source="PDF_12_Result_6359609731107884522" target="Compound_NORADRENALINE">
  <data key="d8">MENTIONS</data>
  <data key="d9">The (+) enantiomer has a weakly preferential effect at u opioid receptors and in inhibiting the reuptake of serotonin, whereas the (-) enantiomer preferentially inhibits the reuptake of noradrenaline.</data>
</edge>
<edge source="PDF_12_Result_7898330476481306524" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Mono-O-desmethyl-tramadol (M1), the one active metabolite of tramadol, has a greater opioid receptor affinity than the parent compound.</data>
</edge>
<edge source="PDF_12_Result_-8915652742990526202" target="Compound_CODEINE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Codeine has 10 times greater affinity for the u opioid receptor than tramadol.</data>
</edge>
<edge source="PDF_12_Result_-8915652742990526202" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Codeine has 10 times greater affinity for the u opioid receptor than tramadol.</data>
</edge>
<edge source="PDF_12_Result_-3082237975900150399" target="Compound_NORADRENALINE">
  <data key="d8">MENTIONS</data>
  <data key="d9">The reuptake inhibitory effects of tramadol on noradrenaline and serotonin are 100 to 1000 times weaker than those of imipramine.</data>
</edge>
<edge source="PDF_12_Result_-3082237975900150399" target="Compound_SEROTONIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">The reuptake inhibitory effects of tramadol on noradrenaline and serotonin are 100 to 1000 times weaker than those of imipramine.</data>
</edge>
<edge source="PDF_12_Result_-3082237975900150399" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">The reuptake inhibitory effects of tramadol on noradrenaline and serotonin are 100 to 1000 times weaker than those of imipramine.</data>
</edge>
<edge source="PDF_12_Result_-3082237975900150399" target="Compound_IMIPRAMINE">
  <data key="d8">MENTIONS</data>
  <data key="d9">The reuptake inhibitory effects of tramadol on noradrenaline and serotonin are 100 to 1000 times weaker than those of imipramine.</data>
</edge>
<edge source="PDF_12_Result_-971115072939932909" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol is rapidly and almost completely absorbed, with an onset of action occurring within 1 hour of oral administration.</data>
</edge>
<edge source="PDF_12_Result_1565443364262036202" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol is extensively metabolised by the liver; only the O-demethylated metabolite has pharmacological activity.</data>
</edge>
<edge source="PDF_12_Result_-2925905954577225094" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">The plasma terminal elimination half-life of tramadol is 6.3 hours after a single 100mg dose.</data>
</edge>
<edge source="PDF_12_Result_-925196915687677708" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Coadministration of tramadol with cimetidine increases the terminal elimination half-life of tramadol; however, these changes are not clinically significant and do not necessitate an adjustment of the tramadol dose.</data>
</edge>
<edge source="PDF_12_Result_-925196915687677708" target="Compound_CIMETIDINE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Coadministration of tramadol with cimetidine increases the terminal elimination half-life of tramadol; however, these changes are not clinically significant and do not necessitate an adjustment of the tramadol dose.</data>
</edge>
<edge source="PDF_12_Result_1896818659557132719" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Concomitant administration of oral tramadol and oral quinidine in humans had no effect on tramadol-induced analgesia.</data>
</edge>
<edge source="PDF_12_Result_1896818659557132719" target="Compound_QUINIDINE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Concomitant administration of oral tramadol and oral quinidine in humans had no effect on tramadol-induced analgesia.</data>
</edge>
<edge source="PDF_12_Result_-8608051912689437436" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Coadministration of carbamazepine resulted in a decrease in the half-life of tramadol.</data>
</edge>
<edge source="PDF_12_Result_-8608051912689437436" target="Compound_CARBAMAZEPINE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Coadministration of carbamazepine resulted in a decrease in the half-life of tramadol.</data>
</edge>
<edge source="PDF_12_Result_-2006356274132936653" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Because tramadol inhibits the uptake of noradrenaline and serotonin, it should be used with caution in patients taking MAO inhibitors.</data>
</edge>
<edge source="PDF_12_Result_-2006356274132936653" target="Compound_NORADRENALINE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Because tramadol inhibits the uptake of noradrenaline and serotonin, it should be used with caution in patients taking MAO inhibitors.</data>
</edge>
<edge source="PDF_12_Result_-2006356274132936653" target="Compound_SEROTONIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">Because tramadol inhibits the uptake of noradrenaline and serotonin, it should be used with caution in patients taking MAO inhibitors.</data>
</edge>
<edge source="PDF_12_Result_-5568255116895183618" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol at a dose of 150mg was significantly better than dextropropoxyphene.</data>
</edge>
<edge source="PDF_12_Result_-5568255116895183618" target="Compound_DEXTROPROPOXYPHENE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol at a dose of 150mg was significantly better than dextropropoxyphene.</data>
</edge>
<edge source="PDF_12_Result_-5453686403668738889" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol 75 and 150mg were found to be as effective as paracetamol 650mg plus dextropropoxyphene 100mg in patients with postcaesarean section pain.</data>
</edge>
<edge source="PDF_12_Result_-5453686403668738889" target="Compound_PARACETAMOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol 75 and 150mg were found to be as effective as paracetamol 650mg plus dextropropoxyphene 100mg in patients with postcaesarean section pain.</data>
</edge>
<edge source="PDF_12_Result_-5453686403668738889" target="Compound_DEXTROPROPOXYPHENE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol 75 and 150mg were found to be as effective as paracetamol 650mg plus dextropropoxyphene 100mg in patients with postcaesarean section pain.</data>
</edge>
<edge source="PDF_12_Result_4065359506097667417" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol 100mg was the optimal single dose treatment for acute pain, and tramadol 50mg showed similar analgesic efficacy to that of codeine 60mg.</data>
</edge>
<edge source="PDF_12_Result_4065359506097667417" target="Compound_CODEINE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol 100mg was the optimal single dose treatment for acute pain, and tramadol 50mg showed similar analgesic efficacy to that of codeine 60mg.</data>
</edge>
<edge source="PDF_12_Result_5114278779626160691" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">At the end of the 6-week study, 9 of 10 tramadol-treated patients and 6 of 11 control patients indicated satisfactory to excellent responses for postherpetic neuralgia.</data>
</edge>
<edge source="PDF_12_Result_5114278779626160691" target="Disease_POSTHERPETIC NEURALGIA">
  <data key="d8">MENTIONS</data>
  <data key="d9">At the end of the 6-week study, 9 of 10 tramadol-treated patients and 6 of 11 control patients indicated satisfactory to excellent responses for postherpetic neuralgia.</data>
</edge>
<edge source="PDF_12_Result_-7152261828659858270" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol provided analgesia comparable to that of paracetamol plus codeine in chronic nonmalignant pain.</data>
</edge>
<edge source="PDF_12_Result_-7152261828659858270" target="Compound_PARACETAMOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol provided analgesia comparable to that of paracetamol plus codeine in chronic nonmalignant pain.</data>
</edge>
<edge source="PDF_12_Result_-7152261828659858270" target="Compound_CODEINE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Tramadol provided analgesia comparable to that of paracetamol plus codeine in chronic nonmalignant pain.</data>
</edge>
<edge source="PDF_12_Result_7667186950944966518" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">An average daily dosage of 245mg tramadol was significantly more effective than placebo in reducing the severity of the pain at rest from osteoarthritis treated with NSAIDs</data>
</edge>
<edge source="PDF_12_Result_7667186950944966518" target="Disease_OSTEOARTHRITIS">
  <data key="d8">MENTIONS</data>
  <data key="d9">An average daily dosage of 245mg tramadol was significantly more effective than placebo in reducing the severity of the pain at rest from osteoarthritis treated with NSAIDs</data>
</edge>
<edge source="PDF_12_Result_1599930704965880782" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Total daily pain scores were lower for patients receiving tramadol than for those receiving pentazocine in patients with painful arthritis of the hip and/or knee.</data>
</edge>
<edge source="PDF_12_Result_1599930704965880782" target="Compound_PENTAZOCINE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Total daily pain scores were lower for patients receiving tramadol than for those receiving pentazocine in patients with painful arthritis of the hip and/or knee.</data>
</edge>
<edge source="PDF_12_Result_1599930704965880782" target="Disease_ARTHRITIS">
  <data key="d8">MENTIONS</data>
  <data key="d9">Total daily pain scores were lower for patients receiving tramadol than for those receiving pentazocine in patients with painful arthritis of the hip and/or knee.</data>
</edge>
<edge source="PDF_12_Result_-5647623402321451362" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">In 40 patients with osteoarthritis of the hip or knee, tramadol 50mg 3 times daily for 3 weeks was slightly more effective than dextropropoxyphene in relieving pain.</data>
</edge>
<edge source="PDF_12_Result_-5647623402321451362" target="Disease_OSTEOARTHRITIS">
  <data key="d8">MENTIONS</data>
  <data key="d9">In 40 patients with osteoarthritis of the hip or knee, tramadol 50mg 3 times daily for 3 weeks was slightly more effective than dextropropoxyphene in relieving pain.</data>
</edge>
<edge source="PDF_12_Result_-5647623402321451362" target="Compound_DEXTROPROPOXYPHENE">
  <data key="d8">MENTIONS</data>
  <data key="d9">In 40 patients with osteoarthritis of the hip or knee, tramadol 50mg 3 times daily for 3 weeks was slightly more effective than dextropropoxyphene in relieving pain.</data>
</edge>
<edge source="PDF_12_Result_-8582382207447656538" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Both diclofenac and tramadol drugs showed comparable efficacy after 4 weeks in patients with osteoarthritis of the hip and/or knee</data>
</edge>
<edge source="PDF_12_Result_-8582382207447656538" target="Compound_DICLOFENAC">
  <data key="d8">MENTIONS</data>
  <data key="d9">Both diclofenac and tramadol drugs showed comparable efficacy after 4 weeks in patients with osteoarthritis of the hip and/or knee</data>
</edge>
<edge source="PDF_12_Result_-8582382207447656538" target="Disease_OSTEOARTHRITIS">
  <data key="d8">MENTIONS</data>
  <data key="d9">Both diclofenac and tramadol drugs showed comparable efficacy after 4 weeks in patients with osteoarthritis of the hip and/or knee</data>
</edge>
<edge source="PDF_12_Result_-6930284550770577579" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Mean daily tramadol dose of 160mg produced overall ‘satisfactory' pain relief in approximately 86% of patients</data>
</edge>
<edge source="PDF_12_Result_6724487634730754546" target="Compound_TRAMADOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Both ibuprofen and tramadol drugs demonstrated equivalent efficacy in patients with hip or knee osteoarthritis.</data>
</edge>
<edge source="PDF_12_Result_6724487634730754546" target="Compound_IBUPROFEN">
  <data key="d8">MENTIONS</data>
  <data key="d9">Both ibuprofen and tramadol drugs demonstrated equivalent efficacy in patients with hip or knee osteoarthritis.</data>
</edge>
<edge source="PDF_12_Result_6724487634730754546" target="Disease_OSTEOARTHRITIS">
  <data key="d8">MENTIONS</data>
  <data key="d9">Both ibuprofen and tramadol drugs demonstrated equivalent efficacy in patients with hip or knee osteoarthritis.</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_4698747440489162178">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-2918929946762459002">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-1264326948666588695">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-452162685896198458">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-2895694798426260474">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-2433814731328786998">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_917555633588458259">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-8468138155765780383">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-7007323564526676114">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-8412380112980374188">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-8843911614121635976">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-1048354603491960383">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_1361837061015144963">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-2253920903812482562">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_5812999850210364681">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_5521930659563623561">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_8305297351042134455">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-3108081169811871539">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_5816630019852456634">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-2111090754358233878">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_2887498797745895915">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_1658112093970035645">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_5446436163520006439">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-2688218205457220709">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-4469746774708237442">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-7235482679999002366">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_2563765306779389364">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_4559622370633345913">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-3891733967867274678">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_4691117518972233469">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_4436157426692650895">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-8823070298879714663">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-8805107246137760054">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_7324330300928826471">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-6656925133536417044">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-1067514607605544875">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_4561285386901556600">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-5950082456397010265">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-8150012407422805875">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_3681192080723752934">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_1721636786537021481">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_-5222279738855471904">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_5436875052255904408">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_3661870917759909080">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_7944410958009257752">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_7378990707650912457">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_2816071552959862711">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_4858937553636521488">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_1210638954632113027">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11" target="PDF_11_Result_6849486154197006296">
  <data key="d8">CONTAINS</data>
</edge>
<edge source="PDF_11_Result_4698747440489162178" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril 4 to 8mg once daily is usually effective for blood pressure control in patients with mild to moderate essential hypertension.</data>
</edge>
<edge source="PDF_11_Result_4698747440489162178" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril 4 to 8mg once daily is usually effective for blood pressure control in patients with mild to moderate essential hypertension.</data>
</edge>
<edge source="PDF_11_Result_-2918929946762459002" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Those patients who do not respond adequately to monotherapy with perindopril usually respond with the addition of a second agent, such as a thiazide diuretic.</data>
</edge>
<edge source="PDF_11_Result_-1264326948666588695" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Preliminary results indicate that perindopril may also be effective in patients with severe hypertension or congestive heart failure.</data>
</edge>
<edge source="PDF_11_Result_-1264326948666588695" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">Preliminary results indicate that perindopril may also be effective in patients with severe hypertension or congestive heart failure.</data>
</edge>
<edge source="PDF_11_Result_-1264326948666588695" target="Disease_HEART FAILURE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Preliminary results indicate that perindopril may also be effective in patients with severe hypertension or congestive heart failure.</data>
</edge>
<edge source="PDF_11_Result_-452162685896198458" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril is generally well tolerated and has an adverse effect profile similar to that of other ACE inhibitors.</data>
</edge>
<edge source="PDF_11_Result_-2895694798426260474" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">After oral administration of perindopril, potent inhibition of ACE, and consequently angiotensin II formation, is achieved in plasma and most tissues.</data>
</edge>
<edge source="PDF_11_Result_-2895694798426260474" target="Protein_ACE">
  <data key="d8">MENTIONS</data>
  <data key="d9">After oral administration of perindopril, potent inhibition of ACE, and consequently angiotensin II formation, is achieved in plasma and most tissues.</data>
</edge>
<edge source="PDF_11_Result_-2895694798426260474" target="Protein_ANGIOTENSIN II">
  <data key="d8">MENTIONS</data>
  <data key="d9">After oral administration of perindopril, potent inhibition of ACE, and consequently angiotensin II formation, is achieved in plasma and most tissues.</data>
</edge>
<edge source="PDF_11_Result_-2433814731328786998" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">The blood pressure lowering effect of perindopril has been shown in animal models of spontaneous and renovascular hypertension.</data>
</edge>
<edge source="PDF_11_Result_-2433814731328786998" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">The blood pressure lowering effect of perindopril has been shown in animal models of spontaneous and renovascular hypertension.</data>
</edge>
<edge source="PDF_11_Result_917555633588458259" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril 4 to 8mg once daily significantly reduces supine and standing blood pressure in patients with essential hypertension.</data>
</edge>
<edge source="PDF_11_Result_917555633588458259" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril 4 to 8mg once daily significantly reduces supine and standing blood pressure in patients with essential hypertension.</data>
</edge>
<edge source="PDF_11_Result_-8468138155765780383" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril also improves arterial structure and reduces left ventricular hypertrophy in hypertensive patients.</data>
</edge>
<edge source="PDF_11_Result_-8468138155765780383" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril also improves arterial structure and reduces left ventricular hypertrophy in hypertensive patients.</data>
</edge>
<edge source="PDF_11_Result_-7007323564526676114" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Beneficial acute haemodynamic effects comprising a reduction in preload and afterload with only a slight reduction in heart rate, and increased renal blood flow are seen after oral administration of perindopril 2 to 4mg in patients with congestive heart failure.</data>
</edge>
<edge source="PDF_11_Result_-7007323564526676114" target="Disease_HEART FAILURE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Beneficial acute haemodynamic effects comprising a reduction in preload and afterload with only a slight reduction in heart rate, and increased renal blood flow are seen after oral administration of perindopril 2 to 4mg in patients with congestive heart failure.</data>
</edge>
<edge source="PDF_11_Result_-8412380112980374188" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">In this indication oral administration of perindopril 4 to 8mg once daily reduces supine and standing systolic and diastolic blood pressure by about 5 to 15%, and adequate diastolic blood pressure control (&lt;90mm Hg) is attained in about 50 to 70% of patients with monotherapy.</data>
</edge>
<edge source="PDF_11_Result_-8843911614121635976" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Limited information in patients with congestive heart failure has indicated beneficial haemodynamic effects with perindopril.</data>
</edge>
<edge source="PDF_11_Result_-8843911614121635976" target="Disease_HEART FAILURE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Limited information in patients with congestive heart failure has indicated beneficial haemodynamic effects with perindopril.</data>
</edge>
<edge source="PDF_11_Result_-1048354603491960383" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril has been well tolerated in clinical trials involving patients with mild to moderate essential hypertension.</data>
</edge>
<edge source="PDF_11_Result_-1048354603491960383" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril has been well tolerated in clinical trials involving patients with mild to moderate essential hypertension.</data>
</edge>
<edge source="PDF_11_Result_1361837061015144963" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Large-scale clinical trials indicate that perindopril is at least as well tolerated as captopril, atenolol and hydrochlorothiazide plus amiloride in patients with essential hypertension.</data>
</edge>
<edge source="PDF_11_Result_1361837061015144963" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">Large-scale clinical trials indicate that perindopril is at least as well tolerated as captopril, atenolol and hydrochlorothiazide plus amiloride in patients with essential hypertension.</data>
</edge>
<edge source="PDF_11_Result_1361837061015144963" target="Compound_CAPTOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Large-scale clinical trials indicate that perindopril is at least as well tolerated as captopril, atenolol and hydrochlorothiazide plus amiloride in patients with essential hypertension.</data>
</edge>
<edge source="PDF_11_Result_1361837061015144963" target="Compound_ATENOLOL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Large-scale clinical trials indicate that perindopril is at least as well tolerated as captopril, atenolol and hydrochlorothiazide plus amiloride in patients with essential hypertension.</data>
</edge>
<edge source="PDF_11_Result_1361837061015144963" target="Compound_HYDROCHLOROTHIAZIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Large-scale clinical trials indicate that perindopril is at least as well tolerated as captopril, atenolol and hydrochlorothiazide plus amiloride in patients with essential hypertension.</data>
</edge>
<edge source="PDF_11_Result_1361837061015144963" target="Compound_AMILORIDE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Large-scale clinical trials indicate that perindopril is at least as well tolerated as captopril, atenolol and hydrochlorothiazide plus amiloride in patients with essential hypertension.</data>
</edge>
<edge source="PDF_11_Result_-2253920903812482562" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">The usual effective dosage of perindopril is 2 to 8mg once daily in patients with mild to moderate essential hypertension.</data>
</edge>
<edge source="PDF_11_Result_-2253920903812482562" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">The usual effective dosage of perindopril is 2 to 8mg once daily in patients with mild to moderate essential hypertension.</data>
</edge>
<edge source="PDF_11_Result_5812999850210364681" target="Disease_HEART FAILURE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Limited experience in patients with congestive heart failure suggests that 4mg once daily is an effective dosage</data>
</edge>
<edge source="PDF_11_Result_5521930659563623561" target="Protein_ACE">
  <data key="d8">MENTIONS</data>
  <data key="d9">The active metabolite per- indoprilat is, however, a potent in vitro ACE in- hibitor</data>
</edge>
<edge source="PDF_11_Result_5521930659563623561" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">The active metabolite per- indoprilat is, however, a potent in vitro ACE in- hibitor</data>
</edge>
<edge source="PDF_11_Result_8305297351042134455" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Oral administration of perindopril produces dose-dependent inhibition of plasma ACE activity in normotensive and hypertensive animals , healthy human subjects , hyperten- sive patients and patients with congestive heart failure</data>
</edge>
<edge source="PDF_11_Result_8305297351042134455" target="Protein_ACE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Oral administration of perindopril produces dose-dependent inhibition of plasma ACE activity in normotensive and hypertensive animals , healthy human subjects , hyperten- sive patients and patients with congestive heart failure</data>
</edge>
<edge source="PDF_11_Result_8305297351042134455" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">Oral administration of perindopril produces dose-dependent inhibition of plasma ACE activity in normotensive and hypertensive animals , healthy human subjects , hyperten- sive patients and patients with congestive heart failure</data>
</edge>
<edge source="PDF_11_Result_8305297351042134455" target="Disease_HEART FAILURE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Oral administration of perindopril produces dose-dependent inhibition of plasma ACE activity in normotensive and hypertensive animals , healthy human subjects , hyperten- sive patients and patients with congestive heart failure</data>
</edge>
<edge source="PDF_11_Result_-3108081169811871539" target="Protein_ACE">
  <data key="d8">MENTIONS</data>
  <data key="d9">As a con- sequence of this ACE inhibition, a decrease in plasma angiotensin II levels occurs, as well as in- creases in plasma renin activity and plasma angio- tensin I levels mediated by negative feedback, and a somewhat variable but frequent decrease in plasma aldosterone levels.</data>
</edge>
<edge source="PDF_11_Result_-3108081169811871539" target="Protein_ANGIOTENSIN II">
  <data key="d8">MENTIONS</data>
  <data key="d9">As a con- sequence of this ACE inhibition, a decrease in plasma angiotensin II levels occurs, as well as in- creases in plasma renin activity and plasma angio- tensin I levels mediated by negative feedback, and a somewhat variable but frequent decrease in plasma aldosterone levels.</data>
</edge>
<edge source="PDF_11_Result_5816630019852456634" target="Protein_ACE">
  <data key="d8">MENTIONS</data>
  <data key="d9">Animal studies have indicated that perindopril produces significant ACE inhibition in most tissues, includ- ing lung parenchyma, pulmonary vessels, heart, aortic wall, adrenal glands, proximal renal tubules, glomerular mesangium, renal vessels, brain cortex and pituitary glands, but not in the testes, medulla oblongata or hypothalamus</data>
</edge>
<edge source="PDF_11_Result_5816630019852456634" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Animal studies have indicated that perindopril produces significant ACE inhibition in most tissues, includ- ing lung parenchyma, pulmonary vessels, heart, aortic wall, adrenal glands, proximal renal tubules, glomerular mesangium, renal vessels, brain cortex and pituitary glands, but not in the testes, medulla oblongata or hypothalamus</data>
</edge>
<edge source="PDF_11_Result_-2111090754358233878" target="Protein_ACE">
  <data key="d8">MENTIONS</data>
  <data key="d9">It should also be noted that administration of per- indopril to pregnant animals leads to significant fe- tal ACE inhibition, indicating placental transfer of perindopril and/or perindoprilat</data>
</edge>
<edge source="PDF_11_Result_-2111090754358233878" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">It should also be noted that administration of per- indopril to pregnant animals leads to significant fe- tal ACE inhibition, indicating placental transfer of perindopril and/or perindoprilat</data>
</edge>
<edge source="PDF_11_Result_2887498797745895915" target="Protein_BRADYKININ">
  <data key="d8">MENTIONS</data>
  <data key="d9">While intravenously administered perindopril potentiates exogenous bradykinin-induced femoral artery vasodilatation in dogs , the effect of perindopril on endogenous bradykinin and prostaglandin levels has not been reported.</data>
</edge>
<edge source="PDF_11_Result_2887498797745895915" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">While intravenously administered perindopril potentiates exogenous bradykinin-induced femoral artery vasodilatation in dogs , the effect of perindopril on endogenous bradykinin and prostaglandin levels has not been reported.</data>
</edge>
<edge source="PDF_11_Result_2887498797745895915" target="Compound_PROSTAGLANDINS">
  <data key="d8">MENTIONS</data>
  <data key="d9">While intravenously administered perindopril potentiates exogenous bradykinin-induced femoral artery vasodilatation in dogs , the effect of perindopril on endogenous bradykinin and prostaglandin levels has not been reported.</data>
</edge>
<edge source="PDF_11_Result_1658112093970035645" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Animal studies by Lo et al. (1990) have shown that most of the cardiovascular effects of long term per- indopril administration are similar to those of anti- renin immunisation, indicating that blockade of the renin-angiotensin system accounts for most of the effects of perindopril.</data>
</edge>
<edge source="PDF_11_Result_5446436163520006439" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril has been reported to normalise the increased plasma atrial natriuretic factor levels in rats with myocardial infarction experimentally in- duced by coronary artery ligation</data>
</edge>
<edge source="PDF_11_Result_-2688218205457220709" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Mean plasma atrial natriuretic factor levels were decreased from 90 to 63 ng/L (p = 0.05) after 15 days' treatment with perindopril 4mg daily in 10 hypertensive patients with chronic nephropathy, an effect which was correlated with the fractional excretion of sodium</data>
</edge>
<edge source="PDF_11_Result_-2688218205457220709" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">Mean plasma atrial natriuretic factor levels were decreased from 90 to 63 ng/L (p = 0.05) after 15 days' treatment with perindopril 4mg daily in 10 hypertensive patients with chronic nephropathy, an effect which was correlated with the fractional excretion of sodium</data>
</edge>
<edge source="PDF_11_Result_-4469746774708237442" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Numerous studies have demonstrated the anti- hypertensive effects of perindopril in animal models of both spontaneous (genetic) and renovascular hypertension</data>
</edge>
<edge source="PDF_11_Result_-4469746774708237442" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">Numerous studies have demonstrated the anti- hypertensive effects of perindopril in animal models of both spontaneous (genetic) and renovascular hypertension</data>
</edge>
<edge source="PDF_11_Result_-7235482679999002366" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">The antihypertensive effect of perindopril was more pronounced in sodium-depleted animals , presumably because of their increased dependence on the renin-angiotensin system for maintenance of blood pressure.</data>
</edge>
<edge source="PDF_11_Result_2563765306779389364" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">An additive antihypertensive effect was noted when perindopril and nitrendipine were administered concomitantly in the spontaneously hypertensive rat</data>
</edge>
<edge source="PDF_11_Result_2563765306779389364" target="Compound_NITRENDIPINE">
  <data key="d8">MENTIONS</data>
  <data key="d9">An additive antihypertensive effect was noted when perindopril and nitrendipine were administered concomitantly in the spontaneously hypertensive rat</data>
</edge>
<edge source="PDF_11_Result_2563765306779389364" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">An additive antihypertensive effect was noted when perindopril and nitrendipine were administered concomitantly in the spontaneously hypertensive rat</data>
</edge>
<edge source="PDF_11_Result_4559622370633345913" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">The reduction in blood pressure produced by perindopril in animals with spontaneous or reno- vascular hypertension was associated with a de- crease in peripheral vascular resistance with no sig- nificant change in heart rate or cardiac output</data>
</edge>
<edge source="PDF_11_Result_4559622370633345913" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">The reduction in blood pressure produced by perindopril in animals with spontaneous or reno- vascular hypertension was associated with a de- crease in peripheral vascular resistance with no sig- nificant change in heart rate or cardiac output</data>
</edge>
<edge source="PDF_11_Result_-3891733967867274678" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Recently, Muller et al. (1990) found that perindopril normalised the elevated cerebrovascular resistance normally associated with untreated renovascular hypertension in the rat.</data>
</edge>
<edge source="PDF_11_Result_-3891733967867274678" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">Recently, Muller et al. (1990) found that perindopril normalised the elevated cerebrovascular resistance normally associated with untreated renovascular hypertension in the rat.</data>
</edge>
<edge source="PDF_11_Result_4691117518972233469" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Perindopril in- hibited and even prevented development of card- iac hypertrophy in the rat; this was also associated with reversal of the isoenzyme shift of myocardial myosin and improvement in coronary blood flow and papillary muscle mechanical per- formance.</data>
</edge>
<edge source="PDF_11_Result_4436157426692650895" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">In addition, perindopril im- proved large artery (carotid and aorta) and small resistance artery (mesenteric) structure, tending to normalise arterial wall thickness as well as collagen and elastin content, and thereby enhance arterial compliance</data>
</edge>
<edge source="PDF_11_Result_4436157426692650895" target="Protein_COLLAGEN">
  <data key="d8">MENTIONS</data>
  <data key="d9">In addition, perindopril im- proved large artery (carotid and aorta) and small resistance artery (mesenteric) structure, tending to normalise arterial wall thickness as well as collagen and elastin content, and thereby enhance arterial compliance</data>
</edge>
<edge source="PDF_11_Result_4436157426692650895" target="Protein_ELASTIN">
  <data key="d8">MENTIONS</data>
  <data key="d9">In addition, perindopril im- proved large artery (carotid and aorta) and small resistance artery (mesenteric) structure, tending to normalise arterial wall thickness as well as collagen and elastin content, and thereby enhance arterial compliance</data>
</edge>
<edge source="PDF_11_Result_-8823070298879714663" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Coronary artery ligation in the rat leads to card- iac hypertrophy and electrophysiological changes, and may be used as a model to study myocardial infarction, left ventricular failure and ventricular arrhythmias. Long term perindopril administra- tion either prevented or inhibited development of experimental cardiac hypertrophy</data>
</edge>
<edge source="PDF_11_Result_-8805107246137760054" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">High doses of perindopril in the perfusate pre- vented these arrhythmias but did not affect nor- adrenaline release in vitro</data>
</edge>
<edge source="PDF_11_Result_7324330300928826471" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Acute administration of perindopril shortly before coronary artery ligation in vivo significantly re- duced mortality and the severity of ventricular tachycardia and fibrillation</data>
</edge>
<edge source="PDF_11_Result_-6656925133536417044" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Oral administration of single or repeated once daily doses of perindopril 1 to 16mg to normoten- sive subjects either had no significant effect on blood pressure or caused a slight, but significant, blood pressure decrease, particularly with higher doses</data>
</edge>
<edge source="PDF_11_Result_-1067514607605544875" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Ajayi et al. (1986) found that a single oral dose of perindopril 8mg did not affect blood pressure and heart rate responses to dynamic exercise, fore- arm isometric exercise, the cold pressor test or Val- salva's manoeuvre, but enhanced the vagally me- diated sinus arrhythmia associated with deep breathing.</data>
</edge>
<edge source="PDF_11_Result_4561285386901556600" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Single oral doses of perindopril 4, 8 and 16mg caused a dose-depend- ent increase in brachial and carotid artery diameter and blood flow with a decrease in forearm vascular resistance, as measured by the pulsed Doppler technique.</data>
</edge>
<edge source="PDF_11_Result_-5950082456397010265" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Appropriate acute reductions in systolic and diastolic blood pressure have been demonstrated with single oral doses of perindopril 4 to 16mg in patients with essential hypertension</data>
</edge>
<edge source="PDF_11_Result_-5950082456397010265" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">Appropriate acute reductions in systolic and diastolic blood pressure have been demonstrated with single oral doses of perindopril 4 to 16mg in patients with essential hypertension</data>
</edge>
<edge source="PDF_11_Result_3681192080723752934" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">After 6 weeks' treatment with perindopril 8mg once daily, haemodynamic responses to Valsalva's man- oeuvre, tilt, isometric forearm exercise and cold pressor testing were unaltered, while there was a significant increase in bradycardia during facial immersion; a resetting of the sino-aortic barore- ceptor reflex occurred within 2 hours after the first dose.</data>
</edge>
<edge source="PDF_11_Result_1721636786537021481" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">There was a statistically significant increase in resting forearm blood flow and a tendency for echocardiographically estimated left ventricular mass to decrease (from 192 to 166g, p = 0.12) after 6 weeks' treatment. Regression of left ventricular hypertrophy on long term therapy (3 to 12 months) with perindopril 4 to 8mg daily has been con- firmed in other studies in patients with essential hypertension</data>
</edge>
<edge source="PDF_11_Result_1721636786537021481" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">There was a statistically significant increase in resting forearm blood flow and a tendency for echocardiographically estimated left ventricular mass to decrease (from 192 to 166g, p = 0.12) after 6 weeks' treatment. Regression of left ventricular hypertrophy on long term therapy (3 to 12 months) with perindopril 4 to 8mg daily has been con- firmed in other studies in patients with essential hypertension</data>
</edge>
<edge source="PDF_11_Result_-5222279738855471904" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Investigation of the effect of perindopril 2 to 8mg daily on the elastic properties of the brachial artery in 15 patients with essential hypertension re- vealed that it increased arterial compliance (as- sessed by a pulsed Doppler technique) by 42%, de- creased pulsed wave velocity (an indicator of arterial stiffness) by 13% and reduced arterial impedance by 29% after 3 months' treatment</data>
</edge>
<edge source="PDF_11_Result_-5222279738855471904" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">Investigation of the effect of perindopril 2 to 8mg daily on the elastic properties of the brachial artery in 15 patients with essential hypertension re- vealed that it increased arterial compliance (as- sessed by a pulsed Doppler technique) by 42%, de- creased pulsed wave velocity (an indicator of arterial stiffness) by 13% and reduced arterial impedance by 29% after 3 months' treatment</data>
</edge>
<edge source="PDF_11_Result_5436875052255904408" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">The acute haemodynamic effects of single oral doses of perindopril 2 to 4mg have been deter- mined in patients with congestive heart failure of varying severity (NYHA classes II to IV) using in- vasive monitoring (table I). Overall, there was a reduction in preload and afterload, with a slight reduction in heart rate.</data>
</edge>
<edge source="PDF_11_Result_5436875052255904408" target="Disease_HEART FAILURE">
  <data key="d8">MENTIONS</data>
  <data key="d9">The acute haemodynamic effects of single oral doses of perindopril 2 to 4mg have been deter- mined in patients with congestive heart failure of varying severity (NYHA classes II to IV) using in- vasive monitoring (table I). Overall, there was a reduction in preload and afterload, with a slight reduction in heart rate.</data>
</edge>
<edge source="PDF_11_Result_7378990707650912457" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">The maximal decrease in mean arterial pressure with perindopril (-15%) did not differ from that with placebo (-16%), while both captopril (-22%) and enalapril (-26%) produced significantly greater decreases (p = 0.012).</data>
</edge>
<edge source="PDF_11_Result_7378990707650912457" target="Compound_CAPTOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">The maximal decrease in mean arterial pressure with perindopril (-15%) did not differ from that with placebo (-16%), while both captopril (-22%) and enalapril (-26%) produced significantly greater decreases (p = 0.012).</data>
</edge>
<edge source="PDF_11_Result_7378990707650912457" target="Compound_ENALAPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">The maximal decrease in mean arterial pressure with perindopril (-15%) did not differ from that with placebo (-16%), while both captopril (-22%) and enalapril (-26%) produced significantly greater decreases (p = 0.012).</data>
</edge>
<edge source="PDF_11_Result_2816071552959862711" target="Protein_ACE">
  <data key="d8">MENTIONS</data>
  <data key="d9">These results might suggest a differential response between ACE inhibitors with respect to their first-dose hypotensive effects.</data>
</edge>
<edge source="PDF_11_Result_4858937553636521488" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">The renal histological changes in rats with ex- perimentally induced renovascular hypertension were prevented by administration of perindopril for 5 weeks</data>
</edge>
<edge source="PDF_11_Result_4858937553636521488" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">The renal histological changes in rats with ex- perimentally induced renovascular hypertension were prevented by administration of perindopril for 5 weeks</data>
</edge>
<edge source="PDF_11_Result_1210638954632113027" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">Renal blood flow and glomerular filtration rate were increased in normotensive and spontaneously hypertensive rats during 1 to 12 weeks' administration of perindopril</data>
</edge>
<edge source="PDF_11_Result_1210638954632113027" target="Disease_HYPERTENSION">
  <data key="d8">MENTIONS</data>
  <data key="d9">Renal blood flow and glomerular filtration rate were increased in normotensive and spontaneously hypertensive rats during 1 to 12 weeks' administration of perindopril</data>
</edge>
<edge source="PDF_11_Result_6849486154197006296" target="Compound_PERINDOPRIL">
  <data key="d8">MENTIONS</data>
  <data key="d9">After administration of a single oral dose of per- indopril 8mg to 11 healthy subjects, 24-hour ur- inary output of sodium and chloride were in- creased by about 25% (p &lt; 0.02) and their renal clearance</data>
</edge>
</graph></graphml>